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highly conserved group of NAD-dependent enzymes, play a critical role in cellular survival and many of the
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improved renal mitochondrial function and decreased oxidative damage. Similarly, resuscitation with
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liver or kidney. Taken together, these data strongly suggest that SIRT1 and SIRT3 play a key role in the
pathophysiology of shock. Although further research is needed to determine if SIRT1 and SIRT3
overexpression improves outcomes or if pharmacologically manipulating NAD metabolism in conjunction
with sirtuin activation provides added benefit, targeting sirtuins appears beneficial in hemorrhagic and septic
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ABSTRACT 
 
TARGETING SIRTUINS TO IMPROVE OUTCOMES IN SHOCK 
Carrie Adelia Sims, MD 
Joseph A. Baur, PhD 
Both acute blood loss and severe infection activate common cellular pathways leading to 
shock – a pathologic condition characterized by systemic inflammation, oxidative stress, 
and mitochondrial dysfunction.  Sirtuins, a highly conserved group of NAD-dependent 
enzymes, play a critical role in cellular survival and many of the benefits associated with 
sirtuin activation are thought to be secondary to decreased inflammation, reduced 
oxidative stress, and improved mitochondrial physiology.  As such, we hypothesized that 
sirtuin pathways play a crucial role in shock and could be could be targeted to improve 
outcomes following acute blood loss and severe infection. In a series of in vivo and in 
vitro experiments recapitulating hemorrhagic shock and severe sepsis, we explored the 
impact of sirtuin activation on inflammation, mitochondrial function, and survival. 
Following decompensated hemorrhagic shock, resuscitation with resveratrol, a SIRT1 
activator, significantly improved renal mitochondrial function and decreased oxidative 
damage.  Similarly, resuscitation with nicotinamide monononucleotide (NMN), a key 
biosynthetic NAD precursor, was found to mitigate inflammation, support cellular 
energetics and improve both physiologic resilience and survival.  In contrast, impaired 
expression of either SIRT1 or SIRT3 resulted in a pro-inflammatory phenotype with 
accelerated mortality in sepsis. Interestingly, deletion of SIRT1 did not significantly 
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worsen the degree of mitochondrial dysfunction observed in septic liver, but was 
associated with decreased CI and CII respiration in kidney.  Deletion of SIRT3 did not 
significantly impact the degree of mitochondrial dysfunction observed in either liver or 
kidney. Taken together, these data strongly suggest that SIRT1 and SIRT3 play a key 
role in the pathophysiology of shock. Although further research is needed to determine if 
SIRT1 and SIRT3 overexpression improves outcomes or if pharmacologically 
manipulating NAD metabolism in conjunction with sirtuin activation provides added 
benefit, targeting sirtuins appears beneficial in hemorrhagic and septic shock. 
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CHAPTER 1:  
Of Shock and Sirtuins	  
“Shock is the manifestation of the rude unhinging of the machinery of life” 
Samuel V. Gross, 1872 
“The pulse, however, does not respond; it grows feebler, and finally disappears, and this 
‘momentary pause in the act of death’ is soon followed by the grim reality.” 
John Collins Warren, 1895 
 
In 1743, the French Army surgeon Henri Francois Le Dran coined the term “choquer” 
or “shock” to describe the progressive clinical failure he observed in dying soldiers, 
noting that many of those that survived their initial wounding would die hours to days 
later with “purulent matter”.(65) It is now recognized that both acute blood loss and 
severe infection, or sepsis, activate common cellular pathways leading to shock –a 
pathological condition characterized by cardiovascular collapse and systemic 
inflammation.  During shock, decreased tissue perfusion leads to cellular hypoxia, 
mitochondrial dysfunction, and bioenergetic failure.  Concurrently, both damaged tissues 
and microbial products activate the immune system through Toll-like receptors; thereby, 
increasing NFĸB signaling and the systemic release of pro-inflammatory cytokines.(17) 
These cytokines not only enhance the recruitment of leukocytes to damaged or infected 
tissues, they further exacerbate hypotension, cellular hypoxia, and oxidant stress.(208) 
Without prompt intervention, shock progresses from cellular injury to organ failure, and 
ultimately, to death.  
Depending on the etiology of the shock state, initial therapy includes prompt 
hemorrhage control, or antibiotics, along with aggressive intravenous fluids and blood 
products resuscitation in order to restore perfusion pressure.  Reperfusion, however, 
unleashes a storm of reactive oxygen species (ROS), inflammatory cytokines, and toxic 
2	  
	  
metabolites – all of which can further activate systemic inflammation.  In response to 
oxidant damage, cytokine induced neutrophil chemoattractant (CINCs) recruit 
neutrophils and the pro-inflammatory cytokine IL6 up-regulate vascular expression of 
intracellular adhesion molecule (ICAM) 1, an endothelial molecule that promotes the 
egress of neutrophils from the circulation into tissues.(237) With increased accumulation 
of tissue neutrophils, more ROS and proteolytic enzymes are released leading to 
increased tissue damage and subsequently more inflammation (Figure 1).  Importantly, 
the severity of shock, and its concomitant inflammatory response, directly contribute to 
the development of multi-organ failure (MOF).(149,208) Clinically, MOF develops in up 
to 50% of hypotensive trauma patients and is a universal finding in patients with septic 
shock.(6,23,56,63,168)   
Although only 12% of the U.S. population is older than 65 years of age, this 
demographic accounts for more than 60% of all sepsis cases and over 80% of sepsis-
related deaths.(5,160) While the elderly frequently have comorbid conditions that can 
exacerbate the course of sepsis, an increasing body of clinical and experimental data 
suggests that age itself is an independent risk factor for sepsis-related 
death.(160,203,231,241,242) With age, two key pro-inflammatory cytokines, IL6 and 
TNFα, are frequently elevated and are thought to contribute to increased oxidative 
stress, mitochondrial dysfunction, and a progressive decline in physiologic function.(28) 
During sepsis, however, this cytokine pattern becomes even more exaggerated and 
exceeds that found in younger patients.(29,130)  Because MOF accounts for nearly 50% 
of all deaths in the intensive care unit (161), there is increasing interest in developing 
therapies that treat shock and target the cellular pathways implicated in organ failure 
Sirtuins, a highly conserved group of NAD-dependent enzymes, play critical roles in 
cellular survival and may be the key to better outcomes in shock. Sirtuins were first 
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described in S. cerevisiae after the Silent information regulator 2 (SIR2) gene was found 
to confer stress resistance and promote longevity.(117) Since then, seven sirtuins have 
been identified in humans; each with a discrete subcellular localization and specific 
targets.(236)  Sirtuins primarily regulate biologic function by removing acyl groups (most 
commonly acetyl) from lysine residues or by functioning as ADP- 
ribosyltransferases.(102) Because the deacetylation reaction requires NAD as a 
substrate, sirtuin activity can be directly influenced by the nutritional and redox state of 
the cell.  Moreover, because nearly every metabolic enzyme is modified by lysine 
acetylation, sirtuins can directly control and coordinate a variety of pathways in times of 
cellular stress.(283) Although incompletely characterized, many of the pro-survival 
benefits associated with sirtuin activation are thought to be secondary to, decreased 
inflammation, reduced oxidative stress, and improved mitochondrial physiology (Figure 
2).(233)  As such, we hypothesized that sirtuin pathways play a key role in shock 
and could be targeted to improve outcomes following acute blood loss and severe 
infection.  
SIRTUIN 1 (SIRT1) 
SIRT1 is the best characterized mammalian SIR2 homologue.(73) Located in the 
nucleus and cytoplasm, SIRT1 is known to deacetylate over 30 target proteins and is 
capable of transcriptionally influencing a number of cellular processes ranging from 
gluconeogenesis to apoptosis.(236) Because SIRT1 absolutely requires NAD as 
cofactor, it can respond to metabolic perturbations and nutrient stress by modulating 
survival pathways. Indeed, calorie restriction is potent SIRT1 activator and has been 
shown to extend lifespan in a variety of organisms including yeast, worms, mice and 
rats.(50,92,146) Interestingly, short-term calorie restriction also appears to improve 
survival following sepsis induced by cecal ligation and puncture (CLP) and is associated 
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with decreased inflammation following hepatic ischemia-reperfusion injury in 
mice.(90,190,194) When SIRT1 was pharmacologically inhibited, however, the 
physiologic benefits of calorie restriction following reperfusion were lost. Taken together 
these data strongly suggest that activating SIRT1 pathways could mitigate the 
pathophysiology of shock. 
SIRT1 AND INFLAMMATION  
NFĸB is considered to be the central mediator of the human immune response and 
its activity increases significantly during hemorrhagic and septic shock.(179,213) As a 
prominent downstream target of SIRT1, NFĸB activity can be modulated to temper 
inflammation.(269) By deacetylating the RelA subunit of NFĸB; SIRT1 inhibits the 
transcription of over 100 target genes involved in the inflammatory response, including 
IL6, TNFα, CINC, cyclooxygenase -2, and ICAM-1.(179,269) In contrast, deletion of 
SIRT1 results in a marked increase in NFĸB activation along with increased cytokine and 
ICAM 1-expression following lipopolysaccharide challenge.(77)  
SIRT1 AND OXIDATIVE STRESS 
Although reactive oxygen species (ROS) are routinely produced in low quantities 
during normal cellular activity, significant oxidative stress is a hallmark of shock and 
reperfusion injury.  During shock, ROS are created by a number mechanisms including 
dysfunctional mitochondria, hypoxanthine recycling by xanthine oxidase, and by 
nicotinamide adenine dinucleotide phosphate oxidase (NOX) during neutrophil 
activation.(148) If left unchecked, ROS can cause oxidative damage to nucleic acids and 
proteins leading to further mitochondrial dysfunction, cell damage, and leukocyte 
recruitment. Mitochondrial derived ROS can also serve as signaling molecules to up-
regulate inflammation. In addition to directly activating NFκB and increasing the 
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transcription of pro-inflammatory cytokines, ROS can enhance the cleavage and 
subsequent release of mature cytokine by activating the NLRP3 
inflammasome.(30,81,286) Finally, oxidative stress from vascular NOX can exacerbate 
shock and local damage by causing endothelial dysfunction, which in turn leads to 
platelet activation, increased vascular permeability, and loss of vasoreactivity.(21,275) 
Therapies that either provide antioxidants or enhance endogenous antioxidant systems 
have been shown to decrease free radical damage, decrease inflammation, and improve 
organ function following hemorrhagic and septic shock.(22,68,187) 
SIRT1 plays a critical role in mitigating oxidant damage.  By deacetylating and 
activating forkhead box O3 (FOXO3), SIRT1 augments the transcription of key 
antioxidant enzymes such as superoxide dismutase and catalase.(128) SIRT1 can also 
enhance antioxidant defenses by increasing the activation and expression of PGC1α.  
Along with its co-regulator NRF2, PGC1α promotes increases the transcription of 
antioxidant genes including superoxide dismutase, heme oxygenase-1, and glutathione 
reductase.(226) Without SIRT1, however, the expression of these key antioxidants is 
significantly impaired and tissues are more susceptible to oxidant stress and cellular 
death. When subjected to ischemia-reperfusion injury, SIRT1 null hearts experienced 
considerably more tissue infarction and damage than wild-type controls. In contrast, 
SIRT1 transgenic hearts demonstrated substantially higher levels of superoxide 
dismutase and were more protected following ischemia-reperfusion, with less infarcted 
myocardium and better contractility.(105)  
SIRT1 AND MITOCHONDRIAL BIOGENESIS 
Mitochondria are subcellular organelles that utilize oxygen to create the majority of 
the available ATP via oxidative phosphorylation.  Any significant decrease in the 
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availability of oxygen, or perturbation in the electron transport chain, however, can lead 
to decreased ATP levels and cellular stress. As previously described, reperfusion of 
hypoxic tissues generates ROS, which, in turn, damages mitochondrial proteins and 
further impairs oxidative phosphorylation in key organs. During hemorrhagic and septic 
shock, arterial smooth muscle cells can also experience mitochondrial dysfunction 
leading to low ATP levels. As a result KATP channels in vascular smooth muscle beds 
open, leading to hyperpolarization, persistent hypotension, and on-going poor tissue 
perfusion.(254)   
Despite adequate resuscitation, persistent mitochondrial dysfunction may contribute 
to ongoing cellular injury and organ failure following shock.  In fact, patients who develop 
organ failure are more likely to demonstrate early evidence of mitochondrial dysfunction 
when compared to similarly injured patients.(33) Notably, septic patients also develop 
mitochondrial dysfunction despite fluid resuscitation and antibiotics.  When skeletal 
muscle biopsies were taken within 24 hours of ICU admission, non-surviving septic 
patients were found to have significantly decreased complex I activity and lower tissue 
ATP levels when compared to both sepsis survivors and healthy controls.  Moreover, the 
severity of septic shock directly correlated with decreased muscle ATP levels.(24) The 
ability to generate sufficient ATP maybe further compromised during sepsis by an overall 
decrease in mitochondrial mass.(34,35,232)  Indeed, patients with MOF were found to 
have 30 to 50% less mitochondrial protein in both intercostal and thigh muscle relative to 
non-septic controls.(70,71)  
SIRT1 promotes mitochondrial biogenesis and oxidative phosphorylation by 
activating PGC1α. In turn, PGC1α increases the transcription of mitochondrial proteins 
and enzymes by coactivating a number of transcription factors, including NRF1 and 2, 
ERRα, PPARα, and TFAM.  In fact, the overexpression of PGC1α leads to a pronounced 
7	  
	  
increase in mitochondrial mass in otherwise healthy mice.(205) Although PGC1α 
expression is increased during hypoxia and in response to ROS,(258) Raju and 
colleagues demonstrated that cardiac PGC1α levels fall dramatically in severe 
hemorrhagic shock and are associated with impaired mitochondrial function and 
recovery.(8,111,112) Resuscitation with the SIRT1 activator, resveratrol, preserved 
PGC1α protein levels and increased expression of key mitochondrial transcription 
factors.  Importantly, mitochondrial function was also enhanced and correlated with both 
improved cardiac contractility and better survival. When animals were co-treated with 
sirtinol, a SIRT1 antagonist, the mitochondrial benefits of resveratrol were entirely lost, 
suggesting that resveratrol’s ability to preserve PGC1α function is SIRT1 dependent. In 
a similar study, Biel et al found that SIRT1 null hepatocytes were significantly more likely 
to die than wild-type following ischemia-reperfusion. In contrast, genetic overexpression 
or pharmacological activation of SIRT1 significantly improved mitochondrial stability, 
suppressed defective autophagy, and decreased tissue damage.(18)  
SIRTUIN 3 (SIRTS)  
Although three sirtuins (SIRT3, SIRT4, and SIRT5), are located in the mitochondria, 
only SIRT3 functions as a deacetylase and there is growing appreciation that this sirtuin, 
in particular, plays a crucial role in regulating mitochondrial metabolism and oxidative 
stress.(1,89,97,250) In fact, in SIRT3 knock out mice, several enzymes in the Kreb’s 
cycle and multiple complexes in the electron transport chain are hyperacetylated, 
suggesting that SIRT3 may directly regulate their activity.(1,69,114)   
During calorie restriction, SIRT3 expression is enhanced and increased 
mitochondrial NAD serves as a potent stimulus for activation of SIRT3 pathways.(14,97) 
In response to a perceived energy deficit, SIRT3 coordinates a switch from glycolysis to 
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fatty acid oxidation.(97) Additionally, SIRT3 activates acetyl-CoA synthase 2 to increase 
levels of mitochondrial acetyl CoA and deacetylates hydroxyl methylglutaryl CoA 
synthase 2 to increase the production of ketone bodies, a key alternative fuel for the 
heart, kidney and brain.(88,215,260) Given the entry of acetyl CoA into the Kreb’s cycle 
is impaired during critical illness (138), activating SIRT3 pathways could provide an 
alternative means of supporting energy metabolism.  
SIRT3 serves as a major regulator of oxidative stress and can modulate both the 
generation and detoxification of ROS. Not only can SIRT3 can modulate the flow, and 
thus potentially the leak, of electrons through complexes I, II, and III, SIRT3 can 
deacetylate and down-regulate enzymes that form low levels of ROS such as pyruvate 
dehydrogenase, α-ketoglutarate dehydrogenase and aconitase.(1,14,69,209)  SIRT3 
also mitigates oxidative stress by directly activating the antioxidant enzyme manganese 
superoxide dismutase (SOD2) and by increasing the concentration of reduced 
glutathione through its interactions with isocitrate dehydrogenase 2, with a subsequent 
increase in NADPH levels.(191,221) While SIRT3 knockout mice appear phenotypically 
normal, these animals demonstrate evidence of impaired complex I function with 
increased oxidative damage, reduced tissue ATP levels, and markedly elevated levels of 
pro-inflammatory cytokines. Overexpression of SIRT3, on the other hand, rescues 
mitochondrial function and minimize oxidative damage.(1)   
Finally, there is increasing data to suggest that SIRT3 can prevent oxidant-induced 
apoptosis. During shock, damage from ROS can lead to mitochondrial membrane 
depolarization and activation of the membrane permeability transition pore 
(mPTP).(59,137,141) SIRT3 is known to deacetylate and stabilize cyclophilin D, a key 
component of the mitochondrial permeability transition pore (mPTP).  When subjected to 
calcium challenge, mitochondria from aged SIRT3 null mice were significantly more 
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prone to swelling; a phenomenon that was completely rescued by the mPTP inhibitor 
cyclosporine A.(87) Similarly, in a cisplatin induced acute kidney injury, SIRT3 
overexpression mitigated ROS-induced mitochondrial membrane depolarization and 
decreased autophagy.  
Although there are limited studies to date specifically investigating the role of SIRT3 
in either hemorrhagic or septic shock, SIRT3 appears play a vital role in mitigating 
inflammation, oxidant damage, and organ dysfunction.(284) Indeed, when the leukocyte 
gene expression profile in 172 blunt trauma patients presenting in hemorrhagic shock 
was investigated, the inability to increase SIRT3 expression was strongly associated 
with poor outcomes including infection, organ failure and death.(216)  
This thesis explores the hypothesis that sirtuin pathways play a crucial role in 
shock and could be could be targeted to improve outcomes. Using a model of 
decompensated hemorrhagic shock in rats, we investigated the impact of 
pharmacologically activating SIRT1 during resuscitation. Specifically, we found that that 
nicotinamide monononucleotide (NMN) supported cellular energetics and enhanced 
physiologic resilience following hemorrhagic shock. NMN is the immediate biosynthetic 
precursor to NAD, and thus, provides an essential cofactor for sirtuin activation (Chapter 
2). Similarly, we report that resuscitation with resveratrol, a naturally occurring SIRT1 
activator, significantly improves mitochondrial function and decreases oxidative damage 
(Chapter 3).  In separate and ongoing investigations, we explore the impact of 
manipulating SIRT1 and SIRT3 in a murine model of severe sepsis; noting that deletion 
of either sirtuin results in a pro-inflammatory phenotype with accelerated mortality 
(Chapter 4 and 5, respectively).    
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CHAPTER 2:  
Nicotinamide Mononucleotide (NMN), a Key NAD Precursor, Improves Cellular 
Metabolism and Physiologic Resilience in Hemorrhagic Shock 
INTRODUCTION  
Hemorrhagic shock is a physiologic condition that occurs with rapid blood loss and is 
characterized by profound vasoconstriction, tissue hypoperfusion, and cellular hypoxia.  
In response to decreased oxygen tension, there is a dramatic decline in oxidative 
phosphorylation with increased anaerobic metabolism in an attempt to preserve cellular 
energy status.(42) Without prompt and adequate resuscitation, hemorrhagic shock 
progresses from cellular dysfunction to organ failure and, ultimately, to death.(183) 
Nicotinamide adenine dinucleotide (NAD) is a ubiquitous molecule whose ability to 
accept and donate electrons via interconversion with NADH is key to cellular metabolism 
and energy generation.  NAD is required at the GAPDH-dependent step in glycolysis 
and provides reducing equivalents to complex I of the electron transport chain to drive 
oxidative phosphorylation.  NAD also serves as an essential co-substrate for a wide 
variety of enzymes involved in cellular resilience, including sirtuins and poly (ADP 
ribose) polymerases.(39) During hemorrhagic shock, the tissue concentration of NAD 
falls rapidly in proportion to the severity of the injury.(262) This decreased availability of 
NAD is further exacerbated by a redox shift in favor of NADH, which is no longer 
efficiently reoxidized to NAD by the mitochondrial electron transport chain under hypoxic 
conditions.(259) In other contexts, it is well established that NAD depletion leads to 
mitochondrial dysfunction and cell death (3,248) , and enhancing NAD has been shown 
to improve tissue function.(38,78,83) Given the central role that NAD plays in cellular 
energy metabolism, signaling, and a host of other biochemical reactions (39), 
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resuscitative strategies that restore NAD could prove therapeutically useful in 
hemorrhagic shock. 
While NAD can be synthesized de novo from dietary tryptophan, nicotinic acid 
(niacin), or from other intermediates in the synthesis pathways, the majority of cellular 
NAD comes from the recycling of liberated nicotinamide.  Nicotinamide is converted to 
nicotinamide mononucleotide (NMN) in a rate-limiting step catalyzed by the enzyme 
nicotinamide phophoribosyltransferase (NAMPT).  NMN is then converted to NAD by 
one of three NMN adenylyltransferase isoforms (NMNAT1-3).(16)  
Chaudry and colleagues first described using NAD precursors during the 
resuscitation of hemorrhagic shock in 1976.(44) Although the infusion of NAD, 
nicotinamide and nicotinic acid each increased NAD concentrations in both liver and 
kidney tissue, treatment did not restore tissue ATP levels and did not improve survival. 
As such, these investigators concluded that “these infusions have no salutary effects” 
and research investigating the impact of NAD metabolism during hemorrhagic shock 
remained relatively stagnant in the following decades.  However, it is possible that the 
minimal resuscitation protocol used in Chaudry’s pioneering experiments may have 
limited the potential benefit of NAD supplementation.  Indeed, recently, very high dose 
oral niacin (1080 mg/kg) has been shown to improve lung injury following hemorrhagic 
shock.(110) When given at the time of resuscitation, niacin restored lung NAD 
concentrations to baseline values, mitigated inflammation, and transformed a uniformly 
lethal model into one with 30% survival. Thus, the use of NAD precursors such as NMN 
warrants further investigation. 
Although the benefit of NMN supplementation has not been investigated in trauma, 
there is a growing body of literature to suggest that NMN could prove therapeutically 
useful.  Providing exogenous NMN bypasses the need for NAMPT in the salvage 
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pathway and has been shown to increase tissue NAD rapidly.(270) This is particularly 
important given the fact that NAMPT may be suppressed in the setting of ischemia-
reperfusion and depressed NAMPT activity could contribute to the decreased NAD 
observed in hemorrhagic shock.(104) Moreover, the NAMPT-catalyzed reaction is 
energetically costly, and thus providing its product directly could be especially helpful 
when cells are energetically stressed.(31)  Importantly, there is evidence that NMN can 
acutely mitigate the effects of ischemia-reperfusion injury.  In a murine model of cardiac 
infarction, pretreatment with NMN 30 minutes before ischemia significantly increased 
basal levels of NAD, prevented a decline in NAD post-ischemic insult, and reduced 
infarct size.(266) As such, using NMN as resuscitative adjunct to support metabolism 
could improve cellular resilience. 
In this study, we investigate the metabolic and mitochondrial impact of exogenous 
NMN on hemorrhagic shock. Our findings suggest that NMN preserves oxidative 
phosphorylation, enhances physiologic reserve, and improves survival after severe 
shock. 
RESULTS  
Pretreatment and resuscitation with NMN during fixed pressure hemorrhagic 
shock reduces lactic acidosis  
To investigate the physiologic impact of NMN during hemorrhagic shock and 
resuscitation, we subjected NMN pretreated rats (400mg/kg/day X 5 days, oral) and 
controls to a fixed pressure shock followed by resuscitation with and without NMN (400 
mg/kg, intravenous) (Figure 3A).  NMN and control animals were maintained at a mean 
arterial blood pressure (MAP) of 40 mmHg for 90 minutes.  Both groups shed a similar 
percentage of blood volume and had similar reductions in circulating hemoglobin (Figure 
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3B, E). Although the volume of fluid required to maintain the shock state for 90 minutes 
and the blood pressure following resuscitation were statistically indistinguishable 
between the groups, NMN treated rats received slightly less volume overall, indicating 
that they were not resuscitated more completely than controls (Figure 3C,D). 
Importantly, despite experiencing the same degree and duration of blood loss, NMN 
treated rats had significantly lower serum lactate than did controls during hemorrhagic 
shock and resuscitation (Figure 3E). As a byproduct of anaerobic metabolism, elevated 
lactate levels reflect ongoing tissue hypoperfusion and correlate with both the severity 
and survivability of shock.(196) Moreover, lactate is used to gauge the success of 
resuscitation in humans.(27) Thus, our findings suggest that NMN partially mitigates a 
key metabolic derangement induced by hemorrhagic shock.  
NMN increases NAD and preserves bioenergetics 
Hemorrhagic shock results in significantly depressed pyridine and adenine 
nucleotide pools, which can negatively impact the function of vital organs.(43)  We 
tested whether exogenous NMN could preserve NAD and ATP levels in kidney and liver 
tissues following shock. In sham animals, NMN significantly increased NAD levels in 
both kidney and liver (Figure 4A, 2B). Following shock, NAD levels were nearly 3 fold 
higher in NMN treated animals compared to shock control animals.  NADH was also 
significantly higher in NMN treated animals following shock.  While the decline in NAD 
during hemorrhagic shock was less dramatic than in previous reports(44), we observed 
robust depression of the NAD/NADH ratio (Figure 4A, B). Importantly, NMN completely 
mitigated the decrease in NAD concentration and the NAD/NADH redox ratio in both 
tissues.  
Hemorrhagic shock and resuscitation are also known to deplete ATP reserves, likely 
as a consequence of mitochondrial dysfunction, which results in increased reliance on 
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anaerobic metabolism.  As expected, ATP levels were significantly decreased following 
shock and resuscitation in both kidney and liver (Figure 4C). NMN treatment 
substantially rescued ATP levels in the kidney, whereas liver stores were more 
depressed and could not be restored (Figure 4C).  
NMN preserves NAD dependent mitochondrial respiration  
Given the restoration of ATP in kidney and decrease in lactate accumulation, we 
wondered if NMN treatment could positively impact mitochondrial respiration.  We found 
that hemorrhagic shock and resuscitation impaired complex I (CI)-dependent respiration 
in both tissues when fatty acids or a standard pyruvate/glutamate/malate mixture were 
provided as substrates (Figure 5A, B).  No defect was apparent when electrons were 
supplied directly to complex II via succinate or to complex IV via TMPD/ascorbate.  
Since CI accepts electrons from NADH, these results suggest a deficiency in the NAD 
pool, an upstream factor involved in the generation of NADH, or in CI itself.  Consistent 
with the possibility that NAD(H) is the limiting factor, treatment with NMN completely 
preserved CI-dependent respiration following hemorrhagic shock (Figure 5A,B).  
To more directly test the hypothesis that mitochondrial NAD depletion causes the 
defect in CI-dependent respiratory capacity, we next sought to determine NAD levels in 
isolated mitochondria following shock.  To our knowledge, the mitochondrial NAD pool, 
which is separate from the nuclear and cytosolic pool,(267) has not previously been 
examined in hemorrhagic shock.  Although NMN significantly increased mitochondrial 
NAD in both kidney and liver, we were surprised to discover that hemorrhagic shock did 
not decrease mitochondrial NAD.  In fact, in contrast to whole tissue NAD, mitochondrial 
levels were maintained in kidney (Figure 5C) and significantly increased in the liver of 
control animals following shock (Figure 5D).  NMN treatment further augmented 
mitochondrial NAD concentrations (Figure 5C, D).  Thus, the size of the mitochondrial 
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NAD pool per se cannot account for the changes in mitochondrial respiration.  NADH 
was not reproducibly detected in isolated mitochondria, most likely due to collapse of the 
redox potential during isolation. 
NMN and hemorrhagic shock influence the expression of enzymes in the NAD 
salvage pathway  
To better understand the impact of hemorrhagic shock on total and mitochondrial 
NAD levels, we examined the expression patterns of enzymes in the NAD salvage 
pathway. Metabolic stress influences the expression of NAMPT and increasing NAMPT 
can mitigate ischemic injury in a variety of models.(104,199,238,266) The expression of 
NAMPT and the downstream enzymes NMNAT1-3, however, have not previously been 
examined in hemorrhagic shock.  Following shock, there was a trend toward increased 
NAMPT gene expression in both kidney and liver (Figure 6A,E).  Of the three NMNAT 
isoforms, NMNAT1 (nuclear) and NMNAT3 (putatively mitochondrial) were readily 
detected while NMNAT2 (which has been reported in the Golgi complex and axons) was 
not.(16)  Hemorrhagic shock and resuscitation had minimal impact on the renal 
expression of NMNAT1, but modestly increased expression of NMNAT3.  In contrast the 
expression of both enzymes was reduced in liver tissue (Figure 6 C, D, G, H).  Although 
NMN had no effect on NAMPT or NMNAT gene expression in sham operated rats, it 
enhanced the gene expression of both NAMPT and NMNAT3 relative to controls 
following hemorrhagic shock (Figure 6A,D,E,H).  Shock, however, was not associated 
with any clear change in NAMPT protein expression at the end of resuscitation (Figure 
6B,F).  These results indicate that NMN can influence NAD metabolism in part via 
enzyme expression independently from its direct contribution to synthesis. 
NMN mitigates inflammation following hemorrhagic shock and resuscitation  
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Hemorrhagic shock and resuscitation results in a pro-inflammatory state 
characterized by elevated cytokine levels, oxidative stress, and insulin resistant 
hyperglycemia. Circulating levels of IL6, a pro-inflammatory cytokine, strongly correlate 
with mortality and directly targeting IL6 improves survival, suggesting that inflammation 
mediated by this pathway is highly relevant to the pathological effects of hemorrhagic 
shock.(165,227) Given the key role that NAD plays in modulating sirtuin-dependent 
inflammatory pathways,(150) we hypothesized that NMN might dampen the 
inflammatory response following hemorrhagic shock and resuscitation.  Indeed, 
pretreatment and resuscitation with NMN significantly reduced systemic IL6 cytokine 
levels and tended to decrease TNFα, while substantially ameliorating shock-induced 
hyperglycemia (Figure 7A, B).  Interestingly, basal TNFα was significantly reduced in 
sham-treated animals, suggesting that NMN can have a potent effect on this pathway, 
although the repression was largely overcome during shock. At the tissue level, NMN 
also significantly improved the post-resuscitation cytokine profile in the kidney (Figure 
7C).  Whether these changes in gene expression reflect immune cell infiltration or the 
activation of inflammatory pathways in resident cells is not yet clear. In contrast, NMN 
had no impact on the induction of inflammatory genes in liver (Figure7D).  
NMN improves mitochondrial function in isolated hepatocytes 
Because NMN improves the inflammatory status, its beneficial effects on 
mitochondrial function may be secondary to either decreased inflammation or direct 
protective effects in targets tissues.  In order to determine whether NMN directly impacts 
cellular mitochondrial function, we exposed primary hepatocytes to plasma harvested 
from both sham and shocked rats.  Consistent with the hypothesis that circulating 
inflammatory factors can induce mitochondrial dysfunction, primary hepatocytes treated 
with shocked plasma had significantly depressed CI-dependent respiration.  When 
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hepatocytes were co-cultured with NMN, however, this CI defect was completely 
prevented (Figure 8A). 
Given that plasma from shocked and sham animals may have varying concentrations 
of many different pro-inflammatory cytokines, we also treated primary hepatocytes with a 
fixed concentration of IL6.  In these experiments, co-treatment with NMN again 
completely prevented mitochondrial dysfunction (Figure 8B).  Thus, NMN can preserve 
mitochondrial function in a cell-autonomous manner, although the reduction in circulating 
IL6 also likely contributes to its net benefit in vivo. 
Interestingly, treatment with IL6 did not significantly impact NAD levels in our primary 
hepatocytes. With the addition of NMN, however, cytokine exposed cells nearly doubled 
their NAD over baseline suggesting that inflammation enhances either NMN uptake or 
the enzymatic activity of NAD biosynthesis pathways, or decreases NAD turnover 
(Figure 8C).(206) 
The impact of NMN on organ function  
In order to determine if NMN preserved organ function, blood samples were taken 
from sham and shocked animals at the end of resuscitation and assayed for markers of 
liver, kidney and cardiac dysfunction.  Although hemorrhagic shock and resuscitation 
resulted in a significant increase in markers of liver and kidney damage, values 
remained within the normal range with only a trend toward decreased injury in NMN 
treated animals (Table 1).  The fact that these injury markers remained relatively low is 
likely a reflection of the early time point examined.  Even at this early time point, 
however, hemorrhagic shock and resuscitation was associated with an increased in 
creatine kinase activity that was mitigated by NMN.  Creatine kinase levels can result 
from either skeletal or cardiac muscle damage. Acute blood loss does not generally lead 
to skeletal muscle damage in the absence of crush injury and is associated more 
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strongly with cardiac injury.(118)  Thus, NMN may have cardioprotective effects that 
warrant further investigation in this model. 
NMN enhances physiologic reserve and decreases mortality  
Based on improvements in inflammatory status, lactate metabolism, mitochondrial 
function, and trends toward decreased injury biomarkers, we hypothesized that NMN 
would enhance physiologic reserve and improve survival following hemorrhagic shock.  
Using a decompensated shock model, we performed a second set of experiments to 
evaluate physiologic reserve, as indicated by the overall time animals could be 
maintained in severe shock without resuscitation (Figure 9A).  Pretreatment with NMN 
increased the time animals could sustain severe shock by nearly 25%, despite equal or 
greater blood loss when compared to controls (Figure. 9B, C).  In spite of enduring this 
more strenuous injury, animals treated with NMN maintained lower lactate levels and 
exhibited improved survival (Figure 9D,F).  As such, pre-treatment and subsequent 
resuscitation with NMN substantially improved the ability of rats to tolerate hemorrhagic 
shock. 
DISCUSSION  
In the United States, traumatic injury is the leading cause of death in those under the 
age of 45, with nearly 40% of patients who develop hemorrhagic shock dying within the 
first 24 hours.(93,122) Because both the severity of blood loss and duration of 
hypoperfusion correlate directly with organ failure and mortality, current resuscitative 
strategies focus on rapidly repairing the injury, restoring blood volume and improving 
perfusion pressure.  If the shock state is too severe or prolonged, however, cellular 
metabolism remains depressed and resuscitation efforts fail to improve clinical 
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outcomes.  Developing therapies to restore and support cellular metabolism following 
hemorrhagic shock could potentially mitigate organ dysfunction and improve survival.  
During prolonged hypoperfusion there is a dramatic decline in NAD availability due to 
both a reduction in the size of the NAD pool as well as a shift toward the reduced form 
(NADH).  Given the essential roles that NAD plays in glycolysis, oxidative 
phosphorylation, and pathways that promote cellular resilience, we investigated the 
possible benefit of using NMN to restore NAD levels as a treatment for hemorrhagic 
shock.(41,172,270)  We specifically focused on the impact on bioenergetics in kidney 
and liver because these organs are at a high risk of failure following acute blood 
loss.(15,91)  Pretreatment and subsequent resuscitation with NMN increased NAD 
levels, restored the NAD/NADH ratio, improved mitochondrial function and mitigated 
inflammation.  Importantly, NMN also enhanced whole organism physiologic resilience 
during hemorrhagic shock and improved survival following resuscitation.  As such, NMN 
holds promise as a therapeutic adjunct and warrants further clinical investigation. 
One of the most prominent metabolic effects of using NMN to restore NAD was the 
improvement in mitochondrial function.  During hemorrhagic shock, there is a 
progressive defect in mitochondrial respiration when NAD-linked substrates such as 
isocitrate, α ketoglutarate and β hydroxybutyrate are used, suggesting that severe blood 
loss preferentially inhibits complex I.(42,193)  Although NMN has been shown to 
improve overall mitochondrial respiratory capacity in chronic models of aging and 
Alzheimer’s disease,(153,167) our research provides the first data demonstrating NMN 
completely preserves CI-dependent mitochondrial respiration following hemorrhagic 
shock.  We initially hypothesized that this rescue was secondary to NMN’s ability to 
mitigate a decline in mitochondrial NAD.  Our data, however, do not support this 
hypothesis. In fact, in contrast to the decline in total tissue NAD that we observed, 
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mitochondria harvested from control animals actually had preserved or increased levels 
of NAD following hemorrhagic shock.  Mitochondrial NAD levels were further enhanced 
in NMN treated animals.  Although surprisingly little is known about the concentration of 
mitochondrial NAD following hemorrhagic shock, our findings do support Hift and 
Strawitz’s description of increased “light absorbing material” in isolated liver 
mitochondria harvested from dogs in “irreversible hemorrhagic shock”.  Writing in 1961, 
these investigators attributed the increased spectrophotometric absorption peak noted at 
265 to 270mµ to “nucleotide material”.(94)  In retrospect, this likely represented NADH, 
with a UV absorption peak of 259 nm.  Although the precise mechanisms accounting for 
the generation and maintenance of the mitochondrial NAD pool remain a subject of 
debate, the finding of increased mitochondrial NAD suggests either augmented 
cytoplasmic to mitochondrial transfer or enhanced mitochondrial NAD recycling.(39)  In 
either case, the ability to increase mitochondrial NAD following hemorrhagic shock may 
reflect an adaptive response to cellular stress, and suggests that the depletion of 
cytosolic NAD may be even greater than indicated by bulk tissue measurements. 
Given the fact that mitochondrial NAD levels are preserved during hemorrhagic 
shock, there must be another mechanism by which NMN benefits mitochondrial function.  
CI is prone to oxidant damage and dysfunction, but can be rescued with the induction of 
antioxidant defenses.(40,84,173,182,228)  Increasing nuclear/cytosolic NAD has been 
shown to modulate the response to cellular stress by up-regulating anti-inflammatory 
and anti-oxidant pathways.(211)  In particular, SIRT1 uses NAD as an obligatory co-
substrate to deacetylate the RelA/p65 subunit of NFκB in macrophages leading to 
decreased expression of pro-inflammatory cytokines such as IL6 and TNFα.(207)  SIRT1 
may also decrease the damage associated with ischemia-reperfusion by deacetylating 
and activating PGC1α.  In turn, PGC1α increases the expression of antioxidant enzymes 
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as well as SIRT3, a mitochondrial NAD-dependent deacetylase that mitigates 
mitochondrial oxidative stress by directly activating isocitrate dehydrogensase 2 and 
manganese superoxide dismutase.(191,277)  In support of a potential role for SIRT1, we 
and others have shown that resuscitation with resveratrol, a SIRT1 activator, improves 
mitochondrial function, attenuates inflammation, mitigates oxidant damage, and 
improves organ function following hemorrhagic shock.(8,188,252,253)  Similarly, Jeung 
et al demonstrated that high dose oral niacin (another NAD precursor and SIRT1 
activator) attenuates systemic inflammation and is associated with decreased pulmonary 
NFkB expression and oxidative stress in a rodent model of hemorrhagic shock.  In this 
study, NMN mitigated both the systemic and tissue specific inflammatory response.(110)  
Importantly, changes in systemic inflammation were not purely responsible for improved 
mitochondrial function because NMN also preserved CI-dependent mitochondrial 
respiration in permeabilized hepatocytes exposed to a controlled dose of inflammatory 
cytokines. Thus, NMN also appears to have a cell-autonomous anti-inflammatory impact.  
Interestingly, while NMN rescued NAD levels and mitochondrial function in both 
kidney and liver, it only preserved ATP in the kidney. The total amount of ATP, however, 
is influenced by both production and consumption. During hemorrhagic shock, ATP 
consumption is significantly decreased in the kidney because hypotension leads to 
decreased glomerular filtration and thus a decreased need for ATP dependent resorption 
in the distal nephron.  In contrast, ATP consumption in liver actually escalates during 
hemorrhagic shock because increased sodium influx requires increased Na+-K+ 
ATPase activity.(9) Thus, failure to rescue ATP in the liver may not reflect a tissue 
difference in how NMN impacts mitochondrial function, but rather a difference in the 
degree of energetic stress experienced by these two tissues during shock. 
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Very little is known about the NAD salvage pathway in hemorrhagic shock. We 
wondered if decreased expression of either NAMPT or NMNAT contributed to the NAD 
depletion during shock, or alternatively, whether any compensatory response would be 
present.  Although ischemia-reperfusion injury decreases NAMPT expression in cardiac 
myocytes,(104) hemorrhagic shock appears to increase the expression of NAMPT 
mRNA in liver and tended to increase it in kidney.  Surprisingly, NMN supplementation 
further enhanced NAMPT mRNA expression in both tissues following resuscitation, but 
not in sham NMN treated controls.  We were also interested in determining if the 
expression of NMNAT1-3 changed following hemorrhagic shock. NMNAT2 was not 
reliably detected, but we were able to quantify transcripts for NMNAT1 and NMNAT3, 
which convert of NMN to NAD in the nucleus/cytoplasm and mitochondria respectively.  
Both NMNAT1 and NMNAT3 were suppressed with shock in the liver, suggesting that 
NAD biosynthetic capacity may be decreased in this organ during acute blood loss.  In 
contrast, NMNAT1 was not affected and NMNAT3 was increased in the kidney.  
Intriguingly, NMN enhanced NMNAT3 expression following shock in both organs.  The 
induction of transcripts related to NAD biosynthesis, particularly when precursors are 
available, likely reflects an adaptive response to cellular stress and may explain why our 
isolated hepatocytes only dramatically increased NAD in the presence of both IL6 and 
NMN.(267)  Thus, hemorrhagic shock leads to organ-specific changes in the expression 
of genes related to NAD biosynthesis, and we reveal that in the setting of severe injury, 
the direct contribution of NMN to the NAD pool may be augmented by the induction of 
biosynthetic enzymes. 
While encouraging, our study has a number of limitations.  First, we investigated 
pretreating and subsequently resuscitating hemorrhagic shock with NMN.  This 
approach suggests that NMN may be useful when significant surgical blood loss (e.g. 
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cardiac or vascular surgery) or traumatic injury is anticipated (e.g. combat).  However, it 
will be important to determine whether NMN can be used post-injury to treat unexpected 
bleeding events or trauma.  We are currently planning experiments to test the benefit of 
using NMN only during resuscitation and are encouraged by recent data from Yamamoto 
et al demonstrating that NMN limits myocardial ischemia when given during 
reperfusion.(266)   Second, we did not investigate the optimal duration of therapy. This is 
particularly important because the duration of increased NAD and the timing of SIRT1 
activation may influence how acute inflammation progresses to a more chronic hypo-
inflammatory state.(150)  Finally, although we did see a trend toward improved organ 
function following hemorrhagic shock in NMN treated animals, studying early changes in 
mitochondrial function required sacrificing rats at a time point that was not optimal for 
these assays; future studies over an extended time course may strengthen these 
findings.  
Together, our findings suggest that NMN holds significant promise as an adjunct to 
resuscitation.  In our severe hemorrhagic shock model, NMN supported cellular 
metabolism by increasing tissue NAD levels, preserving the cellular redox ratio, and 
enhancing CI-dependent mitochondrial respiration.  NMN also appeared to have anti-
inflammatory properties, blunting both the systemic inflammatory response as well as 
the cellular effects of cytokine exposure.  Importantly, NMN’s biochemical and 
immunologic benefits translated to improved physiologic resilience.  NMN treated 
animals were able to tolerate longer periods of hypoperfusion with improved survival.  
Given these encouraging preclinical findings, future research investigating NMN’s 
therapeutic potential in injured patients is warranted.  
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CHAPTER 3:  
Resveratrol Improves Mitochondrial Function but Increases the Risk of 
Hypoglycemia Following Hemorrhagic Shock 
Hemorrhagic shock remains a common cause of death in severely injured patients with a 
significant number of deaths occurring as the result of multi-organ failure (MOF) days to 
weeks after the initial injury.(168,240)  Because impaired tissue oxygen delivery and 
depletion of cellular energy stores during traumatic clearly contribute to the development 
of MOF and early mortality in trauma patients,(61,170,171) current resuscitation 
strategies focus on replacing circulating blood volume in an attempt to restore adequate 
tissue perfusion. 
While re-establishing tissue oxygenation is clearly vital, there is increasing evidence 
to suggest that mitochondrial dysfunction also plays a significant role in the development 
of MOF.(120,129)  Under normal physiologic conditions, mitochondria provide almost 
95% of the available adenosine triphosphate via oxidative phosphorylation; and oxygen 
utilization by the mitochondrial electron transport system is tightly coupled to oxygen 
availability.(115)  “Decoupling” can occur, however, when mitochondrial complexes are 
modified or there is decreased availability of NADH leading to decreased electron 
flow.(4)  Decoupling not only results in decreased ATP production, it is associated with 
the generation of damaging free radical oxygen species.(107)  With prolonged 
hemorrhagic shock, there is a progression from decreased oxidative phosphorylation to 
irreversible, structural damage to the mitochondria.(214,234)  With resuscitation 
previously hypoxic mitochondria cannot effectively transfer electrons; resulting in a 
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deluge of reactive oxygen species (ROS) upon reperfusion and increased damage to 
mitochondrial proteins.(57)   
Importantly, mitochondrial dysfunction persists even if adequate tissue oxygen and 
perfusion are restored.  Using near-infrared spectroscopy (NIRS) in an a rabbit model of 
severe hemorrhagic shock, Rhee et al noted that despite normalization of blood 
pressure, cardiac output and tissue oxygen delivery, mitochondrial cytochrome a,a3 
oxidation remained significantly decreased in splanchnic and skeletal muscle beds.(192)  
In a similar experiment, decoupling of the hepatic cytochrome a,a3 redox state from 
oxygen delivery was associated with increased early mortality following hemorrhagic 
shock.(32)  Clinically, shock-induced mitochondrial dysfunction has also been linked to 
the development of MOF.  In a prospective study of 24 severely injured patients 
monitored continuously with NIRS, Cairns et al noted that patients who developed MOF 
demonstrated a significantly higher incidence of mitochondrial decoupling early in the 
course of their resuscitation when compared to those who did not develop organ 
dysfunction (89% vs 13%, p<0.05).(33)  
Mitochondrial dysfunction also contributes to the phenomenon of post-injury 
hyperglycemia. In addition to damaging proteins, ROS can influence insulin signaling by 
directly oxidizing the insulin receptor or indirectly by activating various protein tyrosine 
phosphatases.(47)  Importantly, the development of post-injury insulin resistance and 
hyperglycemia can be minimized by blocking the production of ROS.(280)  Because 
hyperglycemia is an independent risk factor for adverse outcomes, including renal failure 
and death in trauma patients,(135,169) resuscitation strategies that either mitigate 
mitochondrial dysfunction or improve glycemic control could prove beneficial. 
Resveratrol, a naturally occurring polyphenol found in red wine, has been shown to 
promote mitochondrial function, reduce oxidative damage, and improve glycemic control 
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in a variety of disease states.(134,154,243)  Although many of resveratrol’s biological 
effects are thought to be mediated by SIRT1 – a highly conserved NAD-dependent 
deacetylase, its mechanism as a direct SIRT1 activator has been called into 
question.(13,20,116,178)  In previous studies evaluating resveratrol, fluorophore-tagged 
substrates were used to assess SIRT1 activity.  However, when non-tagged peptides 
were used, SIRT1 activity was not enhanced, suggesting that resveratrol may be binding 
to the unnatural fluorophore.(116,178)  More recently, however, the Sinclair group 
investigated the relationship between resveratrol, and other sirtuin activating compounds 
(STACs), using non-fluorescent techniques.  In addition to discovering that resveratrol 
allosterically interacts with specific hydrophobic motifs shared by SIRT1 substrates, they 
found that a glutamine in SIRT1’s N-terminal domain was essential for activation.(106)  
Resveratrol allosterically lowers the Km for binding peptide substrates and NAD, thereby 
increasing SIRT1’s activity nearly 10 fold even when SIRT1 and NAD levels are limited. 
Resveratrol can also enhance SIRT1 by activating AMPK (12,279) which in turn 
enhances the expression of nicotinamide phosphoribosyltransferase (NAMPT), the rate-
limiting enzyme in the NAD salvage pathway.(74)   
Although there is a growing body of literature to suggest that resveratrol significantly 
reduces inflammation and mitigates organ dysfunction in rodent models of hemorrhagic 
shock (111,239,273,276), there is little data regarding its impact on mitochondrial 
function or glucose regulation following acute blood loss.  Given resveratrol’s interaction 
with SIRT1 can promote mitochondrial function a number of ways (Figure 2) 
(198,205,226), we hypothesized that resuscitation with resveratrol would ameliorate 
shock-induced mitochondrial dysfunction and improve hyperglycemia. 
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RESULTS 
Physiologic and laboratory parameters 
In contrast to previous studies, resuscitation with resveratrol (RSV) did not 
significantly improve the mean arterial blood pressure (MAP) in our model (8). In fact, 
blood pressure during the 18 hours post-resuscitation remained significantly lower than 
baseline values in both groups (Figure 10A).  As expected, our model of decompensated 
hemorrhagic shock did result in severe lactic acidosis as well as a significant anemia 
given the crystalloid-only resuscitation (Figure 10B, Table 2).(222)  Nonetheless, when 
compared to lactated Ringer’s (LR) alone, resuscitation with LR+RSV resulted in 
significantly less lactate production (10.2 ± 3.0 vs. 6.9 ± 3.3mmol/L, p< 0.05).  At 18 
hours, lactate levels in both groups had normalized.  Although clinical assays of acute 
kidney injury (AKI), such as BUN and creatinine, were not elevated above normal values 
in either group post resuscitation, resveratrol did significantly decrease in serum 
neutrophil gelatinase-associated lipocalin (NGAL) levels (Table 2). NGAL is a 25kd 
protein that is covalently bound to matrix metalloproteinase 9 in neutrophils.  Following 
epithelial injury, the expression of NGAL is markedly induced and appears to be a more 
sensitive biomarker for AKI than serum creatinine.(54,98)  Elevations in NGAL precede 
changes in serum creatinine and can be used to diagnose AKI up to 48 h prior to a 
clinical change in creatinine or urine output.  Given this sensitivity, changes in NGAL are 
thought to reflect AKI in real time, and following NGAL levels may allow for the institution 
of earlier, and more effective, renoprotective therapies.(98)   
While previous studies have reported that resveratrol significantly decreases IL6 in 
various tissues following hemorrhagic shock(239,261,272,273), only one has reported a 
decrease in serum TNFα.(111)  In our study, we did not appreciate a significant 
decrease in serum levels of either TNFα or IL6.  Given that tissue cytokines can 
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contribute to local damage, it is possible that we may have observed more of a 
significant difference had we directly assayed renal tissue.  
Resveratrol supplementation during resuscitation restored mitochondrial function 
following hemorrhagic shock and decreased mitochondrial ROS production. 
Using high-resolution respirometry, we observed that hemorrhagic shock significantly 
decreased the respiratory capacity of all mitochondrial complexes in both kidney and 
liver (Figure 11A,B).  Following resuscitation, resveratrol significantly improved CII and 
CIV-dependent respiratory capacity in the kidney and robustly restored the respiratory 
capacity of all complexes in liver.  Notably, resveratrol was associated with sustained 
improvement in respiratory capacity 18 hours post-resuscitation.  resveratrol 
supplementation also significantly decreased mitochondrial ROS production following 
resuscitation (Figure 11C, D). Although treatment with resveratrol continued to mitigate 
ROS production in the liver 18 hours post-resuscitation, the generation ROS in the 
kidney normalized by 18 hours and levels did not differ between resuscitation strategies. 
Resveratrol treatment during resuscitation ameliorated mitochondrial oxidative 
stress following hemorrhagic shock and resuscitation 
Resuscitation with resveratrol resulted in a significant increase in the mRNA 
expression of superoxide dismutase 2 (SOD2) and catalase (CAT) in kidney tissue when 
compared to resuscitation with LR alone (Figure 12B).  In contrast, severe hemorrhagic 
shock was associated with a marked increase in the expression of cyclooxygenase 2 
(COX-2) mRNA that was not influenced by either resuscitative strategy (Figure 12A). 
Oxidative damage to mitochondrial proteins increased dramatically following severe 
hemorrhagic shock and improved with resveratrol treatment during resuscitation.  4-
hydroxynonenal, a measure of lipid peroxidation from reactive oxygen species, 
increased robustly following severe shock (Figure 12B).  Resveratrol supplementation 
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significantly ameliorated the degree of lipid peroxidation observed.  We also measured 
the degree of nitrosative stress.  While 3-nitrotyrosine levels increased with LR 
resuscitation, resveratrol was not associated with a significant improvement in nitrosative 
stress when compared to LR (Figure 12C). 
Resveratrol supplement increased the mRNA expression of SIRT1 and the 
NAD/NADH ratio in kidney 
Severe shock resulted in a dramatic decline in the mRNA expression of SIRT1. 
Resuscitation with resveratrol, however, restored expression of SIRT1 to the levels seen 
in the sham group (Figure 13A).  Although hemorrhagic shock and subsequent 
resuscitation with LR alone did not significantly alter NAD or NADH concentrations, 
resuscitation with resveratrol significantly decreased tissue NADH levels (160.6 ± 21.3 
vs. 265.7 ± 24.5 nmol/mg protein) and nearly doubled the NAD/NADH ratio (Figure 13B). 
Resuscitation with resveratrol enhances pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase activity following hemorrhagic shock  
Hemorrhagic shock is known to decrease the activity of key enzymes in the Krebs 
cycle including pyruvate dehydrogenase.(42)  In order to determine if resveratrol 
enhanced the activity of Krebs cycle enzymes, we measured the rate of NAD conversion 
to NADH spectrophotometrically.  As expected, after hemorrhagic shock, the activity of 
all enzymes measured decreased significantly in the kidney (Figure 14). Resuscitation 
with resveratrol, however, robustly enhanced the activity of pyruvate dehydrogenase and 
α-ketoglutarate dehydrogenase.  Future experiment will determine if this improved 
activity is associated with a change in acetylation status.   
Resveratrol increased transcription of PGC1-α in kidney, but did not promote 
mitochondrial biogenesis 
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To gain further insight into the potential impact of resveratrol on mitochondrial 
biogenesis following hemorrhagic shock, we evaluated citrate synthase activity as a 
proxy for mitochondrial content in the kidney, but did not observe a significant change at 
any time point (Figure 15A).  We also investigated the expression of mitochondrial 
transcriptional regulators including PGC1α.  Notably, while the mRNA expression of 
PGC1α was significantly elevated in the resveratrol L resuscitation group, resveratrol did 
not restore the expression of mitochondrial transcription factor A (TFAM) (Figure 15B).  
Interestingly, the expression of nuclear respiratory factor (NRF) -1 was not significantly 
altered by either hemorrhagic shock or by resuscitation, whereas resuscitation 
significantly up-regulated the expression of NRF-2 regardless of strategy.  
Resveratrol significantly lowered blood glucose and improved insulin resistance 
following resuscitation, but was associated with decreased serum insulin levels 
As previously described (280), hemorrhagic shock resulted in severe hyperglycemia, 
hyperinsulinemia, and increased insulin resistance.  Notably, resuscitation with 
resveratrol lead to a significant reduction in blood glucose that persisted up to 90 
minutes post-resuscitation (Figure 16A).  In fact, resveratrol was associated with glucose 
levels that were significantly lower than sham operated animals with roughly 33% of the 
resveratrol animals developing true hypoglycemia (glucose < 70mg/dl).  No animal in 
any other group developed such low glucose levels. By 18 hours, the hypoglycemia had 
resolved and groups were not significantly different.   
Although resveratrol resulted in lower glucose levels, this was not caused by an 
increase in insulin secretion. In fact, following resuscitation, resveratrol treated animals 
had significantly lower serum insulin levels as well as improved insulin resistance as 
measured by the Ln HOMA-IR index.(113)  All glycemic parameters, however, were 
similar between treatment groups 18 hours post resuscitation (Figure 16A-C). 
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Resveratrol increases plasma glucagon-like peptide-1 (GLP-1) levels following 
resuscitation 
Decompensated hemorrhagic shock resulted in significant hyperglycemia and was 
accompanied by elevated glucagon and corticosterone levels (Figure 16F, G).  
Glucagon-like peptide-1, a gut-derived hormone known to enhance insulin secretion in 
response to glucose, was also elevated (Figure 16E).  Interestingly, when compared to 
resuscitation with LR, resveratrol supplementation resulted in significantly higher levels 
of GLP-1 (Figure 16E).  Resveratrol did not significantly influence either glucagon or 
corticosterone secretion; and at 18 hours, all hormone levels were similar regardless of 
resuscitation strategy. 
Resveratrol supplementation preserved the active form of IRS1 in both liver and 
kidney tissues 
Insulin receptor substrate-1 (IRS1) plays a key role in insulin signaling pathways and 
is activated upon tyrosine phosphorylation (pY612 IRS1).  Following resuscitation with 
LR, the expression level of pY612 IRS1 in liver and kidney tissue was significantly 
reduced and could contribute to post-injury hyperglycemia.  Resveratrol, however, 
preserved the expression of phosphorylated IRS1 immediately post-resuscitation (Figure 
17A,B).  At 18 hours, however, the expression level of pY612 IRS1 did not differ 
between treatment strategies. 
DISCUSSION  
Resveratrol, a naturally occurring polyphenol with known antioxidant, anti-
inflammatory, and anti-glycemic properties, has been shown to be protective in various 
models of human disease.(111,244,274)  Given hemorrhagic shock is frequently 
complicated by mitochondrial dysfunction, exuberant ROS production, and 
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hyperglycemia, we hypothesized that adding resveratrol to standard fluid resuscitation 
would prove beneficial.(120,280)  In our model of decompensated hemorrhagic shock, 
resveratrol supplementation significantly ameliorated mitochondrial dysfunction, 
decreasing both the production of mitochondrial ROS and the subsequent damage from 
lipid peroxidation.  Resveratrol also decreased serum glucose levels and improved 
insulin sensitivity by enhancing GLP-1 secretion and by preserving IRS1 
phosphorylation.  Finally, our data suggests that resveratrol benefits mitochondrial 
function in the acute setting, not by promoting mitochondrial biogenesis, but by activating 
SIRT1 and PGC1α-mediated antioxidant pathways. 
Currently, the initial approach to treating hemorrhagic shock is volume replacement 
with crystalloid fluids in order to increase the circulating intravascular volume, restore 
blood pressure, and maintain organ perfusion.(224)  Crystalloid resuscitation, however, 
does not prevent systemic inflammation or oxidative stress.(2,136)  Moreover, we have 
previously reported that resuscitation with lactated Ringer’s does not restore 
mitochondrial respiratory capacity in vital organs such as the heart, liver and 
kidney.(119)  Similarly, in this study, resuscitation with lactated Ringer’s did not restore 
mitochondrial respiratory capacity or mitigate mitochondrial oxidative stress in the 
kidney.  Because mitochondrial dysfunction can further exacerbate cellular damage by 
reducing aerobic ATP production and increasing the generation of reactive oxygen 
species (ROS) (129), resuscitative fluids that preserve mitochondrial function or 
augment antioxidant capacity could prove beneficial. 
Resveratrol has previously been shown to be protective in several models of critical 
illness.  In septic animals, treatment with resveratrol prevented oxidative damage in 
lymphocytes (7), preserved tissue morphology in the lung and kidney (125), mitigated 
acute lung injury and prevented myocardial depression.(142,220)  Resveratrol has also 
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been shown to be beneficial in several trauma-hemorrhage models.  Resuscitation with 
resveratrol not only improves cardiac output (239), but has been shown to decrease 
hepatic injury and inflammation following hemorrhagic shock.(276)  As such, resveratrol 
may provide a useful therapeutic adjunct to standard fluid resuscitation following 
traumatic injury. 
Although the mechanism underlying resveratrol’s benefit remains controversial (235), 
resveratrol appears to attenuate injury by activating SIRT1 dependent pathways. SIRT1, 
a NAD dependent “survival” enzyme, deacetylates and activates PGC1α; a key regulator 
of mitochondrial function and metabolism.(127,251)  In turn, PGC1α impacts two 
different pathways that may be critical to cell survival following ischemia-reperfusion 
(Figure 1).  Firstly, PGC1α is required for the induction of many ROS-detoxifying 
enzymes, including SOD2 and catalase.(145,226)  Secondly, PGC1α induces 
mitochondrial biogenesis by binding to NRFs and enhancing their activity.(244)  NRFs 
subsequently increase the expression of TFAM, an enzyme directly responsible for the 
transcription of nuclear-encoded mitochondrial proteins.(80,226)  As an upstream 
regulator of PGC1α, strategies that enhance SIRT1 expression or activity may also play 
an important role in regulating oxidative stress and mitochondrial biogenesis in vitro. 
Importantly, the antioxidant and mitochondrial effects of resveratrol also appear to be 
SIRT1 mediated.  In cell culture models, knocking down SIRT1 not only blocked the 
protective effects of resveratrol on mitochondrial oxidative stress (265), it also prevented 
resveratrol-induced up-regulation of mitochondrial biogenesis factors.(55) 
In this study, adding resveratrol to standard resuscitation with lactated ringer’s 
dramatically restored mitochondrial function while mitigating oxidative damage. While 
resveratrol has been shown to enhance the enzymatic activity of succinate 
dehydrogenase, a protein that constitutes complex II on the inner mitochondrial 
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membrane (134), in our study, resveratrol also appears to dramatically restore CIV 
activity.  Although it is possible that resveratrol could directly impact CIV activity, it is 
more likely that the benefit observed stems from resveratrol’s known antioxidant 
effects.(244)  Both ROS and lipid peroxidation products can effectively inhibit CIV activity 
following ischemia-reperfusion.(46,174)  In this current study, resuscitation with 
resveratrol resulted in decreased ROS production and 4-hydroxynonenal damage 
following hemorrhagic shock. Thus, the salutary effect of resveratrol on mitochondrial 
function could be in part secondary to decreased CIV inhibition by oxidant byproducts. 
Resveratrol also appears to enhance antioxidant defenses following hemorrhagic 
shock.  In this study, resveratrol significantly increased the expression of both SOD2 and 
catalase following hemorrhagic shock, which could have contributed to the observed 
decrease in mitochondrial oxidative stress.  Alternatively, resveratrol supplementation in 
our study effectively prevented the reduction in CII and CIV activity following 
hemorrhagic shock, which may have also contributed to the observed decrease in ROS 
production.  Thus, the improvement in oxidative damage observed with resveratrol may 
be multifactorial – resuscitation with resveratrol may either increase antioxidant 
defenses, decrease mitochondrial ROS production, or both. 
In contrast to previous studies demonstrating augmented mitochondrial biogenesis 
(55,134,244), resveratrol did not seem to promote mitochondrial biogenesis in our acute 
hemorrhagic shock model.  Although the expression of PGC1α was enhanced, 
resveratrol had no effect on the other transcriptional factors regulating mitochondrial 
biogenesis (e.g. NRF-1, NRF-2 and TFAM) and did not change mitochondrial content as 
measured by citrate synthase activity.  Since NRF-1, NRF-2 and TFAM are downstream 
targets of PGC1α, further studies with longer observation are needed to determine if 
resveratrol has any long-term effects on mitochondrial biogenesis.  Finally, because 
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resuscitation with resveratrol increased the transcript levels of SIRT1, PGC1α, and the 
downstream targets, SOD2 and catalase, we conclude that the acute benefits of 
resveratrol appear to be mediated via an antioxidant, rather than mitochondrial 
biogenesis pathway. 
Resveratrol may also improve mitochondrial function by favorable impacting cellular 
redox potential.(147,197)  In this study, resveratrol supplementation significantly 
decreased the NADH concentration and nearly doubled the NAD to NADH ratio. It is 
possible that this favorable change in the NAD to NADH ratio have influenced SIRT1 
activity in our model.(201) 
We also found that resveratrol significantly enhanced the activity of two key Krebs 
cycle enzymes, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase.  By 
converting pyruvate to acetyl CoA, pyruvate dehydrogenase serves a key mediator 
between glycolysis and oxidative phosphorylation.  α-ketoglutarate dehydrogenase 
(αKDH), on the other hand, serves as the Krebs cycle rate-limiting enzyme and can be 
reversibly inhibited by ROS.  As such, resveratrol’s ability to increase αKDH may be 
secondary to its antioxidant effects.  Moreover, using resveratrol during resuscitation 
potentially promoted the entry of NADH into electron transport.  
Although resveratrol is known to have anti-glycemic effects in chronic models of 
obesity(12), its impact on glucose metabolism in hemorrhagic shock has not been 
previously reported.   Hyperglycemia and acute insulin resistance frequently develop in 
injured patients and are associated with worse clinical outcomes.(123)  Although a 
number of mechanisms have been implicated, mitochondrial dysfunction appears to play 
a key role.(140,280) Mitochondrial-derived ROS may promote insulin resistance by 
serving as a second messenger and down regulating the insulin signaling 
pathway.(47,124) Indeed, blocking the increase in ROS after injury prevents the acute 
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development of insulin resistance and reduces the severity of hyperglycemia.(280)  In 
our study, resveratrol supplementation not only decreased mitochondrial ROS 
production, it preserved the expression of tyrosine phosphorylated IRS1 following 
hemorrhagic shock. Because only tyrosine phosphorylated IRS1 is capable of activating 
downstream insulin signaling pathways,(86) it is likely that the observed decrease in 
insulin resistance with resveratrol was, in part, secondary to decreased oxidant stress 
and preserved of insulin signaling.  
Resveratrol may also improve glycemic control by stimulating the secretion of 
glucagon-like peptide (GLP-1).(58)  GLP-1 is a gut-derived hormone that enhances 
insulin sensitivity by inducing glucose-dependent insulin secretion while suppressing 
glucagon release.(278)  Although we observed an increase in GLP-1 following 
resuscitation with resveratrol, we did not see a concomitant increase in insulin levels. 
GLP-1, however, has been shown to have independent insulin-like effects on glucose 
metabolism in rat liver, muscle and fat.(157)  Even in depancreatized animals, GLP-1 
can still potentiate glucose utilization in peripheral tissues and has been shown to 
increase the expression and phosphorylation of IRS1.(76,204)  As such, the increased 
secretion of GLP-1 observed in our resveratrol treated rats may have contributed to both 
lower glucose and increased phosphorylated IRS1 expression.  How resveratrol 
increases GLP-1 secretion, however, remains to be determined.  
Consistent with previous studies, hemorrhagic shock in our model resulted in 
significantly elevated TNF-α and IL-6 levels which may have directly contributed to the 
development of hyperglycemia and insulin resistance.(158,264)  Although resveratrol  
has been shown to mitigate inflammation and reduced blood TNF-α, IL-6, and IL-1β 
levels in diabetic rats treated with enteral resveratrol for 30 days (180), cytokine levels 
did not decrease with a single dose of resveratrol in our study.  Increased dosing 
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regimens and longer observation periods maybe needed to determine if resveratrol 
improves the systemic cytokine profile in hemorrhagic shock. 
While the potential benefit of using resveratrol to treat hemorrhagic shock is 
intriguing, there may be some pitfalls. Activation of SIRT1 appears to be beneficial 
during reperfusion, but some of its actions may interfere with the normal response to 
acute hypoxia. SIRT1 deacetylates and inhibits the activities of hypoxia inducible factor 
1α (HIF1α) and HIF2α.(64,144)  Acetylated HIF1α can activate a number of adaptive 
metabolic responses including a switch from oxidative phosphorylation to anaerobic 
metabolism, which could promote cell survival under conditions of hypoperfusion.(60)  
Similarly, while deacetylating and down-regulating its pro-inflammatory response 
appears helpful, NFĸB also coordinates the response to cellular stress and the up-
regulation of its activity in response to ROS may help cells resist apoptosis during 
hemorrhagic shock and resuscitation.(179,213)  Resveratrol can also inhibit 
cyclooxygenase, thereby decreasing the production of thromboxane.  Thromboxane is a 
potent inducer of platelet aggregation and vasoconstriction, therefore, it is at least 
theoretically possible that resveratrol could negatively impact hemostasis in a bleeding 
trauma patient.  
Our study has several limitations that will need to be addressed before resveratrol 
can be translated into clinical care.  First, we only explored the impact of resveratrol 
following acute blood loss.  Further studies are needed to determine if treating 
hemorrhagic shock with resveratrol improves mitochondrial function or prevents organ 
dysfunction in the long-term.  Additionally, we only tested one dose of resveratrol. It is 
possible that alternative dosing regimens may preferentially influence downstream 
targets of SIRT1 or PGC1α. We also only explored the impact of resveratrol on two 
tissue types. Because activating SIRT1 has been reported to both increase and 
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decrease inflammation in different tissues (79,177), it is possible that resveratrol may 
also have tissue-specific effects. Finally, we did not use a hyperinsulinemic-euglycemic 
clamp to assess the impact of resveratrol on insulin sensitivity. While this is considered 
the gold-standard method of assessing insulin sensitivity, the frequent blood samples 
required would have negatively affected the hemorrhage model.  Moreover, the 
continuous insulin and glucose infusions required may have potentially affected 
mitochondrial function.  Instead, we used the Ln HOMA-IR index which has been shown 
to correlate well with the hyperinsulinemic-euglycemic clamp method and is frequently 
used as a clinical surrogate of insulin sensitivity.(45)  Lastly, we did not treat 
hypoglycemic animals.  Glucose administration may provide additional benefit during 
resuscitation with resveratrol, but this requires further study.  
In this work we explored the effects of resveratrol on mitochondrial injury following 
hemorrhagic shock and resuscitation.  Resveratrol supplementation led to a restoration 
of mitochondrial function, alleviated oxidative stress, and improved hyperglycemia 
following hemorrhagic shock.  These mitochondrial-protective effects appear to be 
mediated via stimulation of a SIRT1-PGC1α-antioxidant pathway rather than by 
mitochondrial biogenesis.  Further work is needed, however, to determine if the 
antioxidant benefits observed are mediated by interactions between SIRT1 and PGC1α. 
Additionally, we will need to determine if the restoration of electron transport and Krebs 
cycle enzymatic activity, as well as enhanced glycemic control, is secondary to 
decreased oxidative stress or the result of resveratrol-induced post-translational 
modifications.  Nonetheless, adding resveratrol to standard fluid resuscitation appears to 
be beneficial and warrants further investigation. 
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CHAPTER 4:  
Deleting SIRT1 Promotes a Pro-Inflammatory Phenotype in Sepsis  
 
Sepsis, the physiologic response to overwhelming infection, is a major healthcare 
problem in the United States with significant human and economic costs.(139)  Each 
year, more than 750,000 patients are hospitalized with sepsis resulting in an estimated 
$17 billion in healthcare costs.(5) Despite antibiotics and supportive care, sepsis is the 
most frequent cause of death in the intensive care unit and continues to claim more than 
215,000 lives annually.(131)  Although sepsis is characterized by a profound systemic 
inflammatory state in response to infection, most patients with sepsis do not die of the 
inciting infection per se.  Rather, despite eradication of the underlying infection, the 
majority of non-survivors die days to weeks later after developing progressive organ 
failure and profound muscular weakness. Importantly, sepsis-induced organ failure 
appears to occur even with adequate tissue perfusion and in the absence of significant 
tissue necrosis or apoptosis.(19,101,202,249) 
Recent laboratory and clinical investigations suggest that organ dysfunction may 
develop in sepsis, in part, because pro-inflammatory mediators directly damage the 
mitochondria. In both animal and clinical studies, sepsis results in early mitochondrial 
ultrastructural abnormalities as well as functional impairment. (26,53,101,164,256)  
Sepsis-induced mitochondrial dysfunction subsequently leads to increased reactive 
oxygen species, bioenergetic failure and ultimately cellular dysfunction.(52,200,218)  
Notably, the degree of mitochondrial dysfunction observed closely correlates with the 
severity of clinical disease.(24,25)   When skeletal muscle biopsies were taken within 24 
hours of ICU admission, non-surviving septic patients were found to have significantly 
depressed complex I activity and lower tissue ATP levels when compared to both sepsis 
40	  
	  
survivors and healthy controls.  Moreover, the severity of septic shock directly correlated 
with the decrease in muscle ATP levels.(24)  The ability to generate sufficient cellular 
ATP may be further compromised because sepsis results in a loss of mitochondrial 
mass.(34,232)  Indeed, patients with MOF were found to have 30 to 50% less 
mitochondrial protein in both intercostal and thigh muscle relative to non-septic 
controls.(70,71)  Ultimately, the ability to survive sepsis, may depend on the capacity to 
recover mitochondrial function.(217) 
SIRT1, a highly conserved NAD deacetylase, can activate a number of key 
survival pathways during cellular stress and may hold the key to preserving 
mitochondrial function in sepsis (Figure 1).  SIRT1 can promote mitochondrial resilience 
by suppressing NFκB-mediated inflammation, by enhancing the transcription of 
antioxidant defenses including SIRT3, and by promoting mitochondrial 
biogenesis.(126,128,226)  Indeed, treating sepsis with the SIRT1 activator, resveratrol, 
appears to dramatically decrease cytokine levels, reduce oxidant injury, minimize 
mitochondrial damage, and improve both organ function and survival.(99,125,210,220) 
The benefit of activating SIRT1 in sepsis, however, may not be so clear-cut and 
may depend on the both the model and tissue type. While several studies have shown 
that deleting or inhibiting SIRT1 in macrophages results in a strongly pro-inflammatory 
phenotype (207,268,271), others studies have suggested that SIRT1 either has little 
impact on the immune response or that its inhibition decreases inflammation.(51,67,156)  
Moreover, pharmacologically inhibiting SIRT1 during the adaptive phase of sepsis has 
been shown to improve survival in a murine model of polymicrobial sepsis.(245)  Clearly, 
a better understanding of the functional role, potential tissue specificity, and possible 
temporal influence of SIRT1 during sepsis is needed in order to reconcile these very 
divergent findings.  
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In an attempt to understand the impact of SIRT1 on the pathophysiology of 
sepsis, we conducted a serious of in vitro and in vivo experiments that recapitulated a 
severe infection using inducible SIRT1 knock out mice, as well as various SIRT1 
activators and inhibitors.  
RESULTS  
Survival rates after CLP vary depending model severity 
Cecal ligation and puncture (CLP) is considered the “gold standard” model of sepsis. 
There are many variables, however, that can affect the severity and consistency of the 
model.(195)  In order to determine if we were achieving reliable and reproducible results, 
a series of severity experiments were performed in 3 month old C57BL/6J male mice 
(Jackson Laboratories).  By altering both the length of cecum ligated (full vs ½ length) 
and the gauge of needle used (23g vs 25g), we were able to demonstrate a graduated 
difference in survival over 7 days based on model severity (Figure 18A).  Animals in the 
severe sepsis model had 100% mortality, whereas moderate and mild sepsis carried 
50% and 90% mortality respectively.  Importantly, physiologic variables known to reflect 
sepsis such as temperature and serum glucose also varied with severely septic animals 
developing more pronounced hypothermia and hypoglycemia (Figure 18C,D).(176)  
When endpoints of euthanasia were calculated (Table 3), differences in clinical 
appearance and behavior also correlated with severity of sepsis (Figure 18B).   
Sepsis is associated with decreasing SIRT1 expression over time in liver 
Although SIRT1 expression has been shown to decrease promptly following 
endotoxin exposure in mice (282), CLP is associated with a more gradual and less 
robust cytokine response. As such, we sought to determine if CLP impacted SIRT1 
expression in liver and kidney tissue of sham and CLP treated mice were harvested at 0, 
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3, 9, 18, and 24 hours. SIRT1 expression over time was determined by qPCR. Given 
SIRT1 absolutely requires NAD, we also evaluated the impact of sepsis on the 
expression of NAMPT, a critical enzyme involved in the NAD salvage pathway.  
Our preliminary data suggests that SIRT1 transcripts in liver decreased 
significantly within 18 hours whereas NAMPT expression was markedly elevated at 9 
hours (Figure 19A). In contrast, SIRT1 expression in the kidney did not change, although 
NAMPT decreased significantly by 24 hours (Figure 19B).  
Pharmacologic manipulation of SIRT1 influences survival and physiology  
Sepsis is characterized by an initial hyperinflammatory phase, followed by a 
hypoinflammatory adaptive phase that if left unchecked may progress to a state of 
prolonged immunosuppression.(100)  Recent work by the McCall group suggests that 
SIRT1 plays a crucial role in the epigenetics of sepsis and can be manipulated during 
the adaptive phase to improve survival.(150,151)  Based on our preliminary findings that 
SIRT1 gene expression in liver declines significantly by 18 hours, we elected to start 
pharmacologic interventions 6 hours after CLP. Starting therapy at this delayed time also 
makes clinical sense because it can take several hours for a patient’s infection to 
progress to a diagnosis of sepsis.  Following CLP, intraperitoneal resveratrol significantly 
improved survival when compared to wild type controls (Figure 20A).  In contrast, 
animals treated with the SIRT1 inhibitor Ex-527 demonstrated increased early mortality. 
At 30 hours, however, there appeared to be an inflection point where SIRT1 inhibition 
may extend survival.  Interestingly, at 24 hours EX-527 also significantly improved body 
temperature with a trend toward lower serum glucose (Figure 20B, C).  These findings 
appear to support the theory that enhancing SIRT1 may be beneficial early during 
sepsis, whereas its inhibition may be protective during the adaptive phase.(245)  
Additional studies, however, are needed and will be performed to confirm these findings.  
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Deletion of SIRT1 negatively impacts survival and physiology in sepsis 
In order to determine if deleting SIRT1 negatively impacts clinical outcomes in 
polymicrobial sepsis, 3-4 month old inducible SIRT1 knock out (S1KO) mice and their 
wild type littermates were treated with tamoxifen 2 weeks prior to CLP.  Despite using 
the same technique to induce “severe sepsis”, our in-house bred mice demonstrated 
significantly less overall mortality than in mice purchased from Jackson Labs.  Although 
determining the reason for this difference is outside the scope of this current project, 
animals bred in different locations may have different intestinal flora and we suspect 
differences in mortality may be secondary to differences in the gut microbiome.(95)  
Animals from different venders not only demonstrate significant differences in the viable 
counts of bacteria in their feces, there are striking differences in their cecal microbiota 
when PCR-derived amplicons from bacterial 16S rRNA genes are evaluated by 
denaturing gradient gel electrophoresis.(96,108)   
Nonetheless, when compared to WT mice from the same cohort, S1KO mice were 
significantly more likely to die, with the majority of deaths occurring within the first 48 
hours (p=0.026, Figure 21A).  Overall, S1KO mice also appeared clinically less well with 
a trend toward higher Endpoints of Euthanasia scores and significantly more weight loss 
over the 5 day course (Figure 21B,C).  Physiologically, S1KO mice appeared “more 
septic” (176) with a lower core body temperature and worse hypoglycemia early during 
the course of the experiment (Figure 21D,E C,D).  
Deletion of SIRT1 negatively impacts mitochondrial function the kidney 5 days 
post CLP 
Given S1KO mice appeared more “septic” following CLP, we hypothesized that 
deleting SIRT1 would be associated with significantly worse mitochondrial function 5 
days post-CLP.  Surprisingly, when compared to WT septic mice, deleting SIRT1 only 
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significantly impaired complex II dependent respiration in the kidney (Figure 22D). 
Interestingly, complex II, or succinate dehydrogenase, activity is directly influenced by 
SIRT3.(49)  Given that sepsis has recently been shown to decrease SIRT3 expression in 
the kidney (284), it is possible that deleting SIRT1 further impedes the recovery of 
SIRT3, thus contributing to the decreased CII activity observed in S1KO sepsis 
survivors. In order to address this question, we will be looking at the acetylation status of 
succinate dehydrogenase, as well as SIRT1 and SIRT3 protein expression in WT and 
S1KO mice 5 days post CLP. Additionally, we will perform control experiments in sham 
WT and S1KO mice in order to assess baseline mitochondrial content, respiration, and 
sirtuin expression. 
Deletion of SIRT1 negatively impacts physiologic variables and organ function 36 
hours post-CLP 
Septic S1KO and WT mice were treated with resveratrol (20mg/kg IP every 6hrs) 
and sacrificed at 36 hours post-CLP in order to determine if SIRT1 status influenced 
physiologic variables or organ function. Although all septic animals were more 
hypothermic and hypoglycemic than sham controls, septic S1KO mice tended to have 
lower temperatures and serum glucose values when compared to septic WT mice 
(Figure 23A, B).  Moreover, septic S1KO mice also looked less clinically well, with a 
trend toward higher endpoints of euthanasia scores (Figure 23C).  Notably, SIRT1 
activation with resveratrol did not improve these physiologic variables.  While deletion of 
SIRT1 negatively impacted renal function (Figure 23D), its impact on liver function was 
variable and not statistically significant (Figure 23E).  Again, the use of resveratrol did 
not improve organ function.  In order to determine if the negative trends observed in 
S1KO mice are significant, additional experiments will be performed to increase the 
number of biologic replicates in all groups.  
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Deletion of SIRT1 has minimal impact on liver mitochondrial function following 
sepsis 
It is well known that sepsis negatively impacts mitochondrial function.(217)  In order 
to determine the impact of SIRT1 on mitochondrial respiratory capacity and redox status, 
S1KO and WT mice were randomized to sham treatment, CLP or CLP with resveratrol 
(20mg/kg IP every 6hrs).  At 36 hours post-CLP, liver tissue homogenates were 
assayed.  Sepsis did not significantly change mitochondrial content in liver, but did 
decrease CI, II, and IV respiratory capacity in WT mice (Figure A-C).  S1KO mice had 
significantly decreased CI activity at baseline, however, deleting SIRT1 did not make the 
degree of sepsis-induced mitochondrial dysfunction worse.  In fact, following sepsis, WT 
and S1KO had similar CI, II, and IV dependent respiration regardless of resveratrol 
treatment (Figure 24).   
Preliminary experiments suggest that although the redox state does not significantly 
change in WT animals with sepsis, resveratrol tended to decrease NADH and thereby 
increasing the NAD/NADH ratio. In contrast, S1KO mice may have decreased NAD 
pools at baseline (Figure 24D)  
Deletion of SIRT1 significantly impacts kidney mitochondrial function following 
CLP 
Given our finding that SIRT1 KO mice were more susceptible to sepsis-induced renal 
dysfunction, we wondered if deleting SIRT1 was associated with increased mitochondrial 
dysfunction. As previously described, S1KO and WT mice were randomized to sham 
treatment, CLP or CLP with resveratrol (20mg/kg IP every 6hrs) and euthanized 36 
hours later. Despite similar citrate synthase activity, S1KO mice demonstrated 
significantly worse fatty acid respiration, as well as decreased CI and CII dependent 
respiration, when compared to WT septic mice (Figure 25 A-C). There was a trend 
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toward improved CI function in WT animals treated with resveratrol (Figure 25C).  Renal 
redox status was not influenced by SIRT1 expression remained stable regardless of 
resveratrol treatment and was not influenced by SIRT1 expression (Figure 25D). 
Manipulation of SIRT1 modifies the inflammatory response in vivo and in vitro 
There is controversy regarding whether or not SIRT1 is pro or anti-inflammatory. 
While SIRT1 inhibition has been shown to attenuate the production of pro-inflammatory 
cytokines in lipopolysaccharide (LPS)-–stimulated macrophages and in septic 
animals,(67,156) pharmacologic SIRT1 activation with resveratrol has similarly been 
shown to be protective in sepsis.(125,210,220)  In order to determine if SIRT1 tempers 
the inflammatory response in sepsis, we conducted a series of in vivo and in vitro 
experiments.  IL 6 levels were measured serially by ELISA in WT and S1KO mice 
subjected to CLP.  Although baseline values were similar, IL6 levels were significantly 
more elevated in S1KO mice early during the course of sepsis.  Because macrophages 
are a key source of IL6 during sepsis, we looked at the temporal expression of IL6 in 
cultured bone marrow derived macrophages (BMDMs) treated with LPS.  BMDMs 
harvested from SIRT1 KO mice had a more robust inflammatory response with 
significantly higher gene expression of IL6 than WT cells (Figure 26B). In order to 
confirm gene expression translates to higher protein expression, however, we plan to 
measure both cellular IL6 protein levels by immunoblot as well as secreted IL6 levels by 
ELISA in LPS-stimulated BMDMs in future studies. 
SIRT1 can also modulate inflammation by enhancing the expression of superoxide 
dismutase (SOD2) and catalase (CAT)(128,226), thereby decreasing the impact of ROS.  
Surprisingly, after LPS-stimulation, SIRT1 KO BMDMs actually had higher SOD2 and 
CAT expression than WT cells (Figure 26C, D).  Very preliminary data suggests a similar 
pattern of gene expression in LPS stimulated BMDM treated with the SIRT1 inhibitor, 
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EX-527 (Figure 26E).  This suggests that SOD2 and CAT expression are not exclusively 
controlled by SIRT1 expression and increased expression can be activated in times of 
oxidative stress. This increased expression of antioxidants may reflect an overall 
increased burden of ROS in S1KO cells. We will test this hypothesis in future 
experiments by measuring the generation of ROS after LPS exposure in WT, S1KO, and 
pharmacologically manipulated BMDMs. 
Myeloid deletion of SIRT1 is pro-inflammatory during sepsis.  
Although we demonstrated that deleting SIRT1 was pro-inflammatory using both in 
vivo and in vitro septic challenges, it is possible that nonspecific SIRT1 deletion in the 
whole organism, and not just an enhanced inflammatory response, could account for 
differences in mortality.  Moreover, the impact of myeloid-specific SIRT1 deletion on 
inflammation remains controversial; thus differences in the inflammatory response could 
theoretically be driven by SIRT1 deletion in the immune cells or in key organs such as 
the kidney or liver. (51,207)  In order to determine if deleting SIRT1 significantly 
influenced the immune response in sepsis, SIRT1 was deleted in macrophages and 
granulocytes using LysMCre.  When subjected to CLP, the S1KO LysMCre mice had 
significantly higher serum IL6 levels than their WT littermates at 12 hours. 
S1KOLysMCre also had increased 5 day mortality. Although we have fewer mice in this 
experiment, none of the WT mice died in these experiments which would be highly 
unusual. Previously WT mice in our S1KO cohort experienced an 80% mortality rate. 
This discrepancy is concerning and we will repeat these experiments in order to validate 
that deleting SIRT1 in myeloid cells increases mortality.  
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CONCLUSIONS  
In this ongoing study, we report that deleting or inhibiting SIRT1 results in a pro-
inflammatory phenotype both in vivo and in vitro.  Using a polymicrobial model of intra-
abdominal sepsis, whole body deletion of SIRT1 negatively impacted both survival and 
physiology.  The influence of SIRT1 on mitochondrial function during sepsis, however, 
appears to be organ dependent.  While deleting SIRT1 did not alter mitochondrial 
function in the liver, it did significantly impair both mitochondrial capacity in the kidney 
and was associated with decreased renal function following CLP.  We further 
investigated the role of SIRT1 on the on the immune response by stimulating WT and 
S1KO bone marrow derived macrophages with LPS.  In this cell culture model of sepsis, 
SIRT1 deletion significantly increased IL6 gene expression and may be associated with 
increased generation of ROS.  Similar findings were appreciated when WT BMDMs were 
treated with the SIRT1 inhibitor EX527.  Preliminary data suggest that specifically 
deleting SIRT1 in macrophages and granulocytes recapitulates the pro-inflammatory 
phenotype observed in our whole body SIKO model.  Although future experiments are 
planned to confirm our preliminary findings, SIRT1 appears to play a vital role in sepsis 
and a could potentially be a viable therapeutic target.  
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CHAPTER 5:  
Deleting SIRT3 Enhances the Inflammatory Response in Sepsis  
 
As the major mitochondrial deacetylase, sirtuin 3 (SIRT3) directly modulates cellular 
energetics and.is poised to play a pivotal role in coordinating the mitochondrial response 
to sepsis. In addition to regulating fatty acid oxidation and several of enzymes in the 
Kreb’s cycle, SIRT3 can deacetylate complexes I, II, and III (102); thus influencing the 
flow electrons through the electron transport chain as well as the generation of 
damaging ROS.  SIRT3 can also directly mitigate oxidative stress by activating 
superoxide dismutase and by increasing the concentration of reduced 
glutathione.(191,221)   While SIRT3 knockout mice appear phenotypically normal, these 
animals demonstrate evidence of complex I inhibition as well decreased basal ATP 
levels. Overexpression of SIRT3, on the other hand, rescues mitochondrial function and 
minimize oxidative damage.(1).  Recently, deletion of SIRT3 in C2C12 myoblasts was 
noted to decrease respiratory capacity, increase reactive oxygen species and increase 
insulin resistance.  Interestingly, a similar phenotype is observed in septic patients and in 
LPS treated C2C12 cells.(62,72,155)  In order to determine if SIRT3 could be a potential 
therapeutic target in sepsis, we are currently investigating the impact of modulating 
SIRT3 both in vitro and in vivo.  
RESULTS  
Deleting SIRT3 increases early mortality but doesn’t significantly impact morbidity  
Given the central role SIRT3 plays in mitochondrial metabolism, we anticipated that 
deleting SIRT3 would significantly impact the physiologic response to polymicrobial 
sepsis. Surprisingly, S3KO mice and their WT littermates responded similarly to the 
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septic insult.  Although the deletion of SIRT3 is reported to have minimal impact on 
standard biometrics (1), S3KO mice in our cohort weighed less at baseline than their WT 
littermates.  Both genotypes lost weight at the same rate following CLP, however, S3KO 
mice lost a smaller total percentage of body weight (Figure 28 A, B).  After CLP, S3KO 
and WT mice had similar core body temperatures and serum glucose levels (Figure 28 
C, D).  Moreover, in animals that survived 5 days post-CLP, SIRT3 status did not 
significantly impact organ function (Figure 28E).  While the overall mortality at 5 days 
was similar, S3KO animals died earlier than WT mice (Figure 28F).  
Deleting SIRT3 has minimal clinical impact within the first 36 hours post-CLP 
Given the increased early mortality in S3KO mice, we wondered if SIRT3 deletion 
was associated with worse clinical physiology or increased organ dysfunction. In order to 
address this question, septic mice were assessed every 6 hours starting 12 hours post-
CLP. S3KO and WT mice had similar core body temperatures and looked clinically 
similar with nearly identical endpoints of euthanasia scores (Figure 29A, C).  Although 
S3KO mice had a modest, but statistically significant, increase in their serum glucose 
starting at 24 hours, they were by no means hyperglycemic (Figure 29B).  Both 
genotypes also had a similar degree of organ dysfunction 36 hours post-CLP (Figure 
29D). 
SIRT3 status has minimal impact on mitochondrial function in sepsis  
Using high resolution respirometry, we interrogated mitochondrial respiratory 
capacity in both liver and kidney whole homogenates at 36 hour and 5 days post-CLP.  
Despite its central role in mitochondrial metabolism, SIRT3 status did not significantly 
impact mitochondrial content or respiratory function in our CLP model at these time 
points.  In fact, septic S3KO and WT mice had identical respirometry profiles.  In the 
liver, CLP resulted in decreased CI and CIV activity at 36 hours and persistent CIV 
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dysfunction at 5 days, regardless of genotype (Figure 30B, C).  While the kidney 
demonstrated significant mitochondrial dysfunction 5 days post-CLP, this dysfunction did 
not appear to be influenced by SIRT3 status either (Figure 30 E, F).  Thus, these data 
suggest that S3KO and WT likely share a common pathophysiology that leads to the 
same degree of mitochondrial dysfunction observed at the time points measured. It is 
possible, however, that we missed earlier differences in mitochondrial function by waiting 
until 36 hours.  Indeed, Zhao and colleagues recently reported that S3KO mice 
demonstrated increased sepsis-induced acute kidney injury 24 hours post-CLP.(284)  
Regardless, it does not appear that differences in mitochondrial respiratory capacity 
account for the increased early mortality observed in our SIRT3 cohort. It is possible that 
another tissue that we didn’t examine, like macrophages or cardiac tissue, might have 
mitochondrial dysfunction that could account for the differences in mortality.  
Deleting SIRT3 is pro-inflammatory 
In order to determine if SIRT3 status impacted the acute inflammatory response, we 
serially measured serum IL6 levels in S3KO and WT mice subjected to CLP.  S3KO 
mice demonstrated significantly higher IL6 levels that peaked 6 hours post CLP.  
Interestingly, S3KO and WT mice had similar IL6 levels starting 12 hours post CLP; and 
this similarity in cytokine profile may help explain why we didn’t we observe differences 
in their clinical physiology (Figure 31 A. Figure 29A, C).  We then looked at LPS 
stimulated BMDMs in order to determine if SIRT3 status influenced the temporal 
expression of pro-inflammatory cytokines.  Although the sample size was small, these 
preliminary data suggest that IL6 expression may peak earlier in S3KO cells (Figure 
31B). WT and S3KO BMDM were then pretreated with honokiol, a purported SIRT3 
activator (185) for one hour prior to LPS stimulation in order to determine if SIRT3 
activation would dampen the inflammatory response.  In these preliminary studies, 
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honokiol appears to decrease IL6 and TNFα expression.  These results, however, did 
not reach significance in our small sample size.  Somewhat surprisingly, there was a 
trend toward decreased IL6 expression in honokiol treated S3KO cells suggesting that 
honokiol may have off –target anti-inflammatory (or antioxidant) effects (Figure 31 D, E). 
Indeed, pretreatment with honokiol significantly reduced SOD2 expression in S3KO, but 
not in WT cells co-cultured with LPS (Figure 31F).  Additional experiments are planned 
in order to explore if SIRT3 status changes the temporal expression of pro-inflammatory 
cytokines in vitro.  In addition, we will determine if SIRT3 overexpression mitigates the 
inflammatory response in CLP and in vitro. Finally, we will determine what role ROS play 
in the S3KO pro-inflammatory phenotype by co-culturing cells with the antioxidant N-
acetylcysteine.  
SIRT3 expression dramatically declines during sepsis in multiple tissues 
We were struck with how similar septic S3KO and WT mice were in terms of 
physiology and mitochondrial function following CLP.  Given these similarities, we 
wondered if WT animals adopted a S3KO phenotype as a natural response to sepsis 
and if this transformation was necessary in order to mount an inflammatory response. In 
order to begin to address this hypothesis, we cultured WT BMDMs with LPS and 
measured SIRT3 mRNA overtime.  We also subjected WT mice to CLP and measured 
the temporal expression of SIRT3 in liver and kidney.  Our preliminary data suggest that 
during sepsis, SIRT3 is down regulated in multiple tissues (Figure 32) which may explain 
why septic S3KO and WT share the same phenotype at later time points.   
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CHAPTER 6: 
Conclusions and Future Directions 
Although hemorrhagic and septic shock differ significantly in their underlying etiologies, 
both conditions are associated with a pathologic state of systemic inflammation, vascular 
collapse, mitochondrial dysfunction, and ultimately multiple organ failure (MOF). Given 
MOF remains the most common cause of in-hospital morbidity following shock and 
accounts for 50-80% of all deaths in the intensive care unit (48,66,175), there is 
increasing interest in developing therapies that target shock-induced pathways. Sirtuins 
play a critical role in modulating inflammation, oxidative damage, and mitochondrial 
function during cellular stress. As such, we hypothesized that manipulating SIRT1 and 
SIRT3 would significantly impact the pathophysiology of shock. 
SIRT1 
SIRT1 is a highly conserved NAD-dependent deacetylase that plays a critical role in 
cellular resilience and longevity.(102)  Given its absolute requirement for cytosolic NAD, 
SIRT1 directly responds to cellular stress and hypoxia by providing transcriptional 
regulation of key pro-survival pathways.(11,282)  SIRT1 enhances mitochondrial 
biogenesis by deacetylating the transcriptional co-activator PGC1α, decreases oxidative 
stress by activating the FOXO3 dependent expression of superoxide dismutase and 
catalase, and suppresses NFκB-mediated inflammation by deacetylating the p65 subunit 
of the NFκB complex.(37,121,198)   SIRT1 also deactivates and down regulates the 
expression of poly (ADP-ribose) polymerase (PARP) – a NAD consuming enzyme that 
triggers cell death in the setting of oxidant-mediated DNA damage.  Given its ability to 
modulate the inflammatory response, mitigate oxidative damage and promote cell 
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survival, SIRT1 has become a key therapeutic target for many diseases characterized by 
impaired mitochondria and inflammation.(12,36,134) 
SIRT1 ACTIVATION IN HEMORRHAGIC SHOCK 
Using a model of decompensated hemorrhagic shock, we investigated the impact of 
activating SIRT1 during resuscitation using two different pharmacologic agents - 
resveratrol and nicotinamide mononucleotide (NMN). Resveratrol, a polyphenol found in 
red wine, is thought to increase SIRT1 activity either directly by allosteric interactions or 
indirectly by activating AMPK to increase NAD levels.(12,102,103,181,243)  When given 
during resuscitation, we found that resveratrol enhanced mitochondrial enzymatic 
activity, restored oxidative phosphorylation, mitigated oxidant damage, and preserved 
renal function.(252,253)  Similarly, we found that NMN, a naturally occurring NAD 
precursor, preserved mitochondrial function, mitigated inflammation by decreasing the 
generation of IL6, enhanced physiologic reserve and improved survival following 
hemorrhagic shock.  
Both resveratrol and NMN, however, have pleiotropic effects. Thus, the mechanistic 
benefit of SIRT1 activation following hemorrhagic shock remains encouraging but 
unproven.  In order to better understand if targeting SIRT1 preserves mitochondrial 
function or mitigates inflammation following hemorrhagic shock, we will conduct 
complimentary experiments using inducible SIRT1 knockout (S1KO) and S1KO 
LysMCre mice.  By directly altering SIRT1 expression in both tissue and immune cells, 
we will be able to evaluate the impact of SIRT1 signaling on bioenergetics, mitochondrial 
function, and inflammation in hemorrhagic shock. Future experiments will also include 
SIRT1 transgenic knock in (S1Tg) in order to determine if overexpression of SIRT1 
improves physiologic function. Additionally, we will resuscitate SIKO mice with 
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resveratrol and NMN in order to determine if their benefits in hemorrhagic shock are 
SIRT1 dependent. 
SIRT1 ACTIVATION IN SEPTIC SHOCK 
Although there is some debate regarding the potential benefit (or harm) of activating 
SIRT1 in sepsis (207,268,271), deleting SIRT1 in our polymicrobial model was clearly 
pro-inflammatory and associated with worse clinical outcomes.  Septic S1KO mice 
demonstrated higher levels of the inflammatory cytokine IL6, were more hypothermic, 
had worse renal mitochondrial function, and died sooner than their WT counterparts. 
While preliminary experiments using SIRT1 LysMCre mice suggest that many of these 
findings may be secondary to a pro-inflammatory phenotype rather than a primary tissue 
defect, we are conducting additional experiments given an unexpectedly high survival 
rate in the WT littermates. Additionally, in order to determine if augmenting SIRT1 
activity is anti-inflammatory, S1Tg mice will be subjected to CLP. In addition to 
measuring serial IL6 levels, the deacetylation status of tissues prone to developing MOF 
(eg. lungs, liver, and kidney) will be compared to our septic SIKO and WT mice. We will 
also determine if SIRT1 overexpression improves survival.    
In our sepsis survival experiments, pharmacologic activation of SIRT1 using 
resveratrol decreased overall mortality.  At first glance, these findings appear to 
contradict those reported by Vachharajani et al. Using a similar CLP model, these 
authors report that SIRT1 inhibition with EX527 administered 24 hours after the septic 
insult improved survival.(245)  Interestingly, EX527 appeared to have a biphasic 
response in our model. When given 6 hour hours after cecal puncture, EX527 was 
associated with increased mortality.  However, after 24 hours, EX527 was associated 
with improved clinical parameters, including serum glucose and temperature, with a 
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trend toward improved late mortality. Given that sepsis has a biphasic inflammatory 
response, it is possible that SIRT1 activation improves the early hyperinflammatory 
phase, whereas SIRT1 inhibition promotes the adaptive phase of sepsis.  Clearly, a 
better understanding of the functional role, potential tissue specificity, and temporal 
influence of SIRT1 activation during sepsis is needed.  
SIRT1 EXPRESSION IN CRITICALLY ILL PATIENTS 
Both injury and sepsis trigger an immune response that directly correlates with both 
the frequency and severity of complications(63,109,159).  In a recent analysis of 167 
severely injured patients, Xiao et al noted that >80% of the leukocyte transcriptome was 
altered within 12 hours of injury.(263)  In patients whose post-injury course was 
complicated by the development of  MOF or infection, both the magnitude and time to 
resolution of pro-inflammatory gene expression were significantly prolonged.  Patients 
with complicated courses also had decreased expression of genes involved in 
mitochondrial function and oxidative phosphorylation.  Interestingly, Xiao and colleagues 
noted a significant decrease in SIRT1 expression in all severely injured patients. 
Although the relationship between SIRT1 and inflammation has not been previously 
explored in critically ill patients, SIRT1 activity in peripheral blood mononuclear cells 
(PBMC) has been shown to correlate with severity of inflammation in chronic conditions 
such as rheumatoid arthritis.(257)  Because SIRT1 activity is known to modulate 
inflammation, we will test the hypothesis that PBMC SIRT1 activity is suppressed in 
critically ill patients following hemorrhagic and septic shock.  Moreover, we further 
speculate that decreased SIRT1 activity will predict the development of MOF.(282)  
TARGETING NAD IN SHOCK  
NAD functions as an essential cofactor in a number of cellular reactions and is 
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absolutely essential for both SIRT1 activity and maximal oxidative capacity.  During 
hemorrhagic shock and resuscitation, tissue NAD levels fell significantly in our model; 
potentially creating a competition for the limited amounts of NAD between poly (ADP-
ribose) polymerase-1 (PARP1), an NAD dependent enzyme activated during cellular 
stress, and SIRT1.(10,44,219,230)(53-57)  If PARP1 is preferentially activated, the 
stressed cell goes on to die; whereas if SIRT1 is activated, adaptive survival pathways 
are stimulated.  Because the Km of PARP1 for NAD is lower than that of SIRT1, and 
SIRT1 itself is a repressor of PARP1, falling NAD levels can favor activating PARP1; this 
would exacerbate the loss of SIRT1 activity and make it less effective at inhibiting 
inflammation or promoting cell survival.  Moreover, it has been shown that repleting NAD 
by overexpressing NAMPT can protect against the damage associated with PARP 
overexpression in a SIRT1-dependent manner.(281)  Thus, the availability of NAD plays 
a major role in determining the fate of the cell and strategies to preserve or increase 
NAD could tip the balance in favor of SIRT1 activation.  Indeed, supplementation with 
NMN in our hemorrhagic shock model significantly enhanced tissue NAD levels, restored 
mitochondrial function, and improved survival.  
In addition to providing precursor molecules, cellular NAD levels could be enhanced 
by directly inhibiting PARP1 activity.  PARP1 has previously been shown to play a key 
role in the development of multiple organ damage following acute blood loss.(255)  With 
hemorrhagic shock and resuscitation, PARP1 is dramatically activated and correlates 
with the development of intestinal injury, cardiac failure and acute lung inflammation.  
Genetically knocking out PARP, however, significantly mitigates the development of 
organ damage and nearly doubles the mean survival time.(143)  Similarly, 
pharmacologic inhibiting PARP at the time of resuscitation appears to preserve organ 
function and improve cardiac function in variety of animal models.(162,229)  It is unclear, 
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however, if these benefits are simply related to inhibiting PARP, or if they also preserve 
NAD levels and activate SIRT1 pathways. 
Although we did not observe a decline in tissue NAD in our CLP model, nor did we 
investigate the use of NMN, it is possible that supplementing NAD precursors could 
prove beneficial in sepsis.  To date, niacin is the only NAD precursor that has been 
investigated in sepsis.(133)  When given to endotoxemic rats, high dose niacin 
significantly increased NAD levels in lung tissue and downregulated the NFĸB pathway. 
As a result, animals receiving niacin developed significantly less pulmonary inflammation 
and were more likely to survive than placebo treated animals.  All tissues in sepsis, 
however, may not respond equally to increased intracellular NAD and there is some 
concern that enhancing NAD in immune cells could promote the release of pro-
inflammatory cytokines in a SIRT6 dependent manner.(247)  
Although our results investigating the relationship between NAD and SIRT1 in shock 
are highly encouraging, many important questions remain.  The optimal timing for 
delivery of NAD precursors and SIRT1 activators remains unknown.  It is also unclear if 
strategies to prevent PARP activation can be used to concomitantly augment NAD levels 
and promote SIRT1 activation.  These questions are particularly relevant given the 
suggestion that SIRT1 activation may have both positive and negative effects at different 
times during the inflammatory response.(245,246)  Lastly, the potential for synergy 
between interventions that allosterically activate SIRT1 and those that restore its 
cosubstrate, NAD, remains completely unexplored. 
SIRT3  
There is an increasing appreciation that SIRT3 plays a significant role in age-related 
diseases and as the major mitochondrial deacetylase, is poised to play a pivotal role in 
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coordinating the mitochondrial response to sepsis.(163)  SIRT3 mitigates oxidative 
stress, increasing both the availability and activity of MnSOD and isocitrate 
dehydrogenase 2.  SIRT3 may further minimize oxidative stress by promoting the 
oxidation of fatty acids.(186)   During fatty acid oxidation, some electrons shuttle from 
NADH directly to the electron-transferring flavoprotein,(82) thereby bypassing complex I, 
a key site of free radical generation that is frequently inhibited during shock. SIRT3 may 
also modulate oxidative phosphorylation by deacetylating multiple complexes in the 
electron transport chain.(102,184)  Understanding how SIRT3 impacts the 
pathophysiology of sepsis could potentially lead to more targeted therapies and 
improved outcomes.    
When subjected to CLP, S3KO mice in our study demonstrated a pro-inflammatory 
phenotype with serum IL6 levels that peaked earlier in the course of sepsis.  Septic 
S3KO mice also had a significantly higher mortality than their WT littermates.  Recently 
Zhao et al reported similar findings and suggest that when challenged with a septic 
insult, SIRT3 expression in the kidney decreases.  SIRT3 deletion was also associated 
with a significant upregulation of the NLRP3 inflammasome that was rescued with SIRT3 
overexpression.(284)   
Somewhat surprisingly, SIRT3 deletion did not significantly worsen the mitochondrial 
respiration observed in whole homogenates of septic liver or kidney, nor did it 
significantly impact tissue NAD levels.  It is possible that deleting SIRT3 resulted in 
mitochondrial dysfunction at an earlier time point or that mitochondria from a different 
tissue (e.g., cardiac or immune cells) may be more impaired in our S3KO cohort.  We 
also subjected WT mice to CLP and measured the temporal expression of SIRT3 in liver 
and kidney.  Our preliminary data suggest that during sepsis, SIRT3 is down regulated in 
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multiple tissues which may explain why septic S3KO and WT share the same phenotype 
at later time points.   
Given their striking physiologic similarities at 36 hours, we wondered if WT animals 
adopt a S3KO phenotype as a natural response to sepsis and if this transformation was 
necessary in order to mount an inflammatory response. In order to address this 
hypothesis in future experiments, we will culture bone marrow derived macrophages 
harvested from WT, S3KO and transgenic overexpressing SIRT3 mice (S3OE) with LPS. 
In addition to measuring SIRT3 mRNA expression over time, we will quantify 
mitochondrial derived reactive oxygen species as well as the activation of antioxidants 
and the inflammasome.  S3KO macrophages will also be co-cultured with the antioxidant 
N-acetylcysteine in order to determine if reactive oxygen species are the pro-
inflammatory driver.  Finally, we will compare how the systemic and tissue-based 
inflammatory response to CLP changes over time in WT, S3KO, and S3OE mice. 
SUMMARY 
SIRT1 and SIRT3 play critical roles in mitigating the pathophysiology of shock and 
represent attractive therapeutic targets. Impaired expression of either SIRT1 or SIRT3 
appears to promote a pro-inflammatory phenotype, whereas pharmacologic 
manipulation of either SIRT1 or the availability of their co-substrate NAD decreases 
inflammation, improves mitochondrial function, and enhances physiologic resilience.  
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CHAPTER 7: 
Materials and Methods 
 
All experiments were approved by the Institutional Animal Care and Use Committee at 
the University of Pennsylvania and were conducted in accordance with the guidelines 
established by the National Institutes of Health.  All chemicals and cell culture solutions 
were obtained from Sigma Aldrich or ThermoFisher Scientific unless otherwise stated.  
ANIMALS 
Rodents were housed with constant temperature, humidity, and a timed 12-hour 
light/dark cycle. Regardless of experimental procedure, all animals were allowed access to 
standard rodent chow (PMI Rodent Diet, ASAP, Quakertown, PA) and water ad lib.  
For hemorrhagic shock experiments, male Long Evans rats (250-300g) were 
purchased (Charles River Laboratories, Raleigh, NC) and allowed to acclimate at least 3 
days. For NMN experiments, animals were randomized to either plain drinking water or 
water with NMN (400mg/kg/day, Metro International Biotech, LLC, Cambridge, MA) for 
five days prior to surgery. For resveratrol experiments, animals received standard 
drinking water.  For sepsis experiments, male C57BL/6J mice (3 month old) were 
purchased from Jackson Laboratories. 
Inducible whole-body SIRT1 knockout mice were generated by breeding floxed 
SIRT1Δex4 mice with tamoxifen-inducible cre ERT2 mice.(189)  Heterozygous SIRT1Δex4 
with ERT2 were cross matched and 10 weeks old homozygous SIRT Δex4ERT2 mice 
and wild type littermates were treated with tamoxifen (0.1mg/g) for 5 days by gavage.  
Two to four weeks later, animals were subjected to CLP (or sham) procedures or 
underwent bone marrow harvest.  
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SIRT1Δex4 LysMCre mice were generated by crossing floxed SIRT1 Δex4mice with 
LysM Cre mice (Lyz2 tm(cre)Ifo purchased from Jacskon Laboratories in the C57BL/6J 
background. These mice were also treated with tamoxifen (0.1mg/g) for 5 days by 
gavage in order to directly compare with the inducible whole-body SIRT1 knockout 
cohort.  
SIRT3 knock out mice were originally generated by Lombard et al (152) and were 
backcrossed to the C57BL/6 background for 10 generation prior experiments.  
EXPERIMENTAL PROCEDURES 
NMN and Hemorrhagic Shock  
Spontaneously breathing Long Evans rats were anesthetized using vaporized 
isoflurane by mask (2-4%) and underwent sterile placement of femoral vascular 
catheters (PE50, Braintree Scientific, Inc., Braintree, MA).  Mean arterial pressure 
(MAP) was recorded throughout the experimental protocol (Digi-Med Signal Analyzers, 
Louisville, KY).  A sterile prepped 5-cm midline laparotomy was performed to simulate 
soft tissue trauma.  All surgical sites were bathed in 1% lidocaine (APP Fresenius Kabi, 
Lake Zurich, IL) and closed in layers.  Animals received 0.25% buprenorphine 
(0.05mg/kg, subcutaneously, Reckitt Benkiser Healcare Ltd, Hull, England). Animals 
were then placed in a plexiglass restraining apparatus and allowed to fully emerge from 
anesthesia (~30 minutes). 
Animals were randomized to either fixed pressure hemorrhagic shock (n=9-12 per 
treatment group) or sham controls (n=5 per treatment group).  Shocked animals were 
passively bled via the femoral artery and maintained at a MAP of 40 mmHg for 90 
minutes.  If the MAP fell below a 40 mmHg, small boluses (0.2 ml) of intravenous lactated 
Ringer’s (LR) were provided to maintain the MAP.  At 90 minutes, animals were 
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intravenously resuscitated with 4 times the shed blood volume in LR ± sterile filtered NMN 
(400mg/kg) over 60 minutes (60R).  Sham animals were gently restrained for 90 minutes 
and then were given 5ml of LR ± sterile filtered NMN (400mg/kg) over 60 minutes.).  Blood 
samples were taken at Baseline, 90 minutes and 60R (Figure 3).  Following resuscitation, 
animals were again anesthetized with isoflurane (2-4%).  Liver and kidney tissues were 
rapidly harvested and either immediately clamp frozen in liquid nitrogen or prepared for 
mitochondrial assays.  Animals were euthanized under anesthesia.  
In a separate survival experiment, animals were randomized to water ± NMN 
(400mg/kg/day) for 5 days prior to surgery.  Animals underwent general anesthesia with 
vascular access, laparotomy, and full reversal as described.  Animals were then 
randomized to either decompensated hemorrhagic shock (223) (n=11 per treatment) or 
served as sham controls (n=3 per treatment).  Shocked animals were passively bled via 
the femoral artery and maintained at a MAP of 40 mmHg.  When the blood pressure 
could no longer be maintained without fluid infusion (Decompensation), a MAP of 40 
mmHg was sustained by incrementally infusing 0.2 cc boluses of LR until 40% of the 
total shed volume had been returned in the form of boluses (Severe Shock).  Animals 
were then resuscitated with four times the shed volume in LR ± NMN (400mg/kg) over 
60 minutes and followed for an additional 48 hours (Figure 9).  The total time from 
initiation of bleeding to the start of resuscitation represents each animal’s ability to tolerate 
the shock and reflects individual physiologic resilience.  Animals received buprenorphine 
(0.05mg/kg, every 8 hours) and a subcutaneous LR bolus (50 ml/kg) ± NMN (400 mg/kg) 
at 24 hours.  Blood samples were taken at Baseline, Severe Shock, 60R, 24 and 48 
hours.  At 48 hours, any surviving animals were anesthetized using isoflurane (2-4%) by 
mask followed by tissue harvest and euthanasia.  
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NMN and Primary Hepatocyte Harvest 
Primary hepatocytes were isolated as previously described using a modified two-
step perfusion method.(166)   Animals (n=4) were anesthetized with isoflurane (2-4%). 
The abdomen was prepped and draped in sterile fashion.  The inferior vena cava was 
cannulated with a 24g angiocath and the portal vein was cut.  The liver was then 
infused with 300 ml of liver perfusion media (Invitrogen, 17701-038) at 17ml/kg/minute 
to desanguinate followed by 400 ml of liver digestion media (Krebs Ringer bicarbonate 
buffer (KRBB) + 20 mM HEPES (pH 7.4), 500µM CaCl2, collagenase (≥20,000 
units)/elastase (30 units) (Worthington, LK002066), and DNAseI (200units, Worthington 
LK003170).  After the perfusion, liver was removed, disrupted to release cells using cell 
scrapers.  The cell suspension was then filtered through 70µm filter and centrifuged at 
50g for 5 minutes at 4oC, washed once in KRBB and precipitated in 25% Percoll 
gradient at 120g for 5 minutes at 4oC.  Cells were resuspended in hepatocyte media 
(M199, NaHCO3 (2.2 gm/L), glutamine 0.1g/L, 0.25% BSA, 10% Fetal Bovine Serum 
(Hyclone) and 1% penicillin-streptomycin Using pre-coated collagen 6 well plates, cells 
were plated at 1x106 cells/well and incubated for 12 hours (37◦C, 5% CO2).  
In order to obtain sham and shock plasma for hepatocyte co-culture experiments, 
animals were anesthetized as described, underwent vessel cannulation, and allowed to 
awaken and stabilize prior to bleeding.  Sham animals (n=9) were rapidly bled into 
heparinized collection tubes (BD Vacutainer) and lactate was confirmed to be ≤2 
mmol/L.  The shock animals (n=9) were bled to MAP of 40 mmmHg for 90 minutes, and 
then exasanguinated into heparinized tubes. Collected blood was immediately 
centrifuged (1300 rcf, 10 min, 4◦C) and plasma was immediately stored at -80C. 
Resveratrol and Hemorrhagic Shock  
After vascular line placement, laparotomy and full reversal of anesthesia, male 
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Long Evans rats were bled to a MAP of 40mmHg and subjected to decompensated 
hemorrhagic shock as previously described.  When 40% of the shed volume had been 
returned in the form of LR boluses (Severe Shock), animals were resuscitated with four 
times the shed volume in LR with or without resveratrol (30 mg/kg, 50mg/ml in 50% 
DMSO, Orchid Pharmaceuticals, Lalilab, Durham NC), over 60 minutes and then 
followed for 18 hours.(220)  Animals (n=6 per group) were sacrificed prior to 
hemorrhage (Sham), at Severe Shock, following LR Resuscitation (LR) or 
resveratrol+LR Resuscitation (LR + RSV), 18 hours after LR Resuscitation (18hr LR) or 
LR + resveratrol Resuscitation (18hr LR +RSV).  Animals were re-anesthetized at each 
time point (2% isoflurane) and blood samples and tissues were harvested. 
Cecal Ligation and Puncture (CLP) Sepsis Model 
CLP is considered the gold standard in sepsis research because it closely mimics 
the pathophysiology observed in patients and is highly reproducible.(195)  In this model, 
the cecum is exposed via a midline laparotomy under 2% isoflurane. Using a 4.0 silk, the 
cecum is ligated just below the ileocecal valve and punctured twice with a 23 gauge 
needle. The cecum is returned and the abdominal incision is closed in 2 layers with 4.0 
vicryl.  Cecal perforation subsequently progresses to polymicrobial peritonitis, 
bacteremia, systemic inflammation, multi-organ failure and eventually death.  Control 
animals also undergo laparotomy, however, the cecum is only manipulated and not 
injured.  
Post-CLP, all animals immediately receive normal saline (75µl/g) and 
buprenorphine (0.1mg/kg) subcutaneously.  Animals received subcutaneous fluids 
(normal saline;75µl/g) and antibiotics (ceftriaxone 25mg/kg; flagyl 12.5mg/kg) every 12 
hours starting 12 hours post-CLP for the duration of the experiment.  Buprenorphine 
(0.05mg/kg) was provided subcutaneously every 12 hours for the first 48 hours post 
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CLP.  Depending on the protocol, resveratrol (20mg/kg in solutol), EX-527 (10mg/kg in 
solutol) or solutol as vehicle was given intraperitoneally starting at 6 hours post-CLP 
and then given every 12 hours for the duration of the experiment.  
Blood Chemistries and Inflammatory Cytokines  
Blood was assayed for arterial blood gases, lactate, hemoglobin, and blood urea 
nitrogen (BUN) using point of care veterinary cartridges (i-STAT, Abbot Point of Care Inc., 
Princeton, NJ). Serum creatinine aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and creatinine kinase were analyzed spectrophotometrically using 
commercially available kits (Pointe Scientific, Canton, MI). Serum IL6 TNFα, and neutrophil 
gelatinase-associated lipocalin (NGAL) levels were measured by enzyme-linked 
immunosorbent assays (Invitrogen, ThermoFisher Scientific and Bioporto Diagnostics, 
Hellerup, Denmark). Each sample was run in duplicate with known standards and 
according to the manufacturer’s guidelines. 
Blood glucose was determined at each time point using a standard glucometer for 
rodents (AlphaTRAK, Abbott Laboratories, IL). In resveratrol experiments, blood 
glucose levels post resuscitation were measured every 15 minutes for 1.5 hours and 
then at 120, 240 and 360 minutes. Hypoglycemia was defined as blood glucose lower 
than 70mg/dl.(285) 
NAD/NADH Assays 
NAD was extracted from frozen tissue samples (50mg) isolated mitochondria 
(100µg), or primary hepatocytes (1X106 cells) in ice-cold 0.6M perchloric acid.  Tissues 
were homogenized at 20 Hz for 1 minute by tissue lyser (Qiagen).  Mitochondria and 
cells were vortexed hard for 30-45 seconds.  After centrifugation for 10 minutes 
(15,000g, 4°C), the clear supernatant was removed and diluted 1:100 in ice-cold 100mM 
sodium phosphate buffer, pH 8.  Using a modified Graeff and Lee enzymatic cycling 
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assay (85), NAD was measured in a 96-well format.  In brief, 5µl of NAD standards and 
diluted tissue extracts were mixed with 95µl of cycling mixture (0.2% ethanol, 0.11/ml 
alcohol dehydrogenase, 1.1mg/ml diaphorase, 20 µM resazurin, 10µM flavin 
mononucleotide, 10mM nicotinamide, and 0.1mg/ml BSA in 100mM phosphate buffer, 
pH 8.0).  NAD concentration was determined based on the rate of resorufin 
accumulation using spectrophotometry (excitation at 544nm, emission at 590 nm, 
Synergy H1, Biotek).  
NADH was extracted from frozen tissue (50mg) and isolated mitochondria 
(100µg) in ice-cold extraction buffer (0.25N KOH in 50% ETOH).  Samples were 
homogenized and centrifuged as described.  The supernatant was removed and heated 
at 55°C for 10 minutes to hydrolyze free NAD.  After dilution in ice-cold 100 mM sodium 
phosphate buffer (1:50), samples were assayed using the described enzymatic cycling 
assay.  The protein concentrations from the NAD and NADH extraction pellets were 
determined by using a Pierce BCA Protein Assay kit.  
Primary Hepatocytes: 
Primary hepatocytes were washed with phosphate buffered saline (PBS) 12 hours 
after plating.  Cells were treated with sterile filtered plasma (0.22µm) harvested under 
shock and sham conditions, with and without NMN (100nM) for 24 hours.  Cell survival 
was assessed by trypan blue exclusion (89-96% survival) and did not differ between 
groups.  
In a separate experiment, hepatocytes were washed with PBS after 12 hours after 
initial plating and the media was changed to Dulbecco’s Modified Eagle’s Medium, 10% 
FBS, with 1% penicillin–streptomycin.  Cells were treated with and without recombinant 
rat IL6 (20ng/ml, Sigma SRP4145) ± 100nM NMN for 1 hour.  Survival ranged from 96-
98% and did not differ between treatment groups.  Cells were immediately assessed 
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using high resolution respirometry or were treated with 0.6M perchloric acid and stored 
at -80° C until assayed for NAD. 
ATP Determination 
ATP from frozen tissues (50mg) was measured using a commercially available ATP 
determination kit (Life Technologies) according to the manufacturer’s instructions. 
Isolation of Mitochondria 
Liver and kidney tissues (4-6 g) were immediately immersed in ice-cold mitochondrial 
isolation buffer (MIB) (210 mM mannitol, 70 mM sucrose, 10 mM HEPES, 1 mM EDTA, 
final pH adjusted to 7.2 using KOH, and freshly supplemented with 0.5% fatty acid-free 
BSA). Tissue was homogenized in MIB with 5% BSA and mitochondria were isolated 
using differential centrifugation as previously described.(252,253).  The final 
mitochondrial pellet was resuspended in MIB or treated with 0.6M perchloric acid for 
NAD measurements. Protein concentration was measured by Pierce BCA Protein 
Assay.   
Mitochondrial Respiratory Capacity Using High Resolution Respirometry: 
A standard substrate/inhibitor titration protocol was used for functional analysis of 
mitochondrial respiratory function.(252,253)  Freshly isolated mitochondria (0.15 mg) 
were resuspended in respiration medium (110mM mannitol, 0.5mM EGTA, 3mM MgCl2, 
20mM taurine 10mM KH2PO4, 60mM K lactobionate, 0.3mM DTT, and 0.1% BSA (fatty 
acid free), adjusted to pH of 7.1 with KOH)(132).  Oxygen consumption was measured 
using high-resolution respirometry at 37°C with constant stirring (Oxygraph-2k Oroboros 
Instruments, Innsbruck, Austria).  Following stabilization (3-5 minutes), real-time oxygen 
concentration and flux data were continuously collected (DatLab software 4.3, Oroboros 
Instruments, Innsbruck, Austria).  After the basal respiration rate was recorded, complex 
I (CI)-dependent respiration was induced by adding 10 mM glutamate, 5 mM malate and 
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1 mM ADP to the respiration chamber.  In order to determine complex II (CII)-dependent 
respiration, rotenone (0.5 µM), a selective inhibitor of CI, was added followed by 10 mM 
of succinate.  Antimycin A (5 µM) was then added to inhibit complex III (CIII); followed by 
TMPD (0.5 mM) and ascorbate (2 mM) as artificial substrates for complex IV.  This 
protocol was completed within 60 minutes. 
Similarly, isolated hepatocytes (2.5x105 cells) were resuspended in respiration buffer 
and analyzed using high-resolution respirometry.  After stabilization, baseline oxygen 
consumption was recorded and cells were permeabilized digitonin (3 µg) and allowed to 
stabilize for 10 minutes.  Cells were then subjected to the substrate/inhibitor titration 
protocol used for isolated mitochondria. 
Citrate Synthase Activity 
Citrate synthase activity is commonly used as a quantitative enzyme marker for the 
presence of intact mitochondria.  Citrate synthase activity was determined according to 
the method described by Srere and Matsuoka (225), which couples coenzyme A to 5, 5’-
dithiobis-2-nitrobenzoic acid (DTNB) (212). Kidney and liver tissue (100 µg) were 
suspended in an assay buffer that included 0.1 mM DTNB (in 1M Tris buffer, pH 8.0), 0.3 
mM acetyl coenzyme A and 0.05% Triton X-100. Following the addition of 1 mM 
oxaloacetate, citrate synthase activity was determined spectroph otometrically by 
measuring the absorbance of thio-nitrobenzoic acid at 412 nm at 37°C.  
Total Production of Mitochondrial-Derived ROS 
Isolated mitochondria (10 µg) were suspended in 1 ml of buffer (250 mM 
sucrose, 20 mM 3-[N-morpholino] butane sulfonic acid, 10 mM Tris-base, 100 µMPi [K], 
0.5 mM Mg2+, pH 7.0; 30°C) containing CI substrates (malate/glutamate, 2.5/2.5 mM) 
and 2',7'-dichlorodihydro fluorescein diacetate (10 µM).  Antimycin A was subsequently 
added to inhibit CIII and measure the inherent ROS production.  Background 
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fluorescence was determined and was subtracted from all readings.  After incubation at 
30°C for 1 hour, the fluorescent signal from dichlorofluorescein (DCF) was detected 
(excitation 488 nm, emission 525 nm) and quantified using a Modulus Microplate Reader 
(Turner Biosystems, Sunnyvale, CA). 
Measurements of plasma metabolic hormones 
Blood (1.0 ml) was collected prior to sacrifice and plasma was stored at -80°C until 
analysis. Insulin, corticosterone, total GLP-1and glucagon were determined by the 
Radioimmunoassay and Biomarkers Core (Penn Diabetes Research Center, University 
of Pennsylvania) using commercially available ELISA and radioimmunoassay kits 
(Insulin and corticosterone ELISA -ALPCO Diagnostics, Windham, NH; total GLP-1 and 
glucagon radioimmunoassay -EMD Millipore, Billerica, MA).  All samples were performed 
in duplicate. 
Homeostatic model assessment (HOMA)- insulin resistance (IR) index 
HOMA is a mathematical model of the relationship between glucose and insulin that 
can be used to estimate insulin resistance and β cell function. The natural Log (Ln) 
HOMA-IR index is used clinically to characterize abnormal glucose tolerance and assess 
insulin resistance using the equation: Ln (insulin level (µU/ml) × glucose (mg/dl) /405). 
(113) 
Immunoblotting 
For western blot analysis, frozen liver and kidney tissue was lysed in RIPA buffer 
supplemented with phosphatase inhibitors (PhosSTOP, Roche), protease inhibitors 
(Complete, Roche), nicotinamide (1mM) and trichostatin A (1µM) using a tissue lyzer 
(Qiagen). Lysates were centrifuged for 15 minutes (15,000g, 4°C). Lysates were 
denatured in 25% laemmli buffer + BME at 95°C for 5 minutes and were resolved on 4-
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Gels were 
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transferred to polyvinylidene fluoride membranes (Millipore) blocked with nonfat soy milk 
for 5 minutes.(75)  Individual membranes were probed using anti-NAMPT (1:5000, 
SC67020, Santa Cruz), anti-phospho-Y612-IRS-1(1:1000; Invitrogen Biosource 
International, Carlsbad, CA), anti-actin antibodies (1:10.000, Abcam), in tris-buffered 
saline with 0.1% Tween20.  
Mitochondrial damage by reactive oxygen and nitrogen species was assessed by 
measuring 4-hydroxynonenal and 3-nitrotyrosine by Western blot (Abcam, 
Cambridge,MA).  Briefly, mitochondrial protein (20 µg) was loaded in a 4-12% 
polyacrylamide gel and separated by electrophoresis (Invitrogen, San Diego, CA). 
Proteins were transferred onto a nitrocellulose membrane (Bio-Rad, Richmond, CA). 
After the membranes were blocked for 1 hour at room temperature (10 mmol/L Tris, 150 
mmol/L NaCl, and 0.05% Tween-20 supplemented with 5% dry milk), blots were 
incubated with the respective primary antibodies at 1:1000 dilution overnight at 4°C. 
After washing, membranes were incubated with peroxidase-linked donkey anti-rabbit or 
sheep anti-mouse IgG secondary antibodies (Amersham, Buckinghamshire, UK) at 
1:5,000 dilution for 1 hour at room temperature. 
Proteins of interest were detected by chemiluminescence using horseradish 
peroxidase conjugated secondary antibodies and Western Lightening Plus ECL (Perkin 
Elmer). Images were captured using a Bio-Rad imaging station and quantified using 
Image J (National Institutes of Health, Bethesda, MD)  
Gene Expression 
Liver and kidney RNA was extracted from frozen tissue using Trizol (Sigma-Aldrich) 
with ethanol precipitation.  RNA (1µg) was used to create cDNA using a High Capacity 
cDNA Reverse Transcriptase Kit (Applied Biosystems) according to the manufacter’s 
recommendation.  Real-time polymerase chain reaction was performed using an Applied 
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Biosystems 7900HT system with SYBR green (Applied Biosystems).  Two technical 
replicates per sample were obtained and relative mRNA expression levels were 
calculated using the ΔΔCT method normalized to actin as a housekeeping gene.  
Primers can be found in Table 4.  
Statistical Analysis  
Results are expressed as mean ± standard error of the mean.  Comparison between 
two groups was performed using Students t or Mann Whitney test depending on 
normality of data distribution. One-way analysis of variance was used to compare 3 or 
more groups with a post hoc Students t or Mann Whitney test if statistically significant 
(p<0.05). Survival was analyzed using Kaplan-Meier curves with a log rank Mantel-Cox 
test. A chi square test was used to evaluate survival at 24 hours. All statistical analysis 
were performed using Prism 7 (GraphPad Software, Inc). 
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TABLES 
 
 
Table 1: Clinical variables in hemorrhagic shock treated with NMN. 
 
Organ Function Assay 
Control 
Sham 
NMN  
Sham 
Control 
 Shock 
NMN  
Shock 
Aspartate Aminotransferase (IU/L) 34.6 ± 6.2 34.4 ± 4.2 66.9 ± 4.9* 57.9 ± 4.8§ 
Alanine Aminotransferase (IU/L) 14.1 ± 1.7 11.6 ± 2.2 34.8 ± 5.9* 26.6 ± 4.8§ 
Creatinine (IU/L) 19.2 ± 1.3 22.9 ± 0.9 37.3 ± 4.8* 33.6 ± 4.8§ 
Blood Urea Nitrogen (mg/dL) 22.6 ± 2.0 18.2 ± 2.3 26 ±1.2 27.4 ± 0.6§ 
Creatine Kinase (U/L) 197 ± 53 220 ± 36 613 ± 81* 351 ± 42§♯ 
Results analyzed by one-way ANOVA followed by Student’s t test  
 *p<0.05 Control Sham vs  Control Shock 
§p<0.05 NMN Sham vs NMN Shock 
♯p<0.05 Control Shock vs NMN Shock 
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Table 2. Physiologic and laboratory parameters in hemorrhagic shock treated with 
resveratrol. 
Characteristics 
Sham 
(n=6) 
Severe Shock 
(n=6) 
LR  
(n=6) 
LR+RSV 
(n=6) 
MAP (mmHg) 111 ± 2 41 ± 1a 78 ± 5a,b 86 ± 2a,b 
HR (bpm) 440 ± 12 419 ± 8a 438 ± 23 456 ± 15 
Lactate (mmol/L) 1.3 ± 0.3 17.2 ± 1.3a 10.2 ± 1.2a,b 6.9 ± 1.3b,c 
pH 7.40 ± 0.01 7.05 ± 0.09a 7.20 ± 0.04a,b 7.32 ± 0.03b 
PCO2 (mmHg) 47 ± 4 17 ± 2a 28 ± 1a,b 33 ± 1b 
PO2 (mmHg) 85 ± 4 128 ± 4a 113 ± 5a 105 ± 2b 
HCO3- (mmol/L) 29.1 ± 2.0 5.4 ± 1.6a 11.3 ± 1.1a,b 17.2 ± 1.4b,c 
BUN (mg/dl) 23 ± 2 29 ± 2a 25 ± 1 30 ± 3 
Creatinine (mg/dl) 0.28 ± 0.03 0.63 ± 0.03a 0.53 ± 0.05a 0.57 ± 0.06a 
Na+ (mmol/L) 135 ± 1 128 ± 1a 130 ± 3 138 ± 1bc 
K+ (mmol/L) 4.5 ± 0.3 6.4 ± 0.6a 5.0 ± 0.4b 5.4 ± 0.4b 
Cl- (mmol/L) 103 ± 1 101 ± 1a 100 ± 2 112 ± 3b,c 
Hemoglobin (g/L) 
NGAL (ng/ml) 
12.3 ± 0.4 
60.5 ±8.2  
5.0 ± 0.5a 
73.3 ±23.2 
3.8 ± 0.1b 
107.8 ± 28.5a,b 
4.1 ± 0.3 
53.6 ± 1.0 b,c 
LR = Lactated Ringer's solution; RSV = Resveratrol; MAP = Mean Blood Pressure; HR = 
Heart Rate in beats/min; BUN = Blood Urea Nitrogen. NGAL = neutrophil gelatinase-
associated lipocalin. Values are mean ± SEM. n = 6. 
ap<0.05 versus Sham. 
bp<0.05 versus Severe Shock. 
cp<0.05 versus LR Resuscitation. 
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Table 3. Endpoints of Euthanasia Scoring System  
Adapted from the University of Pennsylvania Institutional Animal Care and Use 
Committee Guidelines on Adopted from the University of Pennsylvania’s Institutional 
Animal Care and Use Committee’s guide for Humane Endpoints for Laboratory Animals 
Physical Appearance 
0 Normal 
1 Lack of grooming 
2 Rough coat, nasal/ocular discharge 
3 Very rough coat, abnormal posture, enlarged pupils  
Clinical Signs 
0 Normal 
1 Small changes of potential signficance 
2 Body temperature change of 1-2 ◦C , respiratory rate ↑up to 30% 
3 Body temperature change of >2 ◦C , respiratory rate ↑up to 50%, or 
markedly ↓ 
Unprovoked Behavior  
0 Normal 
1 Minor changes 
2 Abnormal, reduced mobility, decreased alertness, inactive 
3 Unsolicited vocalizations, self-mutilation, ether very restless or immobile 
Stimulated Behavior 
0 Normal 
1 Minor depression/exaggeration of response 
2 Moderately abnormal responses 
3 Violent reactions, or comatose 
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Table 4.  Primers used for qPCR 
!
Transcript Forward Primer Reverse Primer 
β-actin GGCTGTATTCCCCTCCATCG  CCAGTTGGTAACAATGCCATGT  
IL6 TAGTCCTTCCTACCCCAACTTCC TTGGTCCTTAGCCACTCCTTC 
TNFα CTGTGCCTCAGCCTCTTCTC ACTGATGAGAGGGAGCCCAT 
NAMPT TCTGGAAATCCGCTCGACAC TATCCACTCCGTCCCCTTGA 
NMNAT1 CAGAGCATCCGCTACTTGGT ATCGGGTGGAATGGTTGTGT 
NMNAT2 TCTGACTGGATCAGGGTGGA ATGGTGCTCTAACACACTGC 
NMNAT3 CCTGCGTTTGTTTGAGGTGG ATGATGCCGTTTCCATCCACT 
SIRT1 CAGGTTGCAGGAATCCAAA CAAATCAGGCAAGATGCTGT 
PGC1-α CCAGTCTACGGCTGTTTGGT TGGAAGAACAGATGTGCCCC 
NRF1 ACAGATAGTCCTGTCTGGGGAAA TGGTACATGCTCACAGGGATCT 
NRF2 TGAAGTTCGCATTTTGATGGC CTTTGGTCCTGGCATCTCTAC 
TFAM GTTTCGTGCGGGTTTGTGAA GAAACTGCAATGGCTCTGCC  
SOD2 GCCTGCACTGAAGTTCAATG ATCTGTAAGCGACCTTGCTC 
CAT ACCCTCTTATACCAGTTGGC GCATGCACATGGGGCCATCA 
COX-2 ATTCTTTGCCCAGCACTTCA ATCATCAGACCAGGCACCA 
!
!
!
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FIGURES 
	  
	  
Figure 1: Pathways activated in the resuscitation of shock states.  
Traumatic injury with acute blood loss results in vasoconstriction, activation of the 
coagulation pathway, release of DAMPs (damage associated molecular patterns), and 
the secretion of chemokines and cytokines which activate the immune response. 
Similarly, infection releases PAMPs (pathogen associated molecular patterns) which 
activate the immune system. Both types of shock are associated with tissue hypoxia and 
hypoperfusion. Decreased oxygen and fuel substrates restrict ATP generation and lead 
to reduced NAD levels. With reperfusion, there is massive generation of ROS (reactive 
oxygen species) and mitochondrial dysfunction, which in turn further activates the 
immune system, injures the endothelium and causes more tissue damage.  
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Figure 2: SIRT1 targets and activators.   
SIRT1 can interact with a number of targets involved in the pathophysiology of shock.  
Specifically, SIRT1 can inhibit NFκB and decrease inflammation. SIRT1 deacetylates 
PGC1α (perioxisome proliferator-activated receptor gamma co-activator 1-alpha), a key 
transcriptional co-activator that promotes mitochondrial biogenesis, coordinates a switch 
to fatty acid metabolism and decreases oxidative stress. PGC1α also increases the 
transcription of SIRT3, the major mitochondrial deacetylase. Interactions with FOXO  
FOXO (forkhead box O) increases the expression of key antioxidant enzymes such as 
manganese superoxide dismutase and catalase.  Nicotinamide mononucleotide (NMN) 
can be directly converted to NAD, an essential activator of SIRT1. Resveratrol also can 
increase SIRT1 activity either by increasing NAD or by allosteric interactions.  SIRT1 
inhibits NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells), thereby 
downregulating the transcription of pro-inflammatory cytokines.  
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Figure 3: Fixed pressure hemorrhagic shock design and experimental variables.  
(A) Animals were randomized to water ± NMN (400 mg/kg/day) for 5 days (n=9 -12 per 
group). Animals were bled to a mean arterial blood pressure (MAP) of 40mmHg for 90 
minutes and then resuscitated with 4X the shed volume in lactated Ringer’s ± NMN 
(400mg/kg) over 60 minutes. Control animals did not differ from NMN treated in terms of 
percentage of total blood volume shed (B), the volume of LR needed to maintain a MAP 
of 40 mmHg for 90 minutes (C), or the MAP after 60 minutes of resuscitation (D). 
Hemoglobin was similar between groups (E). NMN treated animals had significantly 
lower lactate levels during shock and following resuscitation (F). Data were analyzed by 
Student’s t test or Mann Whitney as appropriate. * p<0.05.  
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Figure 4: NMN increases NAD and NADH, and preserves renal ATP following 
resuscitation from hemorrhagic shock.  
NAD, NADH, and ATP levels were measured in extracts from snap frozen tissues. In the 
kidney, NMN increased the NAD and NADH levels in both sham (n=5-6 per treatment 
group) and shocked animals (9-12 per treatment group), and prevented the sharp 
decline in NAD/NADH ratio observed in shocked animals (A). In the liver, NMN 
increased NAD levels in both sham and shocked animals, but only increased NADH 
significantly in shocked animals, while again preserving the NAD/NADH ratio (B). ATP 
levels declined in both tissues following hemorrhagic shock and resuscitation (C, D). 
Treatment with NMN, however, completely prevented this decline in renal tissue (C). 
Data were analyzed by one way ANOVA, followed by Student’s t test or Mann Whitney 
as appropriate. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.  
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Figure 5: NMN preserves Complex I-dependent mitochondrial respiration and 
enhances mitochondrial NAD content.  
Following hemorrhagic shock and resuscitation, mitochondria from kidney and liver 
tissue were freshly isolated and evaluated using high-resolution respirometry.  In both 
tissues, a defect in respiration was noted when NAD-dependent substrates such as 
palmatoylcarnitine (PC) and pyruvate/glutamate/malate (CI) were used. Pretreatment, 
and subsequent resuscitation, with NMN completely restored mitochondrial respiration in 
kidney (A) and preserved respiration with CI substrates in liver (B).  Without NMN 
treatment, NAD content was preserved following resuscitation in kidney (C) and 
increased in liver (D). NMN augmented mitochondrial NAD levels in both the sham and 
shocked states (C, D). (n=5-6 per treatment group). Data were analyzed by one-way 
ANOVA, followed by Student’s t test or Mann Whitney as appropriate. 
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Figure 6: NMN increases NAMPT and NMNAT3 following hemorrhagic shock. 
Following hemorrhagic shock, there was a trend toward increased NAMPT mRNA that 
was further enhanced with NMN treatment in kidney (A) and liver (E). NAMPT protein 
expression was not affected by shock in either tissue (B, F). NMNAT1 expression was 
not affected in kidney (C), but declined in liver and was not affected by NMN (G). 
NMNAT3 expression was increased in kidney and decreased in liver following shock, but 
in both tissues was enhanced by NMN treatment only in animals that had been shocked 
(D, H). (n=5-12 per treatment group) Data were analyzed by one-way ANOVA, followed 
by Student’s t test or Mann Whitney as appropriate. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 7: NMN mitigates inflammation following hemorrhagic shock. 
Serum IL6 and TNFα were determined by ELISA. Serum levels of both pro-inflammatory 
cytokines increased with hemorrhagic shock, whereas NMN significantly lowered IL6 
with a trend toward improved TNFa levels (A). The decrease in cytokines correlated with 
improved hyperglycemia following shock (B).  Inflammatory cytokine expression was 
measured by qPCR in kidney and liver tissues. NMN partially mitigated IL6 mRNA 
expression in kidney, but not in liver (C, D). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 8: NMN rescues mitochondrial function and increases NAD in isolated 
hepatocytes after cytokine exposure. 
After co-culture for 24 hours with plasma harvested from animals in hemorrhagic shock, 
digitonin-permeabilized isolated hepatocytes exhibited a defect in complex I dependent 
respiration that was mitigated by concurrent treatment with NMN (100µM) (A).  When 
treated with IL6 (20ng/ml) for 1hour, isolated hepatocytes developed global 
mitochondrial dysfunction with decreased respiratory capacity at every complex that was 
mitigated by co-treatment with NMN (100µM) (B). NMN increased NAD levels only in 
cells that were co-treated with IL6 (C). (n=6-8 per group)*p<0.05, **p<0.01. 
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Figure 9: NMN enhances tolerance to hemorrhagic shock. 
After randomization to water ± NMN (400 mg/kg/day) for 5 days, animals were bled to a 
mean arterial blood pressure (MAP) of 40mmHg and then maintained at 40 mmHg with 
incremental fluid boluses until 40% of the shed blood volume had been returned. 
Animals were then resuscitated with 4X the shed volume in lactated Ringer’s ± NMN 
(400mg/kg) over 60 minutes and observed for 48 hours (n=11 per treatment group)(A).  
Animals pretreated with NMN were able to sustain a shock state longer than controls (B) 
but with a similar percentage of blood loss (C).   NMN treated animals had lower blood 
lactate concentrations following resuscitation (D) and despite having spent more time in 
shock, were significantly more likely to be alive at 24 hours than were controls (E, F). 
*p<0.05. 
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Figure 10: Hemodynamics and lactate values during resuscitation with resveratrol.  
Male Long Evan’s rats were subjected to a decompensated model of hemorrhagic shock 
and then resuscitated with 4X the shed volume in lactated Ringer’s solution (LR) ± 
resveratrol (RSV; 30mg/kg) over 60 minutes.  (A) RSV did not influence mean arterial 
blood pressure. (B) Lactate levels were significantly lower in the RSV treated group at 
60 minutes, but returned to baseline in both groups by 18 hours. RSV treatment did not 
significantly decrease the levels of TNF-α or IL-6 when compared to LR resuscitation 
alone (C,D). TNF-α and IL-6 were measured by ELISA. SS= severe shock, R = after 
resuscitation. Values are mean ± SEM, n = 6 per group. *p<0.05. 
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Figure 11.  RSV supplementation during resuscitation restores mitochondrial 
function and decreases the production of ROS.  
The respiratory capacity of individual complexes in isolated intact mitochondria was 
assessed by high-resolution respirometry. Following hemorrhagic shock, mitochondrial 
CI, CII, and CIV in the liver and kidney demonstrated decreased activity. (A) In the liver, 
RSV supplementation during resuscitation robustly restored the respiratory function of all 
complexes and significantly improved CII- and CIV- dependent respiratory capacity over 
baseline at 18 hours after resuscitation. (B) RSV supplementation significantly restored 
kidney CII- and CIV-dependent respiration following resuscitation and improved the 
respiratory capacity of all mitochondrial complexes 18 hours later. Mitochondrial ROS 
production was detected by measuring the fluorescent signal from dichlorofluorescein. 
RSV supplementation significantly reduced liver (C) and kidney (D) mitochondrial ROS 
production following resuscitation. LR, resuscitation with LR solution; LR + RSV, 
resuscitation with LR solution plus RSV (30 mg/kg); 18hr LR, 18 hours after resuscitation 
with LR solution; 18hr LR + RSV, 18 hours after resuscitation with LR solution plus RSV 
(30 mg/kg). Values are mean ± SEM. n = 6. *p < 0.05 versus sham; †p < 0.05, LR 
versus LR + RSV; ‡p < 0.05, 18hr LR versus 18hr LR + RSV.  
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Figure 12: Resveratrol treatment during resuscitation ameliorates renal 
mitochondrial oxidative stress following hemorrhagic shock and resuscitation. 
(A) LR+RSV resuscitation significantly increased the mRNA expression of superoxide 
dismutase 2 (SOD2) and catalase (CAT) in kidney tissue when compared to LR 
resuscitation. (B) 4- hydroxynonenal (4-HNE) was measured by western blots a marker 
of mitochondrial lipid peroxidation. 4-HNE levels robustly increased following Severe 
Shock and were significantly reduced with LR+RSV resuscitation. (C) Expression levels 
of 3-nitrotyrosine (3-NT) in mitochondria were determined by western blot. 3-NT levels 
increased with LR resuscitation, but did not increase with LR+RSV resuscitation. LR = 
Lactated Ringer’s solution; RSV = Resveratrol; COX = cyclooxygenase. Values are 
mean ± SEM. n = 6, *p<0.05 versus Sham; †p<0.05 versus Severe Shock; ‡p<0.05 
versus LR Resuscitation.  
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Figure 13: Resveratrol supplementation enhances the mRNA expression of Sirtuin 
1 (SIRT1) and increases the nicotinamide adenine dinucleotide (NAD) to 
nicotinamide adenine dinucleotide dehydrogenase (NADH) ratio in kidney.  
(A) The decline in the mRNA expression level of SIRT1 after severe shock and LR 
resuscitation was reversed with RSV administration during resuscitation. (B) NAD+, 
NADH concentration and NAD+-NADH ratio in kidney tissue were obtained by detecting 
the fluorescent signal of resazurin. LR+RSV resuscitation significantly decreased the 
NADH concentration and nearly doubled the NAD/NADH ratio when compared to LR 
resuscitation. LR = Lactated Ringer’s solution; RSV = Resveratrol. Values are mean ± 
SEM. n = 6, *p<0.05 versus Sham; †p<0.05 versus Severe Shock; ‡p<0.05 versus LR 
Resuscitation.  
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Figure 14:  Resuscitation with RSV enhances pyruvate dehydrogenase and α-
ketoglutarate dehydrogenase activity following hemorrhagic shock. 
Kidney tissue harvested after 60 minutes of resuscitation with lactated Ringer’s (LR) or 
LR + resveratrol (30mg/kg). Enzymatic activity of Kreb cycle enzymes was assessed by 
measuring by the spectrophotometric reduction of NAD+ to NADH. All enzyme activities 
decreased with severe shock. When compared to LR, RSV significantly enhanced the 
activity of PHD and a-KDH, but was associated with decreased IDH activity. PDH = 
pyruvate dehydrogenase, IDH = isocitrate dehydrogenase, a-KDH= alpha ketoglutarate 
dehydrogenase, GDH = glutamate dehydrogenase, MDH = malate dehydrogenase.  
Values are mean ± SEM.  n = 6 per time point. *p<0.05, ***p<0.001,****p<0.0001; 
Severe Shock vs LR or LR+RSV. 
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Figure 15:  Mitochondrial content and expression of mitochondrial biogenesis 
factors in the kidney following hemorrhagic shock and resuscitation. 
Citrate synthase activity was determined spectrophotometrically based on coenzyme A 
coupled to 5, 5′-dithiobis-2-nitrobenzoic acid.  (A) Citrate synthase activity, a proxy for 
mitochondrial content, did not significantly change with hemorrhagic shock or with either 
resuscitative strategy.  (B) mRNA expression of peroxisome proliferator-activated 
receptor gamma coactivator 1- alpha (PGC1-α) was significantly elevated in the 
LR+RSV group compared to the LR resuscitation only group. The expression of other 
factors involved in mitobiogenesis such as mitochondrial transcription factor A (TFAM), 
nuclear respiratory factor (NRF) 1 and 2, however, were not affected by RSV.  LR = 
Lactated Ringer’s solution; RSV= Resveratrol. Values are mean ± SEM. n = 6, *p<0.05 
versus sham; †p<0.05 versus Severe Shock; ‡p<0.05 versus LR Resuscitation.  
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Figure 16: Resuscitation with RSV lowers blood glucose and improves insulin 
resistance. 
Decompensated hemorrhagic shock resulted in severe hyperglycemia, hyperinsulinemia, 
and a significantly elevated Ln HOMA-IR index. (A, B)  RSV was associated with 
significantly lower blood glucose values 45, 60, and 90 minutes after the onset of 
resuscitation and animals treated with LR + RSV were more hypoglycemic than those in 
the sham group. (C) RSV supplementation resulted in significantly decreased plasma 
insulin levels, as determined by ELISA. (D) RSV significantly improved insulin resistance 
as calculated by the Ln HOMA-IR index (Ln [insulin × glucose/405]).  (E) Compared with 
LR alone, LR + RSV significantly increased GLP-1 levels following hemorrhagic shock 
but did not influence glucagon or corticosterone values (F, G). GLP-1and glucagon were 
measured by radioimmunoassay; corticosterone was measured by ELISA.  LR= lactated 
Ringer’s solution, RSV = resveratrol (30mg/kg); Ln-HOMA-IR index = the natural Log 
homeostatic model assessment –insulin resistance index; GLP-1= glucagon like peptide-
1 Values are mean ± SEM. n = 6. *p < 0.05 versus sham; †p < 0.05, LR versus LR + 
RSV.  
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Figure 17: Resveratrol (RSV) restores activation of IRS-1 in both liver and kidney.  
The phosphorylated tyrosine 612 of IRS-1 (pY612 IRS-1) is the active form of IRS-1 that 
participates in insulin signaling. Western blotting for this modification indicates that 
hemorrhagic shock and resuscitation with only LR are associated with significantly 
decreased phosphorylation of IRS-1 in liver and kidney tissues. Resuscitation with LR + 
RSV robustly preserved the phosphorylation of IRS-1 in both the liver (A) and the kidney 
(B). LR, resuscitation with LR solution; LR + RSV, resuscitation with LR solution plus 
RSV (30 mg/kg); 18hr LR, 18 hours after resuscitation with LR solution; 18hr LR + RSV, 
18 hours after resuscitation with LR solution plus RSV (30 mg/kg). Values are mean ± 
SEM. n = 4–5. *p < 0.05 versus sham; †p < 0.05, LR versus LR + RSV.  
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Figure 18: Severity of cecal ligation and puncture (CLP) impacts mortality and 
physiology.  
Male C57BL/6J mice (12 weeks, n=6-9/group) were subjected to sham surgery or CLP 
(mild, moderate, or severe) and followed for 7 days.  (A) Mortality varied from 0% 
(Sham) to 100% (Severe). (B). The severity of sepsis clearly impacted the Endpoints of 
Euthanasia Score at every time point.  Both glucose and temperature were negatively 
influenced by the severity of sepsis with clear differences between groups (C and D).  
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Figure 19: The temporal expression of SIRT1 in liver and kidney after CLP. 
Male C57BL/6J mice (12 weeks, n=2-3/group) were subjected to sham surgery or severe 
CLP and sacrificed at 3, 9, 18 and 24hrs. (A) In liver, sepsis was associated with 
decreased SIRT1 and increased NAMPT gene expression that peaked at 9 hours. (B) In 
kidney, sepsis did not significantly change SIRT1 expression, but did result in 
significantly lower expression of NAMPT at 24 hours. Data were analyzed by one-way 
ANOVA, and if significant, reanalyzed with a Student’s t-test or Mann Whitney as 
appropriate. *p<0.05, ***p<0.0005. 
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Figure 20:  Pharmacologic manipulation of SIRT1 influences survival and 
physiology in severe sepsis.  
Six hours after CLP, mice received either placebo (n =12), resveratrol (20 mg/kg; n=12), 
or EX-527(10 mg/kg; n=6) by IP injection. Therapy continued every 12 hours until death. 
Although this model was 100% lethal, resveratrol treated mice lived longer than either 
placebo (p=0.0005) or EX-527 treated animals (p=0.054) by log rank Mantel Cox 
analysis.  When compared to controls and resveratrol, SIRT1 inhibition with EX-527 
significantly improved temperature starting at 24 hours (B) with a trend toward improved 
glucose levels (C). Data were analyzed by one-way ANOVA, and if significant, 
reanalyzed with a Student’s t-test or Mann Whitney as appropriate. *p<0.05, 
****p<0.0001. 
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Figure 21:  SIRT1 deletion increases the severity and mortality of sepsis.  
Wild-type (WT, n=12) and S1KO (n=9) male mice were subjected to severe sepsis and 
followed for 5 days. Temperature, glucose, and endpoints of euthanasia were assessed 
every 6 hours. (A) S1KO mice had significantly worse 5 day survival as determined by 
log rank Mantel Cox analysis (p=0.012) as well as (B) a trend toward higher Endpoints of 
Euthanasia scores. (C) Over the course of 5 days, SIKO mice lost significantly more 
weight than WT mice. Physiologically, S1KO mice tended to be more hypothermic and 
more hypoglycemic early during sepsis than WT mice. Data was analyzed by one-way 
ANOVA, and if significant, reanalyzed with a Student’s t-test or Mann Whitney as 
appropriate.  *p<0.05 
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Figure 22: The impact of SIRT1 deletion on mitochondrial respiratory capacity in 
liver and kidney tissue 5 days post-CLP. 
Five days after CLP, surviving WT (6) and S1KO (n=3) mice were sacrificed and 
mitochondrial function was measured in liver and kidney tissue homogenates.  
Mitochondrial content and respiration in whole tissue homogenates were measured 5 
days after CLP in WT (n=6) and S1K0 (n=3) survivors.  SIRT1 status did not significantly 
impact citrate synthase activity, a proxy for mitochondrial content, in either liver (A) or 
kidney tissue (B). Mitochondrial respiratory capacity was assessed in whole tissue 
homogenates using high resolution respirometry. (C) Although, SIRT1 deletion did not 
influence liver mitochondrial function, (D) it was associated with decreased CII-
dependent respiration in kidney tissue. FA= fatty acid dependent respiration; CI = 
complex I; CII =complex II; CIV = complex IV. Data were analyzed using a Student’s t-
test or Mann Whitney as appropriate. *p<0.05 
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Figure 23: SIRT1 deletion negatively impacts physiologic variables and organ 
function 36 hours post-CLP. 
WT and S1KO mice were subjected to a sham procedure (n= 3, 2), CLP (n= 5, 4) or CLP 
with RSV (20mg/kg, n=6, 4) and sacrificed 36 hours later. Physiologic variables 
(temperature, serum glucose) were measured and endpoints of euthanasia were scored. 
Organ function was assessed by measuring serum blood urea nitrogen (BUN), aspartate 
aminotransferase (AST), and alanine aminotransferase (ALT).  Although not statistically 
significant, S1KO mice tended to be more hypothermic (A), more hypoglycemic (B), and 
less clinically well with higher Endpoints of Euthanasia scores (C) when compared to WT 
mice.  (D) S1KO mice had more renal dysfunction with significantly higher BUN levels. 
(E) S1KO mice demonstrated significant variability in terms of liver dysfunction. 
Resveratrol treatment (RSV) had minimal impact on any variable measured.  
Comparisons were made between WT and S1KO animals within each treatment group 
using Student’s t test or Mann Whitney as appropriate. *p<0.05 
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Figure 24: Liver mitochondrial function and NAD content at 36 hours post-CLP.  
WT and SIKO mice were subjected to a sham procedure (n= 3, 2), CLP (n= 5,4) or CLP 
with resveratrol (RSV; 20mg/kg, n=6,3). Mitochondrial function was measured in liver 
whole homogenates 36 hours after CLP. (A) Mitochondrial content did not differ between 
groups when assessed by citrate synthase activity.  (B) Using high-resolution 
respirometry, fatty acid dependent respiration trended higher in WT animals, but did not 
reach statistical significance. (C) SIRT1 KO sham animals had significantly lower CI, but 
higher CIV respiratory capacity than WT shams. Although S1KO and WT animals had 
similar respiratory capacity following CLP, sepsis significantly reduced CI, II, and IV 
dependent respiration in WT animals. RSV had minimal impact on respiratory capacity, 
although there was a trend toward improved CI-dependent respiration in WT CLP 
animals. (D) NAD and NADH were not significantly different between WT and S1KO 
animals, although RSV was associated with increased NADH levels in S1KO animals. 
RSV= resveratrol; FA= fatty acid dependent respiration; CI = complex I; CII =complex II; 
CIV = complex IV.  Data was analyzed by one-way ANOVA and comparisons were 
made between WT and S1KO animals within each treatment group using Student’s test 
or Mann Whitney as appropriate. *p<0.05, **p<0.01 
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Figure 25: SIRT1 deletion significantly impacts kidney mitochondrial function and 
NAD content 36 hours post-CLP. 
WT and SIKO mice were subjected to a sham procedure (n= 3,2), CLP (n= 5,4) or CLP 
with RSV (RSV; 20mg/kg, n=6,3). 36 hours after CLP, mitochondrial function was 
measured in renal whole homogenates using high resolution. (A) Mitochondrial content 
was similar between WT and S1KO mice as measured by citrate synthase activity. 
Following CLP, (B) S1KO mice demonstrated decreased fatty acid respiration, as well as 
decreased CI and CII dependent respiration when compared to WT septic mice (B, C). 
There was a trend toward improved CI dependent respiration in WT animals treated with 
RSV.  FA= fatty acid dependent respiration; CI = complex I; CII =complex II; CIV = 
complex IV.  Data were analyzed by one-way ANOVA and comparisons were made 
between WT and S1KO animals within each treatment group using Student’s test or 
Mann Whitney as appropriate. *p<0.05. 
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Figure 26:  SIRT1 deletion is pro-inflammatory during sepsis. 
Blood samples were collected from CLP-treated WT (n=7) and S1KO (n=9) mice at 
baseline, 2 hours, 4 hours and 5days. (A) SIRT1 deletion resulted in significantly higher 
serum IL6 levels in septic mice. Cultured bone marrow derived macrophages (BMDM) 
harvested from WT and S1KO mice were treated with LPS (1 µg/ml) and the gene 
expression of IL6 was followed over time (n=5 per group/time).  The expression of two 
antioxidants, SOD2 and catalase, were also measured.  (B,C) SIRT1 deletion resulted in 
significantly higher IL6 and SOD2 expression.  (D) Catalase mRNA expression was 
significantly higher in S1KO BMDM, although its expression decreased with LPS 
exposure over time in both groups.  (E) WT BMDM (n=2 per group) were pretreated for 1 
hour with vehicle, EX-527 (1µM), RSV (50µM), or both EX-527+ RSV and co-cultured 
with LPS (1 µg/ml) for 8 hours. Gene expression of SIRT1 fell with LPS exposure and 
was not affected by pharmacologic interventions. Expression of IL6 and SOD2 increased 
with EX-527 and fell with RSV. In contrast, expression of CAT decreased with LPS 
exposure, but was partially rescued by RSV.  Data were analyzed by one-way ANOVA 
and comparisons were made between WT and S1KO animals at each time point using 
Student’s test or Mann Whitney as appropriate. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 27: Myeloid deletion of SIRT1 is pro-inflammatory in CLP model of sepsis.   
WT (n=8) and SIRT1-LysMCre (n=10) were subjected to CLP and followed for 5 days.  
(A) When compared to WT littermates, S1KO LysMCre mice had significantly higher 
serum IL6 levels 12 hours after CLP and (B) increased 5 day mortality. 
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Figure 28:  The impact of deleting SIRT3 on physiology and mortality over 5 days.  
WT (n=17) and S3KO mice (n=20) were subjected to CLP and followed for 5 days. (A) 
At baseline S3KO mice weighed less than their WT littermates. (B) WT survivors lost a 
larger percentage of body weight than S3KO mice. (C,D) Groups did not differ in terms 
of temperature or serum glucose over time. (E) On day 5, organ function in surviving 
animals was assessed by serum blood urea nitrogen (BUN), aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT).  (F) S3KO mice had increased mortality 
within the first 48 hours, but overall mortality was not significantly different at 5 days by 
log rank analysis.  All other data were analyzed by Mann Whitney or Student’s t tests 
depending on normality of data. *p<0.05.  
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Figure 29:  The impact of deleting SIRT3 on clinical variables and organ function 
36 hours post CLP.  
WT (n=8) and S3KO mice (n=9) were subjected to CLP and followed for 36 hours. (A) 
Both WT and S3KO mice developed significant hypothermia 18 hours post CLP.  (B) 
Although glucose levels fell significantly in both groups, S3KO mice were significantly 
less hypoglycemic than WT animals at 24 and 36 hours.  (C) WT and S3KO animals had 
similar endpoints of euthanasia scores and (D) did not differ in terms of renal (BUN) or 
liver (AST, AST) function tests. Data were analyzed by one-way ANOVA followed and if 
significant were reanalyzed by Mann Whitney or Student’s t tests depending on 
normality of data. *p<0.05. 
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Figure 30:  Deleting SIRT3 does not significantly impact mitochondrial respiration 
in liver or kidney following sepsis.  
WT (n=10,9) and S3KO (n=6,10) were subjected to either 36 hour or 5 days of CLP.  
Sham animals (n=2-3 per group) underwent surgery without CLP. Whole homogenates 
of liver and kidney were used to measure mitochondrial content and complex dependent 
respiration.  (A) In liver, mitochondrial content as measured by citrate synthase activity 
did not differ between groups either at 36 hours or 5 days post-CLP. (B) Both genotypes 
developed a similar CI deficiency by 36 hours and (C) exhibited a CIV defect at 5 days 
post.  (D) Kidney mitochondrial content was similar at each time point. (E) Interestingly, 
there was a trend toward increased FA and CI dependent respiration at 36 hours in both 
WT and S3KO mice. (F) At 5 days, all complexes demonstrated significantly decreased 
respiratory capacity regardless of SIRT3 status. FA= Fatty acid; CI=Complex I, 
CII=Complex II, CIV = Complex IV. Data were analyzed between groups by Mann 
Whitney or Student’s t tests depending on normality of data. *p<0.05, **p<0.01. 
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Figure 
31: Deleting SIRT3 is pro-inflammatory. 
WT (n=10) and S3KO (n=9) mice were subjected to CLP and followed for 5 days. Serum 
IL6 was measured by ELISA at baseline, 3, 6, 12 and 36 hours with a final sample taken 
at 5 days.  (A) IL6 levels peaked at 6 hours and were significantly higher in S3KO mice. 
At 36 hours, IL6 levels were similar. (B) WT and S3KO bone marrow derived 
macrophages (n=2-5/time point) were co-cultured with LPS (1µg/ml) and assayed at 
different time points for cytokine gene expression. IL6 expression trended higher in 
S3KO BMDMs until 8hrs. (C) TNFα mRNA expression was similar. WT and S3KO 
BMDMs (n=3/group) were co-cultured with LPS (1µg/ml) and the SIRT3 activator, 
honokiol (HKL; 10µM) for 4 hours. (D,E) There was a trend toward increased IL6 and 
decreased TNFα mRNA expression in S3KO BMDMs. (F) S3KO BMDMs had increased 
SOD2 expression that decreased with HKL treatment. Data were analyzed between 
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groups by Mann Whitney or Student’s t tests depending on normality of data. *p<0.05, 
**p<0.01. 
 
 
Figure 32:  SIRT3 mRNA expression declines in multiple tissues during sepsis.  
WT BMDM (n=3 per time point) were co-cultured with LPS (1µg/ml). (A) mRNA 
expression of SIRT3 decreased and approached significance after 4 hours of exposure. 
Male C57BL/6J mice (12 weeks, n=2-3/group) were subjected to sham surgery or severe 
CLP and sacrificed at 3, 9, and 24hrs.  (B) There was a significant and progressive 
decline in liver SIRT3 mRNA over time. (C) Kidney SIRT3 mRNA expression increased 
significantly by 3 hours, but then progressively declined.  
 
  
Control 4hr 8hr
0.0
0.5
1.0
1.5
SIRT3 mRNA
Fo
ld
In
cr
ea
se p=0.06
Baseline 3hr 9hr 24hr
0.0
0.5
1.0
1.5
2.0
2.5
Kidney SIRT3 mRNA
Fo
ld
In
cr
ea
se
**
*
Baseline 3hr 9hr 24hr
0.0
0.5
1.0
1.5
Liver SIRT3 mRNA
Fo
ld
In
cr
ea
se
*
** **
A.
B. C.
BMDM$SIRT3$mRNA$
109	  
	  
BIBLIOGRAPHY 
 
1. Ahn BH, Kim HS, Song S, Lee IH, Liu J, Vassilopoulos A, Deng CX, Finkel T. A 
role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. 
Proc Natl Acad Sci U S A 105: 14447-52, 2008. 
2. Aksu U, Bezemer R, Yavuz B, Kandil A, Demirci C, Ince C. Balanced vs 
unbalanced crystalloid resuscitation in a near-fatal model of hemorrhagic shock 
and the effects on renal oxygenation, oxidative stress, and inflammation. 
Resuscitation 83: 767-73, 2012. 
3. Alano CC, Garnier P, Ying W, Higashi Y, Kauppinen TM, Swanson RA. NAD+ 
depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-
mediated neuronal death. J Neurosci 30: 2967-78, 2010. 
4. Alberts B. Energy conversion: Mitochondria and chloroplasts. In: Molecular 
Biology of the Cell. edited by Alberts B BD, Lewis J,. New York: Garland 
Publishing; 1994. pp. 676-677. 
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 
Epidemiology of severe sepsis in the United States: analysis of incidence, 
outcome, and associated costs of care. Crit Care Med 29: 1303-10, 2001. 
6. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 369: 
2063, 2013. 
7. Aydin S, Bacanli M, Taner G, Sahin T, Basaran AA, Basaran N. Protective 
effects of resveratrol on sepsis-induced DNA damage in the lymphocytes of rats. 
Hum Exp Toxicol 32: 1048-57, 2013. 
8. Ayub A, Poulose N, Raju R. Resveratrol Improves Survival and Prolongs Life 
Following Hemorrhagic Shock. Mol Med 21: 305-12, 2015. 
9. Baue AE, Chaudry IH, Wurth MA, Sayeed MM. Cellular alterations with shock 
and ischemia. Angiology 25: 31-42, 1974. 
10. Baue AE, Wurth MA, Sayeed M. Alterations in hepatic cell function during 
hemorrhagic shock. Bull Soc Int Chir 31: 387-92, 1972. 
11. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 1804: 
1626-34, 2010. 
12. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, 
Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, 
Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le 
Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair 
DA. Resveratrol improves health and survival of mice on a high-calorie diet. 
Nature 444: 337-42, 2006. 
13. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. 
Nat Rev Drug Discov 5: 493-506, 2006. 
14. Bause AS, Haigis MC. SIRT3 regulation of mitochondrial oxidative stress. Exp 
Gerontol 48: 634-9, 2013. 
15. Benns M, Carr B, Kallan MJ, Sims CA. Benchmarking the incidence of organ 
failure after injury at trauma centers and nontrauma centers in the United States. 
J Trauma Acute Care Surg 75: 426-31, 2013. 
16. Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and 
differential catalytic properties of the three human nicotinamide mononucleotide 
adenylyltransferase isoforms. J Biol Chem 280: 36334-41, 2005. 
17. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J 
Leukoc Biol 81: 1-5, 2007. 
110	  
	  
18. Biel TG, Lee S, Flores-Toro JA, Dean JW, Go KL, Lee MH, Law BK, Law ME, 
Dunn WA, Jr., Zendejas I, Behrns KE, Kim JS. Sirtuin 1 suppresses 
mitochondrial dysfunction of ischemic mouse livers in a mitofusin 2-dependent 
manner. Cell Death Differ 23: 279-90, 2016. 
19. Boekstegers P, Weidenhofer S, Kapsner T, Werdan K. Skeletal muscle partial 
pressure of oxygen in patients with sepsis. Crit Care Med 22: 640-50, 1994. 
20. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by 
resveratrol. J Biol Chem 280: 17187-95, 2005. 
21. Boueiz A, Hassoun PM. Regulation of endothelial barrier function by reactive 
oxygen and nitrogen species. Microvasc Res 77: 26-34, 2009. 
22. Bowler RP, Arcaroli J, Crapo JD, Ross A, Slot JW, Abraham E. Extracellular 
superoxide dismutase attenuates lung injury after hemorrhage. Am J Respir Crit 
Care Med 164: 290-4, 2001. 
23. Brakenridge SC, Phelan HA, Henley SS, Golden RM, Kashner TM, Eastman AE, 
Sperry JL, Harbrecht BG, Moore EE, Cuschieri J, Maier RV, Minei JP, 
Inflammation, the Host Response to Injury I. Early blood product and crystalloid 
volume resuscitation: risk association with multiple organ dysfunction after 
severe blunt traumatic injury. J Trauma 71: 299-305, 2011. 
24. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, 
Cooper CE, Singer M. Association between mitochondrial dysfunction and 
severity and outcome of septic shock. Lancet 360: 219-23, 2002. 
25. Brealey D, Karyampudi S, Jacques TS, Novelli M, Stidwill R, Taylor V, Smolenski 
RT, Singer M. Mitochondrial dysfunction in a long-term rodent model of sepsis 
and organ failure. Am J Physiol Regul Integr Comp Physiol 286: R491-7, 2004. 
26. Brealey D, Singer M. Mitochondrial Dysfunction in Sepsis. Curr Infect Dis Rep 5: 
365-371, 2003. 
27. Broder G, Weil MH. Excess Lactate: An Index of Reversibility of Shock in Human 
Patients. Science 143: 1457-9, 1964. 
28. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. 
Immunol Allergy Clin North Am 23: 15-39, 2003. 
29. Bruunsgaard H, Skinhoj P, Qvist J, Pedersen BK. Elderly humans show 
prolonged in vivo inflammatory activity during pneumococcal infections. J Infect 
Dis 180: 551-4, 1999. 
30. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, Sack MN, Kastner 
DL, Siegel RM. Mitochondrial reactive oxygen species promote production of 
proinflammatory cytokines and are elevated in TNFR1-associated periodic 
syndrome (TRAPS). J Exp Med 208: 519-33, 2011. 
31. Burgos ES, Schramm VL. Weak coupling of ATP hydrolysis to the chemical 
equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47: 
11086-96, 2008. 
32. Cairns CB. Rude unhinging of the machinery of life: metabolic approaches to 
hemorrhagic shock. Curr Opin Crit Care 7: 437-43, 2001. 
33. Cairns CB, Moore FA, Haenel JB, Gallea BL, Ortner JP, Rose SJ, Moore EE. 
Evidence for early supply independent mitochondrial dysfunction in patients 
developing multiple organ failure after trauma. J Trauma 42: 532-6, 1997. 
34. Callahan LA, Supinski GS. Downregulation of diaphragm electron transport chain 
and glycolytic enzyme gene expression in sepsis. J Appl Physiol (1985) 99: 
1120-6, 2005. 
111	  
	  
35. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, 
Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, 
Mindrinos MN, Davis RW, Tompkins RG, Lowry SF, Inflamm, Host Response to 
Injury Large Scale Collab. Res P. A network-based analysis of systemic 
inflammation in humans. Nature 437: 1032-7, 2005. 
36. Camins A, Sureda FX, Junyent F, Verdaguer E, Folch J, Pelegri C, Vilaplana J, 
Beas-Zarate C, Pallas M. Sirtuin activators: designing molecules to extend life 
span. Biochim Biophys Acta 1799: 740-9, 2010. 
37. Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, Elliott PJ, 
Puigserver P, Auwerx J. AMPK regulates energy expenditure by modulating 
NAD+ metabolism and SIRT1 activity. Nature 458: 1056-60, 2009. 
38. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, 
Fernandez-Marcos PJ, Yamamoto H, Andreux PA, Cettour-Rose P, Gademann 
K, Rinsch C, Schoonjans K, Sauve AA, Auwerx J. The NAD(+) precursor 
nicotinamide riboside enhances oxidative metabolism and protects against high-
fat diet-induced obesity. Cell Metab 15: 838-47, 2012. 
39. Canto C, Menzies KJ, Auwerx J. NAD(+) Metabolism and the Control of Energy 
Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell 
Metab 22: 31-53, 2015. 
40. Carreras MC, Franco MC, Peralta JG, Poderoso JJ. Nitric oxide, complex I, and 
the modulation of mitochondrial reactive species in biology and disease. Mol 
Aspects Med 25: 125-39, 2004. 
41. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, Leoni V, Schon EA, 
Dantzer F, Auwerx J, Viscomi C, Zeviani M. NAD(+)-dependent activation of Sirt1 
corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 
19: 1042-9, 2014. 
42. Chaudry IH. Cellular mechanisms in shock and ischemia and their correction. Am 
J Physiol 245: R117-34, 1983. 
43. Chaudry IH, Sayeed MM, Baue AE. Differences in the altered energy metabolism 
of hemorrhagic shock and hypoxemia. Can J Physiol Pharmacol 54: 750-6, 1976. 
44. Chaudry IH, Zweig S, Sayeed MM, Baue AE. Failure of nicotinamide in the 
treatment of hemorrhagic shock. J Surg Res 21: 27-32, 1976. 
45. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a 
surrogate index for insulin sensitivity using a calibration model. Diabetes 54: 
1914-25, 2005. 
46. Chen J, Henderson GI, Freeman GL. Role of 4-hydroxynonenal in modification of 
cytochrome c oxidase in ischemia/reperfused rat heart. J Mol Cell Cardiol 33: 
1919-27, 2001. 
47. Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in 
metabolism. Trends Endocrinol Metab 21: 589-98, 2010. 
48. Ciesla DJ, Moore EE, Johnson JL, Burch JM, Cothren CC, Sauaia A. A 12-year 
prospective study of postinjury multiple organ failure: has anything changed? 
Arch Surg 140: 432-8; discussion 438-40, 2005. 
49. Cimen H, Han MJ, Yang Y, Tong Q, Koc H, Koc EC. Regulation of succinate 
dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry 49: 
304-11, 2010. 
50. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, Howitz KT, 
Gorospe M, de Cabo R, Sinclair DA. Calorie restriction promotes mammalian cell 
survival by inducing the SIRT1 deacetylase. Science 305: 390-2, 2004. 
112	  
	  
51. Crotty Alexander LE, Marsh BJ, Timmer AM, Lin AE, Zainabadi K, Czopik A, 
Guarente L, Nizet V. Myeloid cell sirtuin-1 expression does not alter host immune 
responses to Gram-negative endotoxemia or Gram-positive bacterial infection. 
PLoS One 8: e84481, 2013. 
52. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ 
dysfunction syndrome. Mitochondrion 4: 729-41, 2004. 
53. Crouser ED, Julian MW, Blaho DV, Pfeiffer DR. Endotoxin-induced mitochondrial 
damage correlates with impaired respiratory activity. Crit Care Med 30: 276-84, 
2002. 
54. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, Piccinni P, 
Ronco C. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker 
for acute kidney injury in an adult ICU population. Intensive Care Med 36: 444-
51, 2010. 
55. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, 
de Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial 
biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 297: H13-20, 
2009. 
56. Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, 
Moore EE, O'Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Early 
elevation in random plasma IL-6 after severe injury is associated with 
development of organ failure. Shock 34: 346-51, 2010. 
57. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new 
pharmacological approach in shock, inflammation, and ischemia/reperfusion 
injury. Pharmacol Rev 53: 135-59, 2001. 
58. Dao TM, Waget A, Klopp P, Serino M, Vachoux C, Pechere L, Drucker DJ, 
Champion S, Barthelemy S, Barra Y, Burcelin R, Seree E. Resveratrol increases 
glucose induced GLP-1 secretion in mice: a mechanism which contributes to the 
glycemic control. PLoS One 6: e20700, 2011. 
59. Dare AJ, Phillips AR, Hickey AJ, Mittal A, Loveday B, Thompson N, Windsor JA. 
A systematic review of experimental treatments for mitochondrial dysfunction in 
sepsis and multiple organ dysfunction syndrome. Free Radic Biol Med 47: 1517-
25, 2009. 
60. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of 
cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 
7: 11-20, 2008. 
61. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. 
Ann Surg 216: 117-34, 1992. 
62. del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and 
insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol 276: 
E849-55, 1999. 
63. Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury 
40: 912-8, 2009. 
64. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA. 
Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive 
deacetylase sirtuin 1. Science 324: 1289-93, 2009. 
65. Dran HFL. A treatise , or reflections, drawn from practice on gun-shot wounds: 
Royan Exchange Cornbill; 1743. 
66. Durham RM, Moran JJ, Mazuski JE, Shapiro MJ, Baue AE, Flint LM. Multiple 
organ failure in trauma patients. J Trauma 55: 608-16, 2003. 
113	  
	  
67. Fernandes CA, Fievez L, Neyrinck AM, Delzenne NM, Bureau F, Vanbever R. 
Sirtuin inhibition attenuates the production of inflammatory cytokines in 
lipopolysaccharide-stimulated macrophages. Biochem Biophys Res Commun 
420: 857-61, 2012. 
68. Fink MP, Macias CA, Xiao J, Tyurina YY, Delude RL, Greenberger JS, Kagan 
VE, Wipf P. Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted 
antioxidants. Crit Care Med 35: S461-7, 2007. 
69. Finley LW, Haas W, Desquiret-Dumas V, Wallace DC, Procaccio V, Gygi SP, 
Haigis MC. Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase 
activity. PLoS One 6: e23295, 2011. 
70. Fredriksson K, Hammarqvist F, Strigard K, Hultenby K, Ljungqvist O, Wernerman 
J, Rooyackers O. Derangements in mitochondrial metabolism in intercostal and 
leg muscle of critically ill patients with sepsis-induced multiple organ failure. Am J 
Physiol Endocrinol Metab 291: E1044-50, 2006. 
71. Fredriksson K, Tjader I, Keller P, Petrovic N, Ahlman B, Scheele C, Wernerman 
J, Timmons JA, Rooyackers O. Dysregulation of mitochondrial dynamics and the 
muscle transcriptome in ICU patients suffering from sepsis induced multiple 
organ failure. PLoS One 3: e3686, 2008. 
72. Frost RA, Lang CH. mTor signaling in skeletal muscle during sepsis and 
inflammation: where does it all go wrong? Physiology (Bethesda) 26: 83-96, 
2011. 
73. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like 
proteins. Biochem Biophys Res Commun 273: 793-8, 2000. 
74. Fulco M, Cen Y, Zhao P, Hoffman EP, McBurney MW, Sauve AA, Sartorelli V. 
Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 
through AMPK-mediated regulation of Nampt. Dev Cell 14: 661-73, 2008. 
75. Galva C, Gatto C, Milanick M. Soymilk: an effective and inexpensive blocking 
agent for immunoblotting. Anal Biochem 426: 22-3, 2012. 
76. Gao H, Wang X, Zhang Z, Yang Y, Yang J, Li X, Ning G. GLP-1 amplifies insulin 
signaling by up-regulation of IRbeta, IRS-1 and Glut4 in 3T3-L1 adipocytes. 
Endocrine 32: 90-5, 2007. 
77. Gao R, Chen J, Hu Y, Li Z, Wang S, Shetty S, Fu J. Sirt1 deletion leads to 
enhanced inflammation and aggravates endotoxin-induced acute kidney injury. 
PLoS One 9: e98909, 2014. 
78. Gero D, Szabo C. Salvage of nicotinamide adenine dinucleotide plays a critical 
role in the bioenergetic recovery of post-hypoxic cardiomyocytes. Br J Pharmacol 
172: 4817-32, 2015. 
79. Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, Muise ES, 
Hsiao JJ, Frederick DW, Yonemitsu S, Banks AS, Qiang L, Bhanot S, Olefsky 
JM, Sears DD, Caprio S, Shulman GI. SirT1 regulates adipose tissue 
inflammation. Diabetes 60: 3235-45, 2011. 
80. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription 
specificity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 
and NRF-2) and PGC-1 family coactivators. Mol Cell Biol 25: 1354-66, 2005. 
81. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen 
species: fifteen years later. Biochem Pharmacol 72: 1493-505, 2006. 
82. Gnaiger E. Mitochondrial pathways and respiratory control. . Innsbruck, Austria: 
MiPNet Publications; 2007. 
114	  
	  
83. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, White JP, 
Teodoro JS, Wrann CD, Hubbard BP, Mercken EM, Palmeira CM, de Cabo R, 
Rolo AP, Turner N, Bell EL, Sinclair DA. Declining NAD(+) induces a 
pseudohypoxic state disrupting nuclear-mitochondrial communication during 
aging. Cell 155: 1624-38, 2013. 
84. Gonzalez R, Ferrin G, Hidalgo AB, Ranchal I, Lopez-Cillero P, Santos-Gonzalez 
M, Lopez-Lluch G, Briceno J, Gomez MA, Poyato A, Villalba JM, Navas P, de la 
Mata M, Muntane J. N-acetylcysteine, coenzyme Q10 and superoxide dismutase 
mimetic prevent mitochondrial cell dysfunction and cell death induced by d-
galactosamine in primary culture of human hepatocytes. Chem Biol Interact 181: 
95-106, 2009. 
85. Graeff R, Lee HC. A novel cycling assay for cellular cADP-ribose with nanomolar 
sensitivity. Biochem J 361: 379-84, 2002. 
86. Gual P, Le Marchand-Brustel Y, Tanti JF. Positive and negative regulation of 
insulin signaling through IRS-1 phosphorylation. Biochimie 87: 99-109, 2005. 
87. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A, Sinclair 
DA. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 
166 suppresses age-related cardiac hypertrophy. Aging (Albany NY) 2: 914-23, 
2010. 
88. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian 
acetyl-CoA synthetases. Proc Natl Acad Sci U S A 103: 10230-5, 2006. 
89. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, Someya S, Shortreed 
MR, Prolla T, Markley JL, Smith LM, Zhao S, Guan KL, Denu JM. Sirt3 promotes 
the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 41: 139-
49, 2011. 
90. Hasegawa A, Iwasaka H, Hagiwara S, Asai N, Nishida T, Noguchi T. Alternate 
day calorie restriction improves systemic inflammation in a mouse model of 
sepsis induced by cecal ligation and puncture. J Surg Res 174: 136-41, 2012. 
91. Heckbert SR, Vedder NB, Hoffman W, Winn RK, Hudson LD, Jurkovich GJ, 
Copass MK, Harlan JM, Rice CL, Maier RV. Outcome after hemorrhagic shock in 
trauma patients. J Trauma 45: 545-9, 1998. 
92. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature 
and implications for studies in humans. Am J Clin Nutr 78: 361-9, 2003. 
93. Heron M. Deaths: Leading Causes for 2013. Natl Vital Stat Rep 65: 1-95, 2016. 
94. Hift H, Strawitz JG. Irreversible hemorrhagic shock in dogs: structure and 
function of liver mitochondria. Am J Physiol 200: 264-8, 1961. 
95. Hilbert T, Steinhagen F, Senzig S, Cramer N, Bekeredjian-Ding I, Parcina M, 
Baumgarten G, Hoeft A, Frede S, Boehm O, Klaschik S. Vendor effects on 
murine gut microbiota influence experimental abdominal sepsis. J Surg Res 211: 
126-136, 2017. 
96. Hirayama K, Endo K, Kawamura S, Mitsuoka T. Comparison of the intestinal 
bacteria in specific pathogen free mice from different breeders. Jikken Dobutsu 
39: 263-7, 1990. 
97. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter 
CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman 
NB, Bain JR, Newgard CB, Farese RV, Jr., Alt FW, Kahn CR, Verdin E. SIRT3 
regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. 
Nature 464: 121-5, 2010. 
115	  
	  
98. Hjortrup PB, Haase N, Wetterslev M, Perner A. Clinical review: Predictive value 
of neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive 
care patients. Crit Care 17: 211, 2013. 
99. Holthoff JH, Wang Z, Seely KA, Gokden N, Mayeux PR. Resveratrol improves 
renal microcirculation, protects the tubular epithelium, and prolongs survival in a 
mouse model of sepsis-induced acute kidney injury. Kidney Int 81: 370-8, 2012. 
100. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from 
cellular dysfunctions to immunotherapy. Nat Rev Immunol 13: 862-74, 2013. 
101. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak 
GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, 
and multiple organ dysfunction. Crit Care Med 27: 1230-51, 1999. 
102. Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and 
healthspan. Nat Rev Mol Cell Biol 13: 225-38, 2012. 
103. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin 
RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule 
activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 
191-6, 2003. 
104. Hsu CP, Oka S, Shao D, Hariharan N, Sadoshima J. Nicotinamide 
phosphoribosyltransferase regulates cell survival through NAD+ synthesis in 
cardiac myocytes. Circ Res 105: 481-91, 2009. 
105. Hsu CP, Zhai P, Yamamoto T, Maejima Y, Matsushima S, Hariharan N, Shao D, 
Takagi H, Oka S, Sadoshima J. Silent information regulator 1 protects the heart 
from ischemia/reperfusion. Circulation 122: 2170-82, 2010. 
106. Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, 
E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour 
SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, 
Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair 
DA. Evidence for a common mechanism of SIRT1 regulation by allosteric 
activators. Science 339: 1216-9, 2013. 
107. Hubbard WJ, Bland KI, Chaudry IH. The role of the mitochondrion in trauma and 
shock. Shock 22: 395-402, 2004. 
108. Hufeldt MR, Nielsen DS, Vogensen FK, Midtvedt T, Hansen AK. Variation in the 
gut microbiota of laboratory mice is related to both genetic and environmental 
factors. Comp Med 60: 336-47, 2010. 
109. Jastrow KM, 3rd, Gonzalez EA, McGuire MF, Suliburk JW, Kozar RA, Iyengar S, 
Motschall DA, McKinley BA, Moore FA, Mercer DW. Early cytokine production 
risk stratifies trauma patients for multiple organ failure. J Am Coll Surg 209: 320-
31, 2009. 
110. Jeong KY, Suh GJ, Kwon WY, Kim KS, Jung YS, Kye YC. The therapeutic effect 
and mechanism of niacin on acute lung injury in a rat model of hemorrhagic 
shock: Down-regulation of the reactive oxygen species-dependent nuclear factor 
kappaB pathway. J Trauma Acute Care Surg 79: 247-55, 2015. 
111. Jian B, Yang S, Chaudry IH, Raju R. Resveratrol improves cardiac contractility 
following trauma-hemorrhage by modulating Sirt1. Mol Med 18: 209-14, 2012. 
112. Jian B, Yang S, Chaudry IH, Raju R. Resveratrol restores sirtuin 1 (SIRT1) 
activity and pyruvate dehydrogenase kinase 1 (PDK1) expression after 
hemorrhagic injury in a rat model. Mol Med 20: 10-6, 2014. 
116	  
	  
113. Jiang Y, Wu GH, Zhang B, Han YS, Zhuang QL. Acute insulin resistance 
following surgical trauma in rats. Exp Clin Endocrinol Diabetes 120: 315-22, 
2012. 
114. Jing E, Emanuelli B, Hirschey MD, Boucher J, Lee KY, Lombard D, Verdin EM, 
Kahn CR. Sirtuin-3 (Sirt3) regulates skeletal muscle metabolism and insulin 
signaling via altered mitochondrial oxidation and reactive oxygen species 
production. Proc Natl Acad Sci U S A 108: 14608-13, 2011. 
115. JR W. Mitochondrial metabolism and cell regulation. In: Mitochondria: 
Bioenergetics, Biogenesis and Membrane Structure. edited by Gomez-Poyon 
LPaA. New York: Academic,; 1976. pp. 79-107. 
116. Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, 
Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK. Substrate-
specific activation of sirtuins by resveratrol. J Biol Chem 280: 17038-45, 2005. 
117. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone 
promote longevity in Saccharomyces cerevisiae by two different mechanisms. 
Genes Dev 13: 2570-80, 1999. 
118. Kapoor R, Kalra J, Prasad K. Cardiac depression and cellular injury in 
hemorrhagic shock and reinfusion: role of free radicals. Mol Cell Biochem 176: 
291-301, 1997. 
119. Karamercan MA, Weiss SL, Villarroel JP, Guan Y, Werlin E, Figueredo R, Becker 
LB, Sims C. Can peripheral blood mononuclear cells be used as a proxy for 
mitochondrial dysfunction in vital organs during hemorrhagic shock and 
resuscitation? Shock 40: 476-84, 2013. 
120. Karamercan MA, Weiss SL, Villarroel JP, Guan Y, Werlin E, Figueredo R, Becker 
LB, Sims C. Can Peripheral Blood Mononuclear Cells be Used as a Proxy for 
Mitochondrial Dysfunction in Vital Organs During Hemorrhagic Shock and 
Resuscitation? Shock, 2013. 
121. Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic 
crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and 
metabolic disorders. Cell Signal 25: 1939-48, 2013. 
122. Kauvar DS, Lefering R, Wade CE. Impact of hemorrhage on trauma outcome: an 
overview of epidemiology, clinical presentations, and therapeutic considerations. 
J Trauma 60: S3-11, 2006. 
123. Kerby JD, Griffin RL, MacLennan P, Rue LW, 3rd. Stress-induced 
hyperglycemia, not diabetic hyperglycemia, is associated with higher mortality in 
trauma. Ann Surg 256: 446-52, 2012. 
124. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin 
resistance. Circ Res 102: 401-14, 2008. 
125. Kolgazi M, Sener G, Cetinel S, Gedik N, Alican I. Resveratrol reduces renal and 
lung injury caused by sepsis in rats. J Surg Res 134: 315-21, 2006. 
126. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, Fang F, Chang Y. Sirtuin 3, a 
new target of PGC-1alpha, plays an important role in the suppression of ROS 
and mitochondrial biogenesis. PLoS One 5: e11707, 2010. 
127. Koo SH, Montminy M. In vino veritas: a tale of two sirt1s? Cell 127: 1091-3, 
2006. 
128. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang 
TT, Bos JL, Medema RH, Burgering BM. Forkhead transcription factor FOXO3a 
protects quiescent cells from oxidative stress. Nature 419: 316-21, 2002. 
117	  
	  
129. Kozlov AV, Bahrami S, Calzia E, Dungel P, Gille L, Kuznetsov AV, Troppmair J. 
Mitochondrial dysfunction and biogenesis: do ICU patients die from mitochondrial 
failure? Ann Intensive Care 1: 41, 2011. 
130. Krabbe KS, Bruunsgaard H, Hansen CM, Moller K, Fonsmark L, Qvist J, Madsen 
PL, Kronborg G, Andersen HO, Skinhoj P, Pedersen BK. Ageing is associated 
with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol 
8: 333-8, 2001. 
131. Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, Jimenez E, 
Mohan A, Khan RA, Whittle J, Jacobs E, Nanchal R, Milwaukee Initiative in 
Critical Care Outcomes Research Group of I. Nationwide trends of severe sepsis 
in the 21st century (2000-2007). Chest 140: 1223-31, 2011. 
132. Kuznetsov AV, Veksler V, Gellerich FN, Saks V, Margreiter R, Kunz WS. 
Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues 
and cells. Nat Protoc 3: 965-76, 2008. 
133. Kwon WY, Suh GJ, Kim KS, Kwak YH. Niacin attenuates lung inflammation and 
improves survival during sepsis by downregulating the nuclear factor-kappaB 
pathway. Crit Care Med 39: 328-34, 2011. 
134. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, 
Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, 
Auwerx J. Resveratrol improves mitochondrial function and protects against 
metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-22, 
2006. 
135. Laird AM, Miller PR, Kilgo PD, Meredith JW, Chang MC. Relationship of early 
hyperglycemia to mortality in trauma patients. J Trauma 56: 1058-62, 2004. 
136. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, Abraham 
E. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: 
involvement of catecholamines in nuclear factor-kappaB regulation and cytokine 
expression. J Clin Invest 99: 1516-24, 1997. 
137. Lei Y, Peng X, Liu L, Dong Z, Li T. Beneficial effect of cyclosporine A on 
traumatic hemorrhagic shock. J Surg Res 195: 529-40, 2015. 
138. Leverve XM. Mitochondrial function and substrate availability. Crit Care Med 35: 
S454-60, 2007. 
139. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal 
SM, Vincent JL, Ramsay G, Sccm/Esicm/Accp/Ats/Sis. 2001 
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit 
Care Med 31: 1250-6, 2003. 
140. Li L, Messina JL. Acute insulin resistance following injury. Trends Endocrinol 
Metab 20: 429-35, 2009. 
141. Li P, Meng X, Bian H, Burns N, Zhao KS, Song R. Activation of sirtuin 1/3 
improves vascular hyporeactivity in severe hemorrhagic shock by alleviation of 
mitochondrial damage. Oncotarget 6: 36998-7011, 2015. 
142. Li T, Zhang J, Feng J, Li Q, Wu L, Ye Q, Sun J, Lin Y, Zhang M, Huang R, 
Cheng J, Cao Y, Xiang G, Wu Q. Resveratrol reduces acute lung injury in a LPS 
induced sepsis mouse model via activation of Sirt1. Mol Med Rep 7: 1889-95, 
2013. 
143. Liaudet L, Soriano FG, Szabo E, Virag L, Mabley JG, Salzman AL, Szabo C. 
Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-
ribose)polymerase. Proc Natl Acad Sci U S A 97: 10203-8, 2000. 
118	  
	  
144. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates 
cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha. 
Mol Cell 38: 864-78, 2010. 
145. Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family 
of transcription coactivators. Cell Metab 1: 361-70, 2005. 
146. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span 
extension by calorie restriction in Saccharomyces cerevisiae. Science 289: 2126-
8, 2000. 
147. Lin SJ, Ford E, Haigis M, Liszt G, Guarente L. Calorie restriction extends yeast 
life span by lowering the level of NADH. Genes Dev 18: 12-6, 2004. 
148. Liu FC, Tsai HI, Yu HP. Organ-Protective Effects of Red Wine Extract, 
Resveratrol, in Oxidative Stress-Mediated Reperfusion Injury. Oxid Med Cell 
Longev 2015: 568634, 2015. 
149. Liu H, Xiao X, Sun C, Sun D, Li Y, Yang M. Systemic inflammation and multiple 
organ injury in traumatic hemorrhagic shock. Front Biosci (Landmark Ed) 20: 
927-33, 2015. 
150. Liu TF, Vachharajani VT, Yoza BK, McCall CE. NAD+-dependent sirtuin 1 and 6 
proteins coordinate a switch from glucose to fatty acid oxidation during the acute 
inflammatory response. J Biol Chem 287: 25758-69, 2012. 
151. Liu TF, Yoza BK, El Gazzar M, Vachharajani VT, McCall CE. NAD+-dependent 
SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin 
tolerance. J Biol Chem 286: 9856-64, 2011. 
152. Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, 
Kim J, Yancopoulos G, Valenzuela D, Murphy A, Yang Y, Chen Y, Hirschey MD, 
Bronson RT, Haigis M, Guarente LP, Farese RV, Jr., Weissman S, Verdin E, 
Schwer B. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine 
acetylation. Mol Cell Biol 27: 8807-14, 2007. 
153. Long AN, Owens K, Schlappal AE, Kristian T, Fishman PS, Schuh RA. Effect of 
nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an 
Alzheimer's disease-relevant murine model. BMC Neurol 15: 19, 2015. 
154. Lopez-Lluch G, Irusta PM, Navas P, de Cabo R. Mitochondrial biogenesis and 
healthy aging. Exp Gerontol 43: 813-9, 2008. 
155. Losser MR, Damoisel C, Payen D. Bench-to-bedside review: Glucose and stress 
conditions in the intensive care unit. Crit Care 14: 231, 2010. 
156. Lugrin J, Ciarlo E, Santos A, Grandmaison G, dos Santos I, Le Roy D, Roger T. 
The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and 
innate immune responses and protects from septic shock. Biochim Biophys Acta 
1833: 1498-510, 2013. 
157. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, Morales M, 
Valverde I, Villanueva-Penacarrillo ML. Glucagon-like peptide-1 (GLP-1) and 
glucose metabolism in human myocytes. J Endocrinol 173: 465-73, 2002. 
158. Ma Y, Toth B, Keeton AB, Holland LT, Chaudry IH, Messina JL. Mechanisms of 
hemorrhage-induced hepatic insulin resistance: role of tumor necrosis factor-
alpha. Endocrinology 145: 5168-76, 2004. 
159. Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. 
Early versus late onset of multiple organ failure is associated with differing 
patterns of plasma cytokine biomarker expression and outcome after severe 
trauma. Shock 28: 668-674, 2007. 
119	  
	  
160. Martin GS, Mannino DM, Moss M. The effect of age on the development and 
outcome of adult sepsis. Crit Care Med 34: 15-21, 2006. 
161. Mayr VD, Dunser MW, Greil V, Jochberger S, Luckner G, Ulmer H, Friesenecker 
BE, Takala J, Hasibeder WR. Causes of death and determinants of outcome in 
critically ill patients. Crit Care 10: R154, 2006. 
162. McDonald MC, Mota-Filipe H, Wright JA, Abdelrahman M, Threadgill MD, 
Thompson AS, Thiemermann C. Effects of 5-aminoisoquinolinone, a water-
soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase on the 
organ injury and dysfunction caused by haemorrhagic shock. Br J Pharmacol 
130: 843-50, 2000. 
163. McDonnell E, Peterson BS, Bomze HM, Hirschey MD. SIRT3 regulates 
progression and development of diseases of aging. Trends Endocrinol Metab 26: 
486-492, 2015. 
164. Mela L, Bacalzo LV, Jr., Miller LD. Defective oxidative metabolism of rat liver 
mitochondria in hemorrhagic and endotoxin shock. Am J Physiol 220: 571-7, 
1971. 
165. Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Essential role for IL-6 in 
postresuscitation inflammation in hemorrhagic shock. Am J Physiol Cell Physiol 
280: C343-51, 2001. 
166. Miller RA, Chu Q, Le Lay J, Scherer PE, Ahima RS, Kaestner KH, Foretz M, 
Viollet B, Birnbaum MJ. Adiponectin suppresses gluconeogenic gene expression 
in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest 121: 
2518-28, 2011. 
167. Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud 
ME, Apte RS, Uchida K, Yoshino J, Imai SI. Long-Term Administration of 
Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in 
Mice. Cell Metab 24: 795-806, 2016. 
168. Minei JP, Cuschieri J, Sperry J, Moore EE, West MA, Harbrecht BG, O'Keefe 
GE, Cohen MJ, Moldawer LL, Tompkins RG, Maier RV, Inflammation, the Host 
Response to Injury Collaborative Research P. The changing pattern and 
implications of multiple organ failure after blunt injury with hemorrhagic shock. 
Crit Care Med 40: 1129-35, 2012. 
169. Mittwede P, Lu S, Clemmer J, Hester R, Xiang L. Attenutation of post-trauma 
hyperglycemia prevents acute kidney injury in obese rats. The FASEB Journal 
29, 2015. 
170. Moore FA, Haenel JB, Moore EE, Whitehill TA. Incommensurate oxygen 
consumption in response to maximal oxygen availability predicts postinjury 
multiple organ failure. J Trauma 33: 58-65; discussion 65-7, 1992. 
171. Moore FA, Sauaia A, Moore EE, Haenel JB, Burch JM, Lezotte DC. Postinjury 
multiple organ failure: a bimodal phenomenon. J Trauma 40: 501-10; discussion 
510-2, 1996. 
172. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C, Mottis 
A, Jo YS, Viswanathan M, Schoonjans K, Guarente L, Auwerx J. The 
NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial 
UPR and FOXO Signaling. Cell 154: 430-41, 2013. 
173. Mukhopadhyay P, Horvath B, Zsengeller Z, Batkai S, Cao Z, Kechrid M, Holovac 
E, Erdelyi K, Tanchian G, Liaudet L, Stillman IE, Joseph J, Kalyanaraman B, 
Pacher P. Mitochondrial reactive oxygen species generation triggers 
inflammatory response and tissue injury associated with hepatic ischemia-
120	  
	  
reperfusion: therapeutic potential of mitochondrially targeted antioxidants. Free 
Radic Biol Med 53: 1123-38, 2012. 
174. Musatov A, Carroll CA, Liu YC, Henderson GI, Weintraub ST, Robinson NC. 
Identification of bovine heart cytochrome c oxidase subunits modified by the lipid 
peroxidation product 4-hydroxy-2-nonenal. Biochemistry 41: 8212-20, 2002. 
175. Nast-Kolb D, Aufmkolk M, Rucholtz S, Obertacke U, Waydhas C. Multiple organ 
failure still a major cause of morbidity but not mortality in blunt multiple trauma. J 
Trauma 51: 835-41; discussion 841-2, 2001. 
176. Nemzek JA, Hugunin KM, Opp MR. Modeling sepsis in the laboratory: merging 
sound science with animal well-being. Comp Med 58: 120-8, 2008. 
177. Niederer F, Ospelt C, Brentano F, Hottiger MO, Gay RE, Gay S, Detmar M, 
Kyburz D. SIRT1 overexpression in the rheumatoid arthritis synovium contributes 
to proinflammatory cytokine production and apoptosis resistance. Annals of the 
Rheumatic Diseases 70: 1866-73, 2011. 
178. Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, 
Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, 
Varghese A, Ward J, Withka J, Ahn K. SRT1720, SRT2183, SRT1460, and 
resveratrol are not direct activators of SIRT1. J Biol Chem 285: 8340-51, 2010. 
179. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. 
Oncogene 18: 6853-66, 1999. 
180. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on 
proinflammatory cytokines, hyperglycemia mediated oxidative stress, and 
pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic 
rats. J Cell Physiol 224: 423-32, 2010. 
181. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, 
Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung 
JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting 
cAMP phosphodiesterases. Cell 148: 421-33, 2012. 
182. Patil NK, Parajuli N, MacMillan-Crow LA, Mayeux PR. Inactivation of renal 
mitochondrial respiratory complexes and manganese superoxide dismutase 
during sepsis: mitochondria-targeted antioxidant mitigates injury. Am J Physiol 
Renal Physiol 306: F734-43, 2014. 
183. Peitzman AB, Billiar TR, Harbrecht BG, Kelly E, Udekwu AO, Simmons RL. 
Hemorrhagic shock. Curr Probl Surg 32: 925-1002, 1995. 
184. Pereira CV, Lebiedzinska M, Wieckowski MR, Oliveira PJ. Regulation and 
protection of mitochondrial physiology by sirtuins. Mitochondrion 12: 66-76, 2012. 
185. Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, 
Arbiser JL, Walker DI, Jones DP, Gius D, Gupta MP. Honokiol blocks and 
reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat 
Commun 6: 6656, 2015. 
186. Pirinen E, Lo Sasso G, Auwerx J. Mitochondrial sirtuins and metabolic 
homeostasis. Best Pract Res Clin Endocrinol Metab 26: 759-70, 2012. 
187. Powell RD, Goodenow DA, Mixer HV, McKillop IH, Evans SL. Cytochrome c 
limits oxidative stress and decreases acidosis in a rat model of hemorrhagic 
shock and reperfusion injury. J Trauma Acute Care Surg 82: 35-41, 2017. 
188. Powell RD, Swet JH, Kennedy KL, Huynh TT, McKillop IH, Evans SL. 
Resveratrol attenuates hypoxic injury in a primary hepatocyte model of 
hemorrhagic shock and resuscitation. J Trauma Acute Care Surg 76: 409-17, 
2014. 
121	  
	  
189. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal 
B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini 
B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, 
Sinclair DA. SIRT1 is required for AMPK activation and the beneficial effects of 
resveratrol on mitochondrial function. Cell Metab 15: 675-90, 2012. 
190. Qin J, Zhou J, Dai X, Zhou H, Pan X, Wang X, Zhang F, Rao J, Lu L. Short-term 
starvation attenuates liver ischemia-reperfusion injury (IRI) by Sirt1-autophagy 
signaling in mice. Am J Transl Res 8: 3364-75, 2016. 
191. Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces 
oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab 12: 662-7, 
2010. 
192. Rhee P, Langdale L, Mock C, Gentilello LM. Near-infrared spectroscopy: 
continuous measurement of cytochrome oxidation during hemorrhagic shock. Crit 
Care Med 25: 166-70, 1997. 
193. Rhodes RS, DePalma RG. Mitochondrial dysfunction of the liver and 
hypoglycemia in hemorrhagic shock. Surg Gynecol Obstet 150: 347-52, 1980. 
194. Rickenbacher A, Jang JH, Limani P, Ungethum U, Lehmann K, Oberkofler CE, 
Weber A, Graf R, Humar B, Clavien PA. Fasting protects liver from ischemic 
injury through Sirt1-mediated downregulation of circulating HMGB1 in mice. J 
Hepatol 61: 301-8, 2014. 
195. Rittirsch D, Huber-Lang MS, Flierl MA, Ward PA. Immunodesign of experimental 
sepsis by cecal ligation and puncture. Nat Protoc 4: 31-6, 2009. 
196. Rixen D, Siegel JH. Bench-to-bedside review: oxygen debt and its metabolic 
correlates as quantifiers of the severity of hemorrhagic and post-traumatic shock. 
Crit Care 9: 441-53, 2005. 
197. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations 
through the PGC-1 alpha and SIRT1 pathways. FEBS Lett 582: 46-53, 2008. 
198. Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient 
control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. 
Nature 434: 113-8, 2005. 
199. Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, Bureau 
F, Andris F, Leo O. Nicotinamide phosphoribosyl transferase/pre-B cell colony-
enhancing factor/visfatin is required for lymphocyte development and cellular 
resistance to genotoxic stress. J Immunol 181: 4685-95, 2008. 
200. Ruggieri AJ, Levy RJ, Deutschman CS. Mitochondrial dysfunction and 
resuscitation in sepsis. Crit Care Clin 26: 567-75, x-xi, 2010. 
201. Sack MN, Finkel T. Mitochondrial metabolism, sirtuins, and aging. Cold Spring 
Harb Perspect Biol 4, 2012. 
202. Sair M, Etherington PJ, Peter Winlove C, Evans TW. Tissue oxygenation and 
perfusion in patients with systemic sepsis. Crit Care Med 29: 1343-9, 2001. 
203. Saito H, Sherwood ER, Varma TK, Evers BM. Effects of aging on mortality, 
hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Mech 
Ageing Dev 124: 1047-58, 2003. 
204. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, 
Satkunarajah M, Irwin DM, Shi ZQ, Brubaker PL, Wheeler MB, Vranic M, Efendic 
S, Giacca A. Glucagon-like peptide 1 increases insulin sensitivity in 
depancreatized dogs. Diabetes 48: 1045-53, 1999. 
205. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 
family regulatory network. Biochim Biophys Acta 1813: 1269-78, 2011. 
122	  
	  
206. Schilling E, Wehrhahn J, Klein C, Raulien N, Ceglarek U, Hauschildt S. Inhibition 
of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory 
responses of human monocytes. Innate Immun 18: 518-30, 2012. 
207. Schug TT, Xu Q, Gao H, Peres-da-Silva A, Draper DW, Fessler MB, 
Purushotham A, Li X. Myeloid deletion of SIRT1 induces inflammatory signaling 
in response to environmental stress. Mol Cell Biol 30: 4712-21, 2010. 
208. Schulte W, Bernhagen J, Bucala R. Cytokines in sepsis: potent 
immunoregulators and potential therapeutic targets--an updated view. Mediators 
Inflamm 2013: 165974, 2013. 
209. Schwer B, Eckersdorff M, Li Y, Silva JC, Fermin D, Kurtev MV, Giallourakis C, 
Comb MJ, Alt FW, Lombard DB. Calorie restriction alters mitochondrial protein 
acetylation. Aging Cell 8: 604-6, 2009. 
210. Sebai H, Ben-Attia M, Sani M, Aouani E, Ghanem-Boughanmi N. Protective 
effect of resveratrol in endotoxemia-induced acute phase response in rats. Arch 
Toxicol 83: 335-40, 2009. 
211. Sebastian C, Satterstrom FK, Haigis MC, Mostoslavsky R. From sirtuin biology to 
human diseases: an update. J Biol Chem 287: 42444-52, 2012. 
212. Sharma P, Walsh KT, Kerr-Knott KA, Karaian JE, Mongan PD. Pyruvate 
modulates hepatic mitochondrial functions and reduces apoptosis indicators 
during hemorrhagic shock in rats. Anesthesiology 103: 65-73, 2005. 
213. Shenkar R, Schwartz MD, Terada LS, Repine JE, McCord J, Abraham E. 
Hemorrhage activates NF-kappa B in murine lung mononuclear cells in vivo. Am 
J Physiol 270: L729-35, 1996. 
214. Shimahara Y, Ozawa K, Ida T, Ukikusa M, Tobe T. Four stages of mitochondrial 
deterioration in hemorrhagic shock. Res Exp Med (Berl) 179: 23-33, 1981. 
215. Shimazu T, Hirschey MD, Hua L, Dittenhafer-Reed KE, Schwer B, Lombard DB, 
Li Y, Bunkenborg J, Alt FW, Denu JM, Jacobson MP, Verdin E. SIRT3 
deacetylates mitochondrial 3-hydroxy-3-methylglutaryl CoA synthase 2 and 
regulates ketone body production. Cell Metab 12: 654-61, 2010. 
216. Sillesen M, Bambakidis T, Dekker SE, Fabricius R, Svenningsen P, Bruhn PJ, 
Svendsen LB, Hillingso J, Alam HB. Histone deactylase gene expression profiles 
are associated with outcomes in blunt trauma patients. J Trauma Acute Care 
Surg 80: 26-32; discussion 32-3, 2016. 
217. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ 
failure. Crit Care Med 35: S441-8, 2007. 
218. Singer M. Cellular dysfunction in sepsis. Clin Chest Med 29: 655-60, viii-ix, 2008. 
219. Skarda DE, Putt KS, Hergenrother PJ, Mulier KE, Beilman GJ. Increased 
poly(ADP-ribose) polymerase activity during porcine hemorrhagic shock is 
transient and predictive of mortality. Resuscitation 75: 135-44, 2007. 
220. Smeding L, Leong-Poi H, Hu P, Shan Y, Haitsma JJ, Horvath E, Furmli S, 
Masoom H, Kuiper JW, Slutsky AS, Parker TG, Plotz FB, dos Santos CC. 
Salutary effect of resveratrol on sepsis-induced myocardial depression. Crit Care 
Med 40: 1896-907, 2012. 
221. Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, Tanokura M, 
Denu JM, Prolla TA. Sirt3 mediates reduction of oxidative damage and 
prevention of age-related hearing loss under caloric restriction. Cell 143: 802-12, 
2010. 
123	  
	  
222. Souba W, Wilmore D. Surgical Research. In: Shock Models: Hemorrhage. edited 
by Ayala A, Wang P, Chaudry I. San Diego, CA: Academic Press; 2001. pp. 325-
327. 
223. Souba W, Wilmore, D. In: Surgical Reserach. edited by Ayala A, Wang, P., 
Chaudry, I. San Diego, CA: Academic Press; 2001. pp. 325-327. 
224. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Gordini G, 
Stahel PF, Hunt BJ, Komadina R, Neugebauer E, Ozier Y, Riddez L, Schultz A, 
Vincent JL, Rossaint R. Management of bleeding following major trauma: a 
European guideline. Crit Care 11: R17, 2007. 
225. Srere PA, Matsuoka Y. Inhibition of rat citrate synthase by acetoacetyl CoA and 
NADH. Biochem Med 6: 262-6, 1972. 
226. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng 
K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of 
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional 
coactivators. Cell 127: 397-408, 2006. 
227. Stensballe J, Christiansen M, Tonnesen E, Espersen K, Lippert FK, Rasmussen 
LS. The early IL-6 and IL-10 response in trauma is correlated with injury severity 
and mortality. Acta Anaesthesiol Scand 53: 515-21, 2009. 
228. Svistunenko DA, Davies N, Brealey D, Singer M, Cooper CE. Mitochondrial 
dysfunction in patients with severe sepsis: an EPR interrogation of individual 
respiratory chain components. Biochim Biophys Acta 1757: 262-72, 2006. 
229. Szabo A, Hake P, Salzman AL, Szabo C. 3-Aminobenzamide, an inhibitor of poly 
(ADP-ribose) synthetase, improves hemodynamics and prolongs survival in a 
porcine model of hemorrhagic shock. Shock 10: 347-53, 1998. 
230. Szabo C. Poly (ADP-ribose) polymerase activation and circulatory shock. 
Novartis Found Symp 280: 92-103; discussion 103-7, 160-4, 2007. 
231. Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide-induced 
lethality and cytokine production in aged mice. Infect Immun 64: 769-74, 1996. 
232. Tavakoli H, Mela L. Alterations of mitochondrial metabolism and protein 
concentrations in subacute septicemia. Infect Immun 38: 536-41, 1982. 
233. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG. Biological and potential 
therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 65: 4000-18, 2008. 
234. Taylor JH, Beilman GJ, Conroy MJ, Mulier KE, Myers D, Gruessner A, Hammer 
BE. Tissue energetics as measured by nuclear magnetic resonance 
spectroscopy during hemorrhagic shock. Shock 21: 58-64, 2004. 
235. Tennen RI, Michishita-Kioi E, Chua KF. Finding a target for resveratrol. Cell 148: 
387-9, 2012. 
236. Toiber D, Sebastian C, Mostoslavsky R. Characterization of nuclear sirtuins: 
molecular mechanisms and physiological relevance. Handb Exp Pharmacol 206: 
189-224, 2011. 
237. Tonnesen MG. Neutrophil-endothelial cell interactions: mechanisms of neutrophil 
adherence to vascular endothelium. J Invest Dermatol 93: 53s-58s, 1989. 
238. Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, 
Stillman IE, Karumanchi SA, Rhee EP, Parikh SM. PGC1alpha drives NAD 
biosynthesis linking oxidative metabolism to renal protection. Nature 531: 528-32, 
2016. 
239. Tsai YF, Liu FC, Lau YT, Yu HP. Role of Akt-dependent pathway in resveratrol-
mediated cardioprotection after trauma-hemorrhage. J Surg Res 176: 171-7, 
2012. 
124	  
	  
240. Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the 
pathophysiology of multiple organ failure after trauma. Injury 41: 21-6, 2010. 
241. Turnbull IR, Clark AT, Stromberg PE, Dixon DJ, Woolsey CA, Davis CG, 
Hotchkiss RS, Buchman TG, Coopersmith CM. Effects of aging on the 
immunopathologic response to sepsis. Crit Care Med 37: 1018-23, 2009. 
242. Turnbull IR, Wlzorek JJ, Osborne D, Hotchkiss RS, Coopersmith CM, Buchman 
TG. Effects of age on mortality and antibiotic efficacy in cecal ligation and 
puncture. Shock 19: 310-3, 2003. 
243. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, Kim MK, Viollet B, 
Chung JH. AMP-activated protein kinase-deficient mice are resistant to the 
metabolic effects of resveratrol. Diabetes 59: 554-63, 2010. 
244. Ungvari Z, Sonntag WE, de Cabo R, Baur JA, Csiszar A. Mitochondrial protection 
by resveratrol. Exerc Sport Sci Rev 39: 128-32, 2011. 
245. Vachharajani VT, Liu T, Brown CM, Wang X, Buechler NL, Wells JD, Yoza BK, 
McCall CE. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis 
enhances immunity and improves outcome. J Leukoc Biol 96: 785-96, 2014. 
246. Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, McCall CE. Sirtuins Link 
Inflammation and Metabolism. J Immunol Res 2016: 8167273, 2016. 
247. Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, Mostoslavsky 
R, Alt FW, De Smedt T, Leo O. Intracellular NAD levels regulate tumor necrosis 
factor protein synthesis in a sirtuin-dependent manner. Nat Med 15: 206-10, 
2009. 
248. van Wijk SJ, Hageman GJ. Poly(ADP-ribose) polymerase-1 mediated caspase-
independent cell death after ischemia/reperfusion. Free Radic Biol Med 39: 81-
90, 2005. 
249. VanderMeer TJ, Wang H, Fink MP. Endotoxemia causes ileal mucosal acidosis 
in the absence of mucosal hypoxia in a normodynamic porcine model of septic 
shock. Crit Care Med 23: 1217-26, 1995. 
250. Verdin E, Hirschey MD, Finley LW, Haigis MC. Sirtuin regulation of mitochondria: 
energy production, apoptosis, and signaling. Trends Biochem Sci 35: 669-75, 
2010. 
251. Villalba JM, Alcain FJ. Sirtuin activators and inhibitors. Biofactors 38: 349-59, 
2012. 
252. Wang H, Guan Y, Karamercan MA, Ye L, Bhatti T, Becker LB, Baur JA, Sims CA. 
Resveratrol Rescues Kidney Mitochondrial Function Following Hemorrhagic 
Shock. Shock 44: 173-80, 2015. 
253. Wang H, Guan Y, Widlund AL, Becker LB, Baur JA, Reilly PM, Sims CA. 
Resveratrol ameliorates mitochondrial dysfunction but increases the risk of 
hypoglycemia following hemorrhagic shock. J Trauma Acute Care Surg 77: 926-
33, 2014. 
254. Wang X, Song R, Bian HN, Brunk UT, Zhao M, Zhao KS. Polydatin, a natural 
polyphenol, protects arterial smooth muscle cells against mitochondrial 
dysfunction and lysosomal destabilization following hemorrhagic shock. Am J 
Physiol Regul Integr Comp Physiol 302: R805-14, 2012. 
255. Watts JA, Grattan RM, 2nd, Whitlow BS, Kline JA. Activation of poly(ADP-ribose) 
polymerase in severe hemorrhagic shock and resuscitation. Am J Physiol 
Gastrointest Liver Physiol 281: G498-506, 2001. 
125	  
	  
256. Welty-Wolf KE, Simonson SG, Huang YC, Fracica PJ, Patterson JW, Piantadosi 
CA. Ultrastructural changes in skeletal muscle mitochondria in gram-negative 
sepsis. Shock 5: 378-84, 1996. 
257. Wendling D, Abbas W, Godfrin-Valnet M, Kumar A, Guillot X, Khan KA, Vidon C, 
Coquard L, Toussirot E, Prati C, Herbein G. Dysregulated serum IL-23 and 
SIRT1 activity in peripheral blood mononuclear cells of patients with rheumatoid 
arthritis. PLoS One 10: e0119981, 2015. 
258. Wenz T. Regulation of mitochondrial biogenesis and PGC-1alpha under cellular 
stress. Mitochondrion 13: 134-42, 2013. 
259. Wheaton WW, Chandel NS. Hypoxia. 2. Hypoxia regulates cellular metabolism. 
Am J Physiol Cell Physiol 300: C385-93, 2011. 
260. White H, Venkatesh B. Clinical review: ketones and brain injury. Crit Care 15: 
219, 2011. 
261. Wu CT, Yu HP, Chung CY, Lau YT, Liao SK. Attenuation of lung inflammation 
and pro-inflammatory cytokine production by resveratrol following trauma-
hemorrhage. Chin J Physiol 51: 363-8, 2008. 
262. Wurth MA, Sayeed MM, Baue AE. Nicotinamide adenine dinucleotide (NAD) 
content of liver with hemorrhagic shock. Proc Soc Exp Biol Med 144: 654-8, 
1973. 
263. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, 
Hennessy L, Moore EE, Minei JP, Bankey PE, Johnson JL, Sperry J, Nathens 
AB, Billiar TR, West MA, Brownstein BH, Mason PH, Baker HV, Finnerty CC, 
Jeschke MG, Lopez MC, Klein MB, Gamelli RL, Gibran NS, Arnoldo B, Xu W, 
Zhang Y, Calvano SE, McDonald-Smith GP, Schoenfeld DA, Storey JD, Cobb 
JP, Warren HS, Moldawer LL, Herndon DN, Lowry SF, Maier RV, Davis RW, 
Tompkins RG, Inflammation, Host Response to Injury Large-Scale Collaborative 
Research P. A genomic storm in critically injured humans. J Exp Med 208: 2581-
90, 2011. 
264. Xu J, Kim HT, Ma Y, Zhao L, Zhai L, Kokorina N, Wang P, Messina JL. Trauma 
and hemorrhage-induced acute hepatic insulin resistance: dominant role of tumor 
necrosis factor-alpha. Endocrinology 149: 2369-82, 2008. 
265. Xu Y, Nie L, Yin YG, Tang JL, Zhou JY, Li DD, Zhou SW. Resveratrol protects 
against hyperglycemia-induced oxidative damage to mitochondria by activating 
SIRT1 in rat mesangial cells. Toxicol Appl Pharmacol 259: 395-401, 2012. 
266. Yamamoto T, Byun J, Zhai P, Ikeda Y, Oka S, Sadoshima J. Nicotinamide 
mononucleotide, an intermediate of NAD+ synthesis, protects the heart from 
ischemia and reperfusion. PLoS One 9: e98972, 2014. 
267. Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, 
Souza-Pinto NC, Bohr VA, Rosenzweig A, de Cabo R, Sauve AA, Sinclair DA. 
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095-
107, 2007. 
268. Yang SR, Wright J, Bauter M, Seweryniak K, Kode A, Rahman I. Sirtuin 
regulates cigarette smoke-induced proinflammatory mediator release via 
RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: 
implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol 
Physiol 292: L567-76, 2007. 
269. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW. 
Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 
deacetylase. EMBO J 23: 2369-80, 2004. 
126	  
	  
270. Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key 
NAD(+) intermediate, treats the pathophysiology of diet- and age-induced 
diabetes in mice. Cell Metab 14: 528-36, 2011. 
271. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, Oh DY, 
Lu M, Milne JC, Westphal C, Bandyopadhyay G, Olefsky JM. SIRT1 inhibits 
inflammatory pathways in macrophages and modulates insulin sensitivity. Am J 
Physiol Endocrinol Metab 298: E419-28, 2010. 
272. Yu HP, Hsu JC, Hwang TL, Yen CH, Lau YT. Resveratrol attenuates hepatic 
injury after trauma-hemorrhage via estrogen receptor-related pathway. Shock 30: 
324-8, 2008. 
273. Yu HP, Hwang TL, Hsieh PW, Lau YT. Role of estrogen receptor-dependent 
upregulation of P38 MAPK/heme oxygenase 1 in resveratrol-mediated 
attenuation of intestinal injury after trauma-hemorrhage. Shock 35: 517-23, 2011. 
274. Yu HP, Hwang TL, Yen CH, Lau YT. Resveratrol prevents endothelial 
dysfunction and aortic superoxide production after trauma hemorrhage through 
estrogen receptor-dependent hemeoxygenase-1 pathway. Crit Care Med 38: 
1147-54, 2010. 
275. Yu HP, Lui PW, Hwang TL, Yen CH, Lau YT. Propofol improves endothelial 
dysfunction and attenuates vascular superoxide production in septic rats. Crit 
Care Med 34: 453-60, 2006. 
276. Yu HP, Yang SC, Lau YT, Hwang TL. Role of Akt-dependent up-regulation of 
hemeoxygenase-1 in resveratrol-mediated attenuation of hepatic injury after 
trauma hemorrhage. Surgery 148: 103-9, 2010. 
277. Yu W, Dittenhafer-Reed KE, Denu JM. SIRT3 protein deacetylates isocitrate 
dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. J Biol Chem 
287: 14078-86, 2012. 
278. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of 
glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell 
function in type 2 diabetes: a parallel-group study. Lancet 359: 824-30, 2002. 
279. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, 
Verbeuren TJ, Cohen RA. Polyphenols stimulate AMP-activated protein kinase, 
lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-
deficient mice. Diabetes 55: 2180-91, 2006. 
280. Zhai L, Ballinger SW, Messina JL. Role of reactive oxygen species in injury-
induced insulin resistance. Mol Endocrinol 25: 492-502, 2011. 
281. Zhang T, Berrocal JG, Frizzell KM, Gamble MJ, DuMond ME, Krishnakumar R, 
Yang T, Sauve AA, Kraus WL. Enzymes in the NAD+ salvage pathway regulate 
SIRT1 activity at target gene promoters. J Biol Chem 284: 20408-17, 2009. 
282. Zhang Z, Lowry SF, Guarente L, Haimovich B. Roles of SIRT1 in the acute and 
restorative phases following induction of inflammation. J Biol Chem 285: 41391-
401, 2010. 
283. Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, 
Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, 
Guan KL. Regulation of cellular metabolism by protein lysine acetylation. Science 
327: 1000-4, 2010. 
284. Zhao WY, Zhang L, Sui MX, Zhu YH, Zeng L. Protective effects of sirtuin 3 in a 
murine model of sepsis-induced acute kidney injury. Sci Rep 6: 33201, 2016. 
127	  
	  
285. Zhou L, Podolsky N, Sang Z, Ding Y, Fan X, Tong Q, Levin BE, McCrimmon RJ. 
The medial amygdalar nucleus: a novel glucose-sensing region that modulates 
the counterregulatory response to hypoglycemia. Diabetes 59: 2646-52, 2010. 
286. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 
inflammasome activation. Nature 469: 221-5, 2011. 
 
